US Pat. No. 10,213,613

SYSTEM AND METHOD FOR USING DIAGNOSTIC PULSES IN CONNECTION WITH DEFIBRILLATION THERAPY

PHYSIO-CONTROL, INC., Re...

1. A method of treating a patient, comprising:outputting a diagnostic stimulus signal to elicit a physiologic response from the patient, wherein the physiologic response comprises at least one of mechanical cardiac response, electrical cardiac response in the absence of mechanical cardiac response, or absence of both mechanical cardiac response and electrical cardiac response;
detecting the elicited physiologic response;
selecting one of a plurality of resuscitation protocols based upon the detected physiologic response, wherein at least one of the plurality of resuscitation protocols includes application of a defibrillation therapy, the selection based at least in part on a likely patient response to the defibrillation therapy; and
initiating the selected resuscitation protocol,
wherein, if the physiologic response is one of electrical cardiac response in the absence of mechanical cardiac response, initiating the selected resuscitation protocol includes initiating a protocol recommending drug therapy and outputting a recommendation to administer cardio pulmonary resuscitation (CPR) with the drug therapy.

US Pat. No. 10,213,612

VISUAL AND AURAL USER INTERFACE FOR AN AUTOMATED EXTERNAL DEFIBRILLATOR

1. An automatic defibrillator comprising:a storage capacitor adapted to be charged;
a discharge circuit;
an aural output device communicably coupled to a processor;
at least one electrode communicably coupled to the processor;
a visual output device communicably coupled to the processor;
an input device communicably coupled to the processor;
wherein the processor is configured to execute instructions that cause the defibrillator to be configured to:
monitor ECG signals through the at least one electrode;
analyze the ECG signals through the processor to detect a shockable heart rhythm;
responsive to detecting a shockable heart rhythm, cause at least one of the aural and visual output devices to deliver information that includes a prompt to deliver a response through the input device to prevent the initiation of an emergency protocol; and
responsive to an expiry of a predetermined period of time to deliver the response, autonomously initiate the emergency protocol including: causing the discharge circuit to discharge the charged storage capacitor through the electrodes, delivering a defibrillation pulse to the patient.

US Pat. No. 10,213,611

METHOD OF MANUFACTURING FEEDTHROUGH

Osong medical innovation ...

1. A method of manufacturing a feedthrough comprising:mounting a ceramic structure on a mounting groove of a lower jig, the ceramic structure having a plurality of grooves formed uniformly;
inserting a platinum/iridium pin formed of platinum and iridium into the grooves of the ceramic structure;
disposing a titanium flange on the ceramic structure, to form a feedthrough structure having the ceramic structure, the platinum/iridium pin and the titanium flange;
disposing the feedthrough structure on a groove of an upper jig and pressing the feedthrough structure, so that the upper jig is combined with the mounting groove of the lower jig and moves toward a diffusion chamber, for diffusion welding the ceramic structure of the feedthrough structure, the platinum/iridium pin and the titanium flange with each other;
decreasing a temperature of the diffusion chamber for cooling the feedthrough structure welded with each other;
disposing the ceramic structure of the feedthrough structure to face a laser machining device;
irradiating a laser to the ceramic structure into which the platinum/iridium pin is inserted, to form a hole in the ceramic structure; and
moving a melted platinum/iridium pin toward an upper side of the ceramic structure through the hole of the ceramic structure, so that the platinum/iridium pin is partially exposed through the upper side of the ceramic structure.

US Pat. No. 10,213,610

COMMUNICATIONS IN A MEDICAL DEVICE SYSTEM WITH LINK QUALITY ASSESSMENT

CARDIAC PACEMAKERS, INC.,...

1. A method of performing a diagnostic test in an implantable medical device system comprising:generating a first conducted signal from a first medical device intended for receipt by a second medical device comprising an output pattern for a selected period;
receiving the conducted signal by the second medical device and calculating a first communication metric of the first conducted signal as received;
wherein the selected period exceeds an expected or detected length of a recurring biological cycle.

US Pat. No. 10,213,609

MOBILE APPLICATIONS AND METHODS FOR CONVEYING PERFORMANCE INFORMATION OF A CARDIAC PACEMAKER

1. A system, comprising:a pulse monitor;
a pacemaker;
an internal device separate from the pacemaker;
a processing system including a processor coupled to the pulse monitor and the pacemaker; and
a memory that stores executable instructions that, when executed by the processing system, facilitate performance of operations, the operations comprising:
monitoring, by the pacemaker, performance of the internal device to obtain monitored information;
determining, by the pacemaker, a reporting requirement based on the monitored information;
responsive to the reporting requirement:
generating, by the pacemaker, a modulation signal based on the monitored information;
initiating, by the pacemaker, a timer to stimulate a heart muscle of a patient according to an interval to cause a first adjustment of a heartbeat associated with the heart muscle;
modifying, by the pacemaker, the interval by adding or subtracting a subinterval to generate a modified interval, wherein the subinterval is representative of a binary digit according to the modulation signal; and
stimulating, by the pacemaker, the heart muscle according to the modified interval to cause a second adjustment of the heartbeat, wherein the pulse monitor detects a pulse based on the second adjustment of the heartbeat and according to the modulation signal;
forwarding, from the pulse monitor to a mobile device, the pulse comprising a binary digit, based on detection by the pulse monitor of the second adjustment to the heartbeat, wherein the mobile device comprises decoding logic adapted to decode information, to obtain decoded information based on the binary digit; and
receiving the decoded information obtained by way of the mobile device,
wherein the internal device communicates with the pacemaker via a wired connection, and wherein a signal provided by the internal device to the pacemaker via the wired connection represents a measurement regarding a measurable aspect of the patient.

US Pat. No. 10,213,608

NEUROSTIMULATION SYSTEM WITH FLEXIBLE PATTERNING AND WAVEFORMS

Boston Scientific Neuromo...

1. A method for programming a neurostimulator to provide a neurostimulation therapy, comprising:customizing a pulse pattern for the neurostimulation therapy on a pulse-by-pulse basis in response to user input; and
generating information for the neurostimulator, the neurostimulator configured to use the information to generate electrical stimulation energy in accordance with the customized pulse pattern for the neurostimulation therapy.

US Pat. No. 10,213,607

USER INTERFACE WITH VIEW FINDER FOR LOCALIZING ANATOMICAL REGION

Boston Scientific Neuromo...

1. An external control device for use with a medical component implanted within a patient, comprising:a user interface configured to display a view of a graphical representation of an anatomical region of the patient and a medical component in the context of the graphical representation of the anatomical region of the patient;
the user interface further configured to receive a first user input to pan the view to display a different portion for the graphical representation and a second user input to change a size of the view; and
control circuitry configured to, in response to the first user input, display the different portion for the graphical representation, the control circuitry further configured to, in response to the second user input, automatically change a size of the view.

US Pat. No. 10,213,606

MODULATE PACING RATE TO INCREASE THE PERCENTAGE OF EFFECTIVE VENTRICULAR CAPTURE DURING ATRIAL FIBRILLATION

Medtronic, Inc., Minneap...

1. An apparatus for determining whether a ventricular pacing stimulus is capturing a paced ventricle during atrial fibrillation, comprising:processing means for determining whether a patient is experiencing atrial fibrillation;
delivering means for delivering the ventricular pacing stimulus in response to determining the patient is in atrial fibrillation;
sensing means for sensing a signal in response to the ventricular pacing stimulus;
processing means for determining whether the ventricular pacing stimulus is effectively capturing the paced ventricle;
modifying means for modifying a pacing rate during atrial fibrillation in response to the determination of effective capture; and
increasing a percentage of effective ventricular capture during atrial fibrillation responsive to modifying the pacing rate during atrial fibrillation.

US Pat. No. 10,213,605

SYSTEMS AND METHODS FOR SPINAL CORD STIMULATION

DUKE UNIVERSITY, Durham,...

1. A method of optimizing temporal pulse patterns for stimulation delivery to a subject, the method comprising:generating a first generation temporal pulse pattern;
delivering stimulation according to the first generation temporal pulse pattern to a subject;
measuring efficacy, efficiency and side-effect parameters affected by the delivered stimulation;
determining a fitness of the first generation temporal pulse pattern using the measured efficacy, efficiency and side-effect parameters;
generating a second generation temporal pulse pattern using the first generation temporal pulse pattern according to the determined fitness of the first generation temporal pulse pattern; and
delivering stimulation according to the second generation temporal pulse pattern to the subject,
wherein generating the second generation temporal pulse pattern comprises using a genetic algorithm that uses an output of a computational model including representations of dorsal horn wide-dynamic range (WDR) neurons responsible for transmitting nociceptive information and dorsal column nuclei (DCN) neurons associated with side-effect paresthesias.

US Pat. No. 10,213,604

CONTROLLING ELECTRICAL STIMULATION BASED ON EVOKED COMPOUND MUSCLE ACTION POTENTIAL

Medtronic, Inc., Minneap...

1. A method comprising:applying, via one or more electrodes, stimulation therapy to a patient according to a set of stimulation therapy parameters;
detecting, using at least one electrode of the one or more electrodes used for applying the stimulation therapy to the patient, a signal including an evoked compound muscle action potential (eCMAP) in response to the application of the stimulation therapy;
detecting, using a posture state module, a posture state of the patient; and
adjusting, by a processor, one or more stimulation therapy parameters of the set of stimulation therapy parameters based on the detected signal and the detected posture state.

US Pat. No. 10,213,603

ARBITRARY WAVEFORM GENERATOR AND NEURAL STIMULATION APPLICATION WITH SCALABLE WAVEFORM FEATURE AND CHARGE BALANCING

NUVECTRA CORPORATION, Pl...

1. A medical waveform generator, comprising:a waveform generator configured to generate an output waveform comprised of any of a plurality of differently shaped waveforms;
a time scaling circuit configured to time scale, by a factor of k, the generator output waveform, wherein k is an integer;
a current divider configured to scale, by a factor of 1/k, an amplitude of the time scaled generator output waveform for outputting an amplitude scaled output waveform; and
an amplifier configured to amplify the amplitude scaled output waveform for outputting a stimulation waveform.

US Pat. No. 10,213,602

TREATMENT OF HEADACHES BY ELECTRICAL STIMULATION

Theranica Bio-Electronics...

1. A method, comprising:coupling a plurality of electrodes to skin of a lateral surface of an upper arm of a subject; and
using a computer processor, in response to the subject experiencing a headache, without using any element that is implanted in the subject, and without using any element that penetrates skin of the subject, treating the headache, by transcutaneously stimulating the subject, by applying an electrical current to the skin, via the electrodes.

US Pat. No. 10,213,601

NON-INVASIVE VAGUS NERVE STIMULATION DEVICES AND METHODS TO TREAT OR AVERT ATRIAL FIBRILLATION

Electrocore, Inc., Baski...

1. A device for at least one of treating atrial fibrillation or averting an imminent episode of atrial fibrillation in a patient, the device comprising:a housing having an electrically permeable contact surface for contacting an outer skin surface of the patient; and
an energy source within the housing configured to generate an electric field sufficient to transmit an electrical impulse through the outer skin surface of the patient to a vagus nerve at a target region within the patient;
wherein the electrical impulse comprises bursts of pulses with each of the bursts having a frequency of about 3 Hz to about 100 Hz, each of the bursts comprising a plurality of pulses, and each of the pulses having a duration of about 50 microseconds to about 1000 microseconds, and wherein the electrical impulse is sufficient to modulate the vagus nerve such that the vagus nerve transmits an action potential sufficient to at least one of treat the atrial fibrillation or avert the imminent episode of atrial fibrillation.

US Pat. No. 10,213,600

HYBRID METHOD FOR MODULATING UPPER AIRWAY FUNCTION IN A SUBJECT

CASE WESTERN RESERVE UNIV...

8. A controller device comprising:a memory storing computer-executable instructions; and
a processor to execute the computer-executable instructions to at least:
set a first timing parameter of a first therapy signal, wherein the first therapy signal is delivered to a nerve innervating an extrinsic laryngeal muscle of a subject to promote anteriosuperior motion of a hyolaryngeal complex;
set a second timing parameter of a second therapy signal, wherein the second therapy signal is delivered to a recurrent laryngeal nerve (RLN) of the subject to promote vocal fold closure;
receive an input related to at least one of a physiological parameter detected by a sensor and a volitional input; and
adjust the first timing parameter of the first therapy signal and the second timing parameter of the second therapy signal to promote swallowing based on synergistic anteriosuperior motion of the hyolaryngeal complex and the vocal fold closure to prevent or mitigate aspiration in the subject during a swallow cycle based on the input.

US Pat. No. 10,213,599

WIRELESS TISSUE STIMULATION DEVICES

Board of Regents, The Uni...

1. A wirelessly powered muscular stimulation device comprising:a substrate;
at least one antenna disposed on the substrate and configured to receive an electromagnetic signal and to generate an electrical current from the electromagnetic signal;
a circuit disposed on the substrate, the circuit comprising a capacitor, an inductor, and a controller; and
at least one electrode operable to deliver the electrical current to a muscle in contact with a top surface of the device and/or a bottom surface of the device,wherein the device has a thickness of less than 5 mm,wherein the device does not comprise a battery,wherein the device is configured to directly generate stimulation pulses from the received electromagnetic signal, andwherein the substrate is foldable and the foldable substrate can be rolled upon itself and subsequently unrolled without breaking.

US Pat. No. 10,213,598

SYSTEMS AND METHODS FOR REDUCING OR ALTERING ORAL BACTERIA AND METHODS FOR MANUFACTURING THE SAME

Bioelectrics LLC, Clevel...

1. A method of manufacturing a mouthpiece, the method steps comprising:providing a first mold having a top portion and a bottom portion, the top portion and the bottom portion defining a first mold cavity, and a fill port in fluid communication with the first mold cavity;
arranging a first wire, a second wire, a third wire, and a fourth wire within the first mold cavity;
injecting an electrically non-conductive material through the fill port into the first mold cavity to form a partially formed mouthpiece;
providing a second mold having a plurality of second mold cavities, and a plurality of fill ports in fluid communication with the plurality of second mold cavities;
placing the partially formed mouthpiece into the second mold;
injecting an electrically conductive material into the plurality of second mold cavities and into electrical contact with the wires; and
removing the mouthpiece from the second mold.

US Pat. No. 10,213,597

ELECTRODE LEAD THAT AVOIDS ELECTRODE ARRAY MIGRATION FROM THE COCHLEA

MED-EL Elektromedizinisch...

1. A cochlear implant electrode arrangement comprising:an electrode lead configured to carry cochlear stimulation signals from a signal processor through an oval shaped posterior tympanotomy in a facial recess of a patient;
an electrode array having stimulation contacts on a surface of the electrode array, the stimulation contacts configured to deliver the stimulation signals from the electrode lead to adjacent neural tissue of a cochlea of the patient; and
a retraction limiter having a central opening that surrounds at least a portion of an outer surface of the electrode lead, the retraction limiter having a projection length and a height and having opposing projection arms and a pair of securing ends, the securing ends configured to be moved closer to one another in order to make the central opening smaller, each projection arm having a distal end, wherein the projection length is defined between the distal ends of the projection arms and the height is less than the projection length, and the projection length is configured to be
less than a long diameter of the posterior tympanotomy and
greater than a short diameter of the posterior tympanotomy, and the height is configured to be less than the short diameter of the posterior tympanotomy,
wherein the retraction limiter is configured:
i. to slide over the electrode lead to a proximal end of the electrode array with the projection arms at a first position,
ii. to rotate relative to the electrode lead in order to align the projection arms in a second position approximately 90 degrees from the first position, and
iii. to be secured to the electrode lead when the securing ends are moved closer to one another in order to prevent further movement of the retraction limiter relative to the electrode lead.

US Pat. No. 10,213,596

SKULL-MOUNTED OPTICAL IMPLANT

Boston Scientific Neuromo...

1. A medical device, comprising:a housing configured to mount to a patient's skull, wherein the housing comprises:
a light source contained within the housing, and
a light pipe fitting comprising a first window wherein the light pipe fitting is configured to accept a light pipe and a light pipe ferule,
a light pipe ferule configured to hold a light pipe and comprising a second window and configured to hold a light pipe, and
a light pipe, wherein
the medical device is configured so that when the light pipe ferule and the light pipe are accepted within the light pipe fitting, the first and second windows provide a light path from the light source to the light pipe.

US Pat. No. 10,213,595

METHODS AND DEVICES FOR IHIBITING TISSUE GROWTH FROM RESTRICTING A STRAIN RELIEF LOOP OF AN IMPLANTABLE MEDICAL LEAD

MEDTRONIC, INC., Minneap...

1. A method of inhibiting tissue growth from restricting a strain relief loop of an implantable medical lead, comprising:providing a lead body of the lead with a tissue growth inhibitor;
positioning the lead body of the implantable medical lead to produce a strain relief loop such that the tissue growth inhibitor is present at the loop; and
coupling an object directly to the strain relief loop of the lead such that the object is present within the strain relief loop and obstructs an area within the loop while allowing the strain relief loop to provide strain relief.

US Pat. No. 10,213,594

ELECTRICAL CONNECTOR, IN PARTICULAR FOR A CUTANEOUS DEVICE

1. An electrical connector for a device configured to be fixed on the skin of a user, comprising:a base secured to the device; and
a plug configured to be secured to an electrical conductor, wherein the plug comprises a first connection means and the base comprises a plurality of second connection means, each of the plurality of second connection means being individually configured for cooperating with the first connection means of the plug to ensure a connection between the base and the plug, the plug and the base including magnetic means on the plug and corresponding magnetic means on the base, the plurality of second connection means of the base including a plurality of holes and the first connection means of the plug including a protuberance, the magnetic means exerting attractive magnetic forces causing an insertion of the protuberance of the plug in one of the holes of the base.

US Pat. No. 10,213,593

METHOD AND APPARATUS FOR NONINVASIVE INHIBITION OF DEEP VEIN THROMBOSIS

StimMed LLC, Buffalo, NY...

1. A wearable device for positioning at least two electrodes adjacent the sole of a wearer's foot, comprising:a substantially I-shaped flexible support comprising:
a bottom portion configured to extend along a least a portion of the bottom of the foot, posteriorly from an arch;
an ankle portion of the support configured to extend upwardly along the back of the wearer's foot from the heel, wherein the ankle portion comprises a lateral edge and a medial edge, the lateral and medial edges of the ankle portion both being configured to be positioned along a posterior side of the wearer's leg;
a heel portion configured to extend around the heel, the heel portion joining the bottom portion to the ankle portion;
a foot strap carried by the support, the foot strap comprising two wings extending laterally from the bottom portion and being configured to attach to one another to secure the bottom portion to the bottom of the foot;
an ankle strap carried by the support, the ankle strap comprising two wings extending laterally from the lateral and medial edges of the ankle portion and being configured to extend from the posterior side of the wearer's leg entirely around a lower circumference of the wearer's leg to attach to one another so as to secure the ankle portion to the wearer's leg, wherein the substantially I shaped flexible support has a length extending from the foot strap to the ankle strap configured to position the ankle strap around a lower portion of the wearer's leg above the ankle; and
a posterior electrode and an anterior electrode carried by the bottom portion, the anterior electrode being positioned anteriorly to the posterior electrode;
wherein the bottom portion and the ankle portion are configured to lie flat adjacent one another such that the wearer may step onto the flexible support to position the wearer's foot over the posterior electrode and the anterior electrode, the heel portion configured to flex so that the ankle portion may extend upwardly from the bottom portion, and
wherein the two wings of the foot strap are configured to lie flat adjacent the bottom portion and the two wings of the ankle strap configured to lie flat adjacent the ankle portion.

US Pat. No. 10,213,592

ASEPTIC COUPLING DEVICES

Colder Products Company, ...

1. A method of using an aseptic coupling device, the method comprising:removing, from a front face of the aseptic coupling device, a membrane,
wherein prior to the removing: (i) a first portion of the membrane was attached directly to the front face completely around an opening defined by the front face to thereby cover the opening, (ii) a fold in the membrane separated the first portion of the membrane from a second portion of the membrane, and (iii) a low friction member defining an aperture was positioned between the first and second portions of the membrane, and wherein the second portion of the membrane covered the aperture.

US Pat. No. 10,213,591

PLUG-IN CONNECTOR FOR MEDICAL TUBES

1. A medical system comprising:a medical tube plug-in connector comprising an elastic section, a first plug-in part and a second plug-in part, wherein the second plug-in part extends around the first plug-in part in a plugged-together state, wherein the second plug-in part has at least one forwardly protruding snap-in element, which has at a front end at least one inwardly protruding projection, which is provided for engaging a complementary recess in an outer surface of the first plug-in part in order to hold the second plug-in part fixed in an axial direction on the first plug-in part due to the projection meshing with the recess, each of the first plug-in part and the second plug-in part having a central passage opening, one of the first plug-in part and the second plug-in part having a surface defining an open end area radially expanding as a function of axial position towards an outlet opening in a connection area and the other of the first plug-in part and the second plug-in part being connected to the elastic section with the elastic section arranged in an interior thereof, said open end area being in communication with one end of said central passage of said one plug-in part, the elastic section protruding into the connection area, so that an outer and axially facing front end surface of the elastic section is pressed into contact with the surface defining the expanded end area of the opposite one of the first plug-in part and the second plug-in part when the projection of the at least one snap-in element maintains the second plug-in part meshed with the first plug-in part, so that the axially facing front end surface of the elastic section exerts a sealing function due to a pressure of the elastic section on the surface defining the expanding end area;
a sphygmomanometer cuff for detecting the blood pressure;
a medical tube connected to said sphygmomanometer cuff, said central passage and said open end area of said one plug-in part being in communication with a passage of said medical tube;
a monitor for analysis and display of the blood pressure of a test subject, said sphygmomanometer cuff being connected to said monitor by said medical tube and said medical tube plug-in connector.

US Pat. No. 10,213,590

VASCULAR ACCESS SYSTEM WITH CONNECTOR

Merit Medical Systems, In...

1. A method for coupling tubular segments of a fluid conduit in a cardiovascular system, the method comprising:providing a connector having an outer surface defining a first outer perimeter and an inner surface defining a lumen and a connecting device positioned between a proximal and distal end of the connector, the connecting device having a disengaged configuration and a plurality of engaged configurations for securing tubular segments of different thicknesses;
engaging an end of a fluid conduit with the connector such that the lumen of the connector is in fluid communication with the lumen of the fluid conduit; and
actuating the connecting device from the disengaged configuration to one of the engaged configurations such that the fluid conduit is compressed by the connecting device,
wherein the actuating comprises moving two jaw members past each other to cause at least one tooth on a first jaw to engage with at least one tooth on a second jaw, and
wherein the moving comprises deflecting at least one of the two jaw members in a direction parallel to a longitudinal axis of the connector.

US Pat. No. 10,213,589

CARRIER ASSEMBLY WITH CAPS FOR MEDICAL CONNECTORS

Merit Medical Systems, In...

1. An assembly mounting medical connector caps for use, the assembly comprising:a carrier shaped as a sheet of material, the carrier having an array of holes; and
a plurality of medical connector caps, each cap of the plurality of medical connector caps having an openable end configured to cover a medical connector and a closed graspable end, wherein each cap of the plurality of medical connector caps is inserted into a hole of the array of holes, such that each cap of the plurality of medical connector caps is retained in the hole of the array of holes and portions of each cap of the plurality of medical connector caps extend from an upper side and an underside of the carrier.

US Pat. No. 10,213,588

TRANSDERMAL DELIVERY OF HIGH VISCOSITY BIOACTIVE AGENTS

SORRENTO THERAPEUTICS, IN...

1. A device for delivery of a bioactive agent across a dermal barrier, the device comprising:a microneedle and a plurality of nanostructures and microstructures fabricated on a surface of the microneedle, the nanostructures and microstructures being arranged in a predetermined pattern, wherein at least a portion of the microstructures have a cross-sectional dimension of greater than about 500 nanometers and less than about 10 micrometers and a height of from about 20 nanometers to about 1 micrometer, and wherein at least a portion of the nanostructures have a cross-sectional dimension of less than about 500 nanometers and greater than about 5 nanometers and an aspect ratio of from about 0.2 to about 5, wherein the microneedle further contains a channel; and
a reservoir that is in fluid communication with the channel of the microneedle and that contains a composition having a viscosity of greater than about 5 centipoise and comprising a bioactive agent.

US Pat. No. 10,213,587

DISPENSING APPLICATOR FOR FLUIDS

BIOMED PACKAGING SYSTEMS,...

1. A dispensing applicator comprising a frangible applicator tip, said applicator comprising:an elongated tubular body including a fluid source region, a fracture member region, and a tongue element, said tongue element extending outwardly from said fracture member region from a first end of the elongated tubular body;
an applicator head including an inner cavity for receiving at least said tongue element;
a frangible region defined as a region at the juncture of said fracture member region and said tongue element, fracture of said frangible region allowing partial fluid release from said fracture member region to said applicator head; and
a cap assembly including a cap secured to a second end of the elongated body, the second end generally opposing the first end,
wherein the tongue element and the fracture member region each includes at least one projecting engagement member that is configured to engage an inner surface of said applicator head.

US Pat. No. 10,213,586

DRUG DELIVERY METHODS AND SYSTEMS

Chrono Therapeutics Inc.,...

1. A method for delivering a bioactive agent to a user, the method comprising:connecting a reusable part of a delivery system to a disposable part of the delivery system;
during the connecting step, compressing a first spring extending from an agent reservoir of the disposable part to pressurize the bioactive agent within the agent reservoir;
actuating a valve driver in the reusable part to move a valve in the disposable part to a first position to transfer the bioactive agent from the agent reservoir to a bolus chamber;
actuating the valve driver to move the valve to a second position to transfer the bioactive agent from the bolus chamber to an agent outlet; and
compressing a second spring extending from the bolus chamber to pressurize the bioactive agent within the bolus chamber.

US Pat. No. 10,213,585

ADJUSTABLE HEIGHT HYDROCEPHALUS VALVE LOCATION DEVICE

1. An adjustable height tool for locating a readable and settable valve, the locator comprising:a wall having a first perimeter;
a platform disposed within the first perimeter;
a valve cut-out disposed within the platform and receiving a portion of the valve;
a movable foot disposed below the platform; and
a displacement element configured to move the foot at least one of toward or away from the platform, upon movement of the displacement element, and controlling the amount of the valve received in the valve cut-out.

US Pat. No. 10,213,584

METHOD AND APPARATUS FOR GUIDING A CATHETER

THE CLEVELAND CLINIC FOUN...

1. A method for guiding a catheter within a patient's body, the method comprising:inserting a distal end of a first wire into a first body lumen;
advancing the distal end of the first wire through the first body lumen toward an intersection of the first body lumen with second and third body lumens;
directing the distal end of the first wire into the second body lumen;
inserting a distal end of the catheter into the first body lumen;
associating the first wire with the catheter to create an associated first wire;
advancing the distal end of the catheter, guided by the associated first wire, through the first body lumen toward the intersection of the first body lumen with the second and third body lumens;
inserting a distal end of a second wire into a lumen of the catheter;
advancing the distal end of the second wire through the catheter toward the intersection of the first body lumen with the second and third body lumens;
directing the distal end of the catheter into the third body lumen, including
directing the distal end of the catheter into the second body lumen by advancing the distal end of the catheter, guided by the associated first wire, into the second body lumen,
providing an aperture substantially laterally through a sidewall of the catheter proximally adjacent to the distal end of the catheter,
at least partially withdrawing the first wire from the catheter, and
redirecting the distal end of the catheter from the second body lumen to the third body lumen with the aperture opening toward the second body lumen;
selectively advancing the distal end of the first wire through the catheter and out through the aperture into the second body lumen;
with the first wire extending through the aperture into the second body lumen, directing, with the catheter, the distal end of the second wire into the third body lumen via
directing the distal end of the second wire through the catheter and out the distal end of the catheter;
directing, with the catheter, the distal end of the second wire into the third body lumen and the distal end of the catheter into the second body lumen via
at least partially withdrawing the first wire from the catheter;
directing the distal end of the catheter into the second body lumen,
with the distal end of the catheter maintained in the second body lumen and the aperture opening toward the third body lumen, advancing the first wire through the distal end of the catheter and into the second body lumen, and advancing the second wire through at least a portion of the lumen of the catheter toward the distal end of the catheter, and
directing the distal end of the second wire out of the lumen of the catheter through the aperture into the third body lumen; and
directing, with the catheter, the distal end of the second wire and the catheter into the third body lumen and the distal end of the first wire into the second body lumen via
at least partially withdrawing the first and second wires from the catheter,
advancing the distal end of the catheter into the third body lumen with the aperture opening toward the second body lumen,
directing the distal end of the first wire through the aperture and into the second body lumen, and
directing the distal end of the second wire through the distal end of the catheter into the third body lumen.

US Pat. No. 10,213,583

BALLOON CATHETER WITH TRANSIENT RADIOPAQUE MARKING

CLEARSTREAM TECHNOLOGIES ...

1. A kit for treating a treatment area in the vasculature, comprising:a first catheter adapted for positioning at the treatment area, said first catheter including a first balloon having a transient radiopaque material corresponding to the treatment area;
and
a second catheter adapted for positioning at the treatment area, said second catheter having a treatment that substantially matches the transient radiopaque material while on the first balloon, so that the length or position of the treatment corresponds to the length or position of the treatment area.

US Pat. No. 10,213,582

METHODS AND SYSTEMS FOR TREATMENT OF ACUTE ISCHEMIC STROKE

Route 92 Medical, Inc., ...

1. A method of performing a medical procedure at a treatment site in a cerebral vessel of a patient, the method comprising:assembling a coaxial system of devices, the assembled coaxial system of devices comprising:
a catheter having a catheter lumen and a distal end; and
a tapered inner member extending through the catheter lumen, wherein a distal end of the tapered inner member extends distal to the distal end of the catheter, the tapered inner member having a lumen; and
advancing the assembled coaxial system of devices together through the internal carotid artery from a transfemoral access site of the patient;
further advancing the assembled coaxial system of devices together after the distal end of the catheter is distal to a petrous portion of the internal carotid artery.

US Pat. No. 10,213,581

DIRECTIONAL SUBINTIMAL ACCESS FOR CHEMICAL AGENT DELIVERY

Covidien LP, Mansfield, ...

1. A delivery member configured to deliver a chemical agent to tissue, the delivery member comprising:a body including a plurality of discrete, separable sections comprising:
a first section comprising:
a first housing having a first opening formed therein and defining a first internal cavity; and
a first penetrating member extending from the first housing; and
a second section comprising:
a second housing having a second opening formed therein and defining a second internal cavity; and
a second penetrating member extending from the second housing,
wherein each of the first and second penetrating members comprises a tip configured to facilitate passage of the delivery member through the tissue, and wherein the first penetrating member extends through the second opening and into the second internal cavity of the second housing; and
the chemical agent, wherein the chemical agent is coated onto a surface of at least one section of the plurality of discrete, separable sections or incorporated within a material of the at least one section, such that the chemical agent is absorbable by tissue in contact with the at least one section.

US Pat. No. 10,213,580

CURVED CATHETER

MAGENTA MEDICAL LTD, Kad...

1. A method comprising:inserting a catheter into a body of a subject via an artery of a groin of the subject, and
advancing the catheter distally such that:
a distal end of the catheter is disposed inside a renal artery of the subject, and
respective stabilizing portions of the catheter stabilize the catheter by being in contact with inner walls of, respectively, an iliac artery of the subject, and an aorta of the subject; and
subsequently, deploying a medical device inside the renal artery by retracting the distal end of the catheter, such that the distal end of the catheter is in a retracted state, in which the respective stabilizing portions of the catheter still stabilize the catheter by being in contact with the inner walls of, respectively, the subject's iliac artery and the subject's aorta.

US Pat. No. 10,213,578

CATHETER ASSEMBLY

TERUMO KABUSHIKI KAISHA, ...

1. A catheter assembly comprising:an outer catheter comprised of a tubular outer catheter body, the outer catheter body possessing a distal end portion terminating at a distal-most end of the outer catheter body, the distal end portion of the outer catheter body possessing an outer circumferential surface;
a shaft comprised of a shaft body insertable into the outer catheter body;
the shaft including an accommodation unit extending in a proximal direction from the shaft body in axial overlying and spaced apart relation to an outer circumferential surface of a portion of the shaft body so that a gap exists between the accommodation unit and the portion of the shaft body defining an accommodation space that is configured to receive the distal end portion of the outer catheter body; and
the distal end portion of the outer catheter body being separable from the accommodation unit by relatively moving the shaft body in a distal end direction with respect to the outer catheter body from a state of being accommodated in the accommodation unit so that the outer diameter of the distal end portion of the outer catheter body expands upon being separated from the accommodation unit;
wherein the distal end portion of the outer catheter body possesses a thickness in a radial direction thicker than the thickness of a portion of the outer catheter body proximal of the distal end portion.

US Pat. No. 10,213,577

METHODS FOR ENHANCING EXPOSURE THERAPY USING PAIRING WITH VAGUS NERVE STIMULATION

MICROTRANSPONDER, INC., ...

1. A post-traumatic stress disorder (PTSD) therapy method comprising:providing, to a patient, an exposure event which is sensory-recreative of a traumatic event that contributed to the PTSD; and
electrically stimulating the patient's vagus nerve during the exposure event.

US Pat. No. 10,213,576

VALVE WITH INTERNAL MEMBER

1. A valve configured for use in positive airway pressure therapy, the valve comprising:a body comprising:
a first end configured to be in fluid communication with a mask for providing positive airway pressure therapy;
a second end configured to be in fluid communication with a gases conduit; and
an interior surface defining a passageway extending between the first end and the second end;
one or more ports through the body configured to provide fluid communication between the passageway and the environment; and
at least one internal member retained on the interior surface of the body at two or more discontinuous attachment positions on the internal member,
wherein the at least one internal member is configured to be in a closed configuration in which the internal member occludes the one or more ports such that substantially all gas from the gases conduit flows through the passageway to be delivered to the mask when a gas pressure in the valve is above a threshold pressure,
wherein the at least one internal member is configured to be in an open configuration in which the internal member allows gas from the gases conduit to pass from the passageway to the environment through the one or more ports when the gas pressure in the valve is at or below the threshold pressure;
wherein the at least one internal member forms a curved surface between each of the two or more discontinuous attachment points when in the open configuration; and
wherein flow through the passageway is permitted when the internal member is in the open configuration.

US Pat. No. 10,213,575

VALVE

KONINKLIJKE PHILIPS N.V.,...

1. A valve comprising:a housing;
a plurality of ports (A-E) disposed in the housing, said plurality of ports (A-E) comprising a first pair of ports (A, B) which are adjacent to one another and a second pair of ports (C, D) which are adjacent to one another;
a movable valve element disposed within the housing, the valve element having a stem to which a first valve member and a second valve member are affixed;
a first seal portion connected to the housing, the first seal portion being connected to the housing between the first pair of ports;
a second seal portion connected to the housing, the second seal portion being connected to the housing between the second pair of ports;
wherein a first distance between the first valve member and the second valve member is different from a second distance between the first seal portion and the second seal portion, wherein the first distance and the second distance are measured in a direction of movement of the valve element;
wherein at least one of the first seal portion, the second seal portion, the first valve member, and the second valve member is deformable so as to counteract the difference between the first distance the second distance and allowing both (i) the first seal portion to be brought into a sealed configuration with the first valve member and, at the same time, (ii) the second seal portion to be brought into a sealed configuration with the second valve member, in order to seal the first pair of ports from one another and to seal the second pair of ports from one another at the same time.

US Pat. No. 10,213,574

INHALER DEVICE FOR INHALABLE LIQUIDS

1. An inhaler device for the storage and delivery of an inhalable liquid to a patient, said inhaler device comprising a puck-shaped body wherein the puck-shaped body comprises:(1) a receptacle comprising a passive evaporation support material pre-loaded with the inhalable liquid;
(2) a receptacle lid;
(3) at least one air inlet opening; and
(4) at least one vapour inhalation opening;wherein the at least one air inlet and at least one vapour inhalation openings are in a closed position when the receptacle lid is closed for storing the inhalable liquid and further wherein as the inhalable liquid forms a vapour upon storage, the puck-shaped body forms a vapour chamber such that the stored vapour is available for direct administration to a patient when the receptacle lid is opened to provide an air/vapour pathway through the vapour chamber via the at least one air inlet and at least one vapour inhalation openings.

US Pat. No. 10,213,573

HUMIDIFIERS FOR RESPIRATORY APPARATUS

ResMed Limited, Bella Vi...

37. A tub for a humidifier configured to humidify pressurized respiratory gas, the tub comprising:an inner reservoir configured to hold a supply of water and comprising a nozzle configured to discharge the water;
a tub base with an air inlet, the tub base being configured to receive the inner reservoir in a way that forms a cavity between the tub base and the inner reservoir, the cavity being positioned to receive the water discharged through the nozzle;
a valve configured to control a flow of the water through the nozzle; and
a barrier positioned around the nozzle to form a chamber within the cavity, the barrier being configured to limit a water level outside the barrier,
wherein the air inlet of the tub base is configured to open into a portion of the cavity that is outside the chamber, and
wherein an opening in the barrier is located to prevent water in the cavity from reaching the air inlet for all tub orientations.

US Pat. No. 10,213,572

NITROGEN DIOXIDE STORAGE CASSETTE

VERO BIOTECH LLC, Atlant...

1. A cassette for conversion of nitrogen dioxide to nitric oxide comprising:a sealed housing,
a first cartridge capable of converting nitrogen dioxide gas to nitric oxide within the sealed housing,
the first cartridge comprising an inlet, a diverter, a body, an outlet, and a first porous solid matrix including a reducing agent,
the first porous solid matrix being positioned within the first cartridge such that there is a space between the body of the first cartridge and the first porous solid matrix, wherein the first porous solid matrix includes an open passage parallel to the length of the body of the first cartridge,
a second cartridge capable of converting nitrogen dioxide gas to nitric oxide, wherein an outlet of the first cartridge and an inlet of the second cartridge is connected,
the second cartridge comprising an inlet, a diverter, a body, an outlet, and a second porous solid matrix including a reducing agent,
the second porous solid matrix being positioned within the second cartridge such that there is a space between the body of the second cartridge and the second porous solid matrix wherein the second porous solid matrix includes an open passage parallel to the length of the body of the second cartridge; and
an inerting chamber including a mixture including a nitrogen dioxide inerting material, wherein the inerting chamber connects the first cartridge and the second cartridge and is within the sealed housing.

US Pat. No. 10,213,571

COMPONENT FOR MEDICAL CIRCUIT

1. A medical tube comprising:a tube wall comprising a first end and a second end and defining a passageway that provides fluid communication between the first end and the second end;
one or more first preformed components;
one or more second preformed components; and
a cuff having a unitary construction and over-moulded about the one or more first preformed components, the one or more second preformed components, and at least a portion of the tube wall such that a first portion of the cuff forms a permanent connection with the at least a portion of the tube wall at a first over-moulded joint and a second portion of the cuff forms a permanent connection with the one or more first preformed components at a second over-moulded joint,
wherein the one or more first preformed components define a longitudinal axis, wherein the one or more first preformed components are spaced apart from the at least a portion of the tube wall along the longitudinal axis to form a gap therebetween, wherein the cuff extends across the gap and connects the one or more first preformed components and the tube wall, and wherein the one or more second preformed components are located longitudinally between and spaced from the one or more first preformed components and the at least a portion of the tube wall, the one or more second preformed components being seated within and separate from the cuff, the cuff forming a pneumatic seal about the tube wall, the one or more first preformed components and the one or more second preformed components;
wherein the one or more first preformed components are in fluid communication with the passageway and configured for fluid connection with one or more second components of a breathing circuit, and the one or more second preformed components are receivable of one or more auxiliary medical tube appliances.

US Pat. No. 10,213,570

PATIENT INTERFACE DEVICE WITH AUTO-ADJUSTING CUSHION

KOININKLIJKE PHILIPS N.V....

1. A method of adjusting a patient interface device structured to deliver a flow of breathing gas to an airway of a patient, comprising:(a) donning the patient interface device, wherein the patient interface device includes:
a frame member comprising a generally annular central member defining a central orifice, a first main arm extending from a first side of the central member, and a second main arm extending from a second side of the central member, the frame member being a unitary structure and defining a first orifice and a second orifice; and
a cushion having a main body, a sealing portion coupled to the main body, an end opposite the sealing portion, and a first post extending from a first side of the main body and a second post extending from a second side of the main body, wherein the end is structured to receive the flow of breathing gas and is received through the central orifice, wherein the first post is rotateably received within the first orifice and the second post is rotateably received within the second orifice in a manner that permits the cushion to rotate relative to the frame member; and
(b) causing the cushion to rotate relative to the frame member when the sealing portion is engaged with the face of the patient.

US Pat. No. 10,213,569

BREATHING MASK WITH A SEALING LIP DEVICE

1. A mask to administer breathable gas to a user, the mask comprising:a body structure having a connection opening to connect to a line device to deliver the breathable gas;
a sealing lip device configured to seal against the user's face, the sealing lip device joined to the body structure, and the sealing lip device having an upper bridge portion configured to cross the bridge of the user's nose in use, a pair of side portions configured to be positioned along corresponding side surfaces of the user's nose in use, and a lower bridge portion configured to cross the user's upper lip or chin region in use; and
a pair of elongated gel cushions, each of the pair of elongated gel cushions positioned in a corresponding one of the pair of side portions.

US Pat. No. 10,213,568

NASOPHARYNGEAL CANNULA FOR SIDE-STREAM CAPNOGRAPHY

Deltamedics, Gouvieux (F...

1. A nasopharyngeal cannula comprising a body formed by a tubular portion that is curved, and by a collar, the cannula comprising a main conduit forming a fluid passage between the collar and the tubular portion of the body, and two auxiliary conduits which are formed in the body and extend from the collar into the main conduit, characterized in that each auxiliary conduit opens into the collar at an input/output orifice oriented radially with respect to an axis of the main conduit so as to be oriented laterally on each side of a patient's nostril.

US Pat. No. 10,213,567

EASILY REMOVABLE INTUBATING LMA

1. An airway assembly comprising: a flexible airway tube having a proximal aperture and a distal aperture; said distal aperture coupled with a bowl of a mask having a proximal end and a distal end; a rim of said mask forming a cuff, said cuff surrounding an orifice of said bowl; wherein said bowl and cuff adapted to conform to a patient's supraglottic structures; a proximal end of said cuff being adjacent from said distal aperture and said distal end being a point on said cuff furthest away from said distal aperture; wherein a point where said distal aperture coupled with said bowl of said mask is located is substantially closer to said proximal end of said mask; said flexible airway tube having a hollow channel beginning from said proximal aperture and terminating at said distal aperture, wherein said distal aperture opening into said orifice, said hollow channel being a conduit for an endotracheal tube and scoping tools threaded through said hollow channel into said orifice; a fissure line disposed on a bottom side of said flexible airway tube originating from said proximal aperture until said proximal end; said fissure line of said flexible airway tube continuing in a substantially straight line over said proximal end of said cuff; said fissure line held closed with an elastic membrane; and wherein said elastic membrane capable of sustaining a degree of expansion before splitting along said fissure line; a flap having a right and left ends and a proximal edge and a distal edge; wherein said fissure line passes beneath said flap in between said right end and said left end; wherein said distal edge disposed adjacent to a base of said cuff facing said orifice and said proximal edge reaching a rim of said cuff; and wherein said right end or said left end of said flap permanently attaching to a surface of said cuff and wherein an unattached end of said flap loosely covering said fissure line.

US Pat. No. 10,213,566

SYSTEMS AND METHODS FOR PROVIDING RESPIRATORY THERAPY WITH VARYING FLOW RATES

VAPOTHERM, INC., Exeter,...

1. A system for providing respiratory therapy to a patient comprising:a source of breathing gas;
a patient interface comprising an inlet port configured to receive a flow of breathing gas from the source of breathing gas and an outlet port configured to deliver the flow of breathing gas to the patient; and
a flow control device in communication with the flow of breathing gas, the flow control device configured to automatically change a rate of the flow of breathing gas,
wherein the flow control device is configured to periodically vary the rate of the flow of breathing gas between a high flow rate and a low flow rate at a frequency slower than a frequency of breathing of the patient without being caused to do so by the patient, wherein the high flow rate is higher than the low flow rate, and wherein the flow control device maintains the high flow rate and the low flow rate for predetermined periods of time prior to automatically changing the rate of the flow of breathing gas.

US Pat. No. 10,213,565

RESPIRATORY PHYSIOTHERAPY DEVICE

HOUWELING POTTER PTY LTD ...

1. A portable standalone device to treat a patient using positive expiratory pressure therapy, said device comprising:a container adapted to hold a liquid;
an air inlet adapted to allow entry of air into the container; and
an air outlet adapted to allow air to vent from the container;
wherein the air inlet comprises a fixed conduit that has an outlet within the container adapted to discharge exhaled air;
wherein the container comprises a cap and a body and the container cap and body are sealed together by a rotatable collar and the collar has an aperture adapted to align with the air outlet on the container to allow air to vent from the container when in use;
wherein the conduit outlet is in a fixed position that does not change based on a level of the liquid within the container and the fixed position is adapted to be below the level of the liquid when the device is in use by the patient;
wherein the level of the liquid within the container determines a level of positive expiratory pressure experienced by the patient when exhaling into the air inlet; and
wherein the positive expiratory pressure is changed by changing the level of the liquid in the container with the introduction of additional liquid to the container or removal of a volume of the liquid from the container while the conduit outlet remains in a fixed position irrespective of the liquid level.

US Pat. No. 10,213,564

BIOMEDICAL AURAL DELIVERY SYSTEMS AND METHODS

1. An inner ear treatment delivery device, comprising:a cylindrical pressurized vessel containing a substance;
a control valve within the pressurized vessel;
a flexible seal within the pressurized vessel;
a nozzle directly attached to an outer surface of a first end of the pressurized vessel and in fluid communication with the control valve, wherein the control valve is used to fill the pressurized vessel with the substance and deliver the substance to a patient's inner ear through the nozzle;
a microprocessor adapted to operate the control valve; and
a power source providing energy to the delivery device;
wherein the microprocessor and the power source are coupled externally to a second opposite end of the pressurized vessel; and
wherein the device has a length such that an entirety of the length of the device is capable of being non-invasively insertable and removable from a patient's ear canal without piercing the patient.

US Pat. No. 10,213,563

DRIVE MECHANISM FOR AN INJECTION DEVICE

1. An injection device for self-administration of settable doses of a liquid drug comprising:a housing grippable by a user,
a dose setting element by which the size of the dose is set,
a needle cannula having a distal tip for penetrating the skin of the user during injection,
a needle shield which is telescopically movable in a proximal direction from a first position to a second position and in a distal direction from the second position back to the first position by a resilient element, and wherein the needle shield in the first position is extended distally to cover at least the distal tip of the needle cannula and in the second position is retracted proximally to expose the distal tip of the needle cannula,
a rotatable scale sleeve indicating the size of the set dose which scale sleeve is helically guided relatively to the housing, the scale sleeve being helically moved away from an initial “zero” position during dose setting and helically returned to the same initial “zero” position during dose injection,
wherein a stopping structure interconnects the needle shield and the scale sleeve, which stopping structure engages the scale sleeve when the scale sleeve is in the “zero” position such that the needle shield is prevented from being moved in the proximal direction from the first position and into the second position but is allowed to be moved in the distal direction from the second position and into the first position, and
wherein the needle shield carries the stopping structure such that the needle shield and the stopping structure move together at least in the axially direction.

US Pat. No. 10,213,562

VACCINATION SYRINGE

UNL Holdings LLC, New Yo...

1. A replaceable needle assembly for a retractable syringe comprising a plunger and a barrel that comprises a mounting member, the replaceable needle assembly comprising:a needle mount that is removably mountable to the mounting member of the barrel;
a retractable needle including a cannula and a needle body that is removably mountable to the needle mount, the needle body being engageable by the plunger to facilitate retraction of the retractable needle from the needle mount; and
a needle retainer that releasably engages the needle body of the retractable needle to prevent inadvertent retraction of the retractable needle, the retractable needle extending both proximally and distally from the needle mount and needle retainer prior to retraction;
wherein the needle retainer permits retraction of the retractable needle solely in response to a retraction force applied by the plunger when engaged with the needle body.

US Pat. No. 10,213,561

MEDICAL NEEDLE COVER ARRANGEMENT

TIP-TOP.COM LTD, (GB)

1. A medical needle cover arrangement comprising:a syringe having a syringe barrel provided with a needle hub at a forward end thereof;
a medical needle having a sharp tip mounted on the needle hub to project forwardly therefrom;
a needle shield in the form of a sleeve having a diameter greater than a diameter of the syringe barrel, wherein the sleeve is slideably coupled to the syringe, and the needle shield is configured to transition between an initial shielding position and a non-shielding position, a forward end of the needle shield having an opening and a lip reducing an inside diameter of the needle shield; and
a soft needle cover overlying the needle, the soft needle cover including:
a forward portion extending beyond the needle shield and a rearward portion disposed within the needle shield such that the soft needle cover extends throughout the opening;
a step engaging the lip; and
a formation engaging the needle hub to effect a substantially airtight seal therebetween, wherein inter-engagement of the step with the lip and the formation with the needle hub subjects at least a portion of the soft needle cover to a compressive force along a longitudinal axis of the medical needle;wherein:the soft needle cover is resilient such that it is compressible radially to allow the step to pass through the opening and permit removal of the cover from the shield with the shield remaining coupled to the syringe.

US Pat. No. 10,213,560

INJECTION DEVICE

Sanofi, Paris (FR)

1. An injection device comprisinga housing;
a dose setting member being movable in a first direction relative to the housing to set a desired dose to be dispensed during dose setting and being operable in a second direction relative to the housing to cancel a set dose during dose cancelling;
a piston rod being adapted to engage a piston to eject the set dose from a cartridge during dose dispensing;
a feedback mechanism comprising a first part and a second part, the first part being adapted to rotate within the housing and relative to the housing during the dose setting, and the first part and the second part being rotatable relative to one another during the dose dispensing and adapted to generate a non-visual signal to a user only at an end of the dose dispensing; and
a third part movable between a dose setting position or a dose cancelling position and a dose dispensing position relative to the feedback mechanism, the third part being configured to contact the feedback mechanism in the dose setting position and the dose dispensing position.

US Pat. No. 10,213,559

DRUG DELIVERY DEVICE WITH BRAKE MECHANISM

1. A drug delivery device comprising or being adapted to receive a cartridge, the cartridge comprising a cylindrical body portion, an axially displaceable piston, and a distal outlet portion, the drug delivery device comprising:a housing,
an expelling assembly adapted to axially move the piston of a cartridge to thereby expel a dose of drug, comprising:
a drive spring which in an energized state is adapted to drive the expelling assembly,
a rotating component adapted to rotate relative to an axis of rotation during expelling of a dose of drug,
a user actuated release structure for releasing the drive spring to thereby expel a dose of drug,the device further comprising a brake element being moveable in a plane perpendicular to the axis of rotation, the brake element being adapted to engage the rotating component such that during rotation thereof the brake element is moved back and forth by the rotating component, whereby the brake element provides a braking action on the rotating component,wherein the brake element(s) is/are arranged non-rotational relative to the housing.

US Pat. No. 10,213,557

MEDICAMENT DELIVERY DEVICE AND METHOD OF CONTROLLING THE DEVICE

Sanofi-Aventis Deutschlan...

13. A method of controlling a medicament delivery device for the administration of one or more drug agents, wherein the device has (i) a priming mode for discharging air or a residual medicament from the device and (ii) a drug delivery mode for administering delivery of a dose of the medicament, wherein the device has a plurality of states including one or more first states and one or more second states, wherein the device has a user interface having a priming button for activating the priming mode and a dose-delivery button for activating the drug delivery mode, the method comprising:determining whether the device is in at least one of the one or more first states;
responsive to determining that the device is in at least one of the one or more first states, enabling the priming mode via the priming button of the user interface and disabling the drug delivery mode via the drug-delivery button of the user interface during the at least one of the one or more first states, wherein enabling the priming mode and disabling the drug-delivery mode sets the device in a mandatory priming mode, and wherein during the mandatory priming mode the dose of the medicament cannot be delivered;
determining whether the device is in at least one of the one or more second states; and
responsive to determining that the device is in at least one of the one or more second states, enabling the priming mode via the priming button of the user interface and enabling the drug delivery mode via the drug-delivery button of the user interface during the at least one of the one or more second states.

US Pat. No. 10,213,556

ACCURATE DOSE CONTROL MECHANISMS AND DRUG DELIVERY SYRINGES

UNL Holdings LLC, New Yo...

1. A dose control mechanism for a syringe comprising:a housing having a longitudinally extending channel having an interior surface;
an adapter including a channel having a fine pitch thread,
a plunger having an exterior surface and an axially extending channel, the axially extending channel including a first key aspect;
a screw having a screw exterior surface, a proximal end of the screw disposed at least partially within the axially extending channel of the plunger, the screw exterior surface including a second key aspect along a proximal portion of the screw exterior surface, at least a portion of the second key aspect disposed within the axially extending channel of the plunger and engaging the first key aspect for sliding movement such that rotational movement of the plunger causes rotational movement of the screw, a distal portion of the screw exterior surface including a fine pitch thread at least partially disposed within and interfacing with the fine pitch thread of the adapter; and
an engaging screw thread arrangement including at least one thread segment and a variable pitch thread, at least a portion of the longitudinally extending channel of the housing including one of the variable pitch thread and the at least one thread segment, the plunger including the other of the variable pitch thread and the at least one thread segment, the plunger residing at least partially within the housing with the at least one thread segment engaged with the variable pitch thread.

US Pat. No. 10,213,555

SYRINGE HAVING A MECHANICALLY OPERATED MECHANISM FOR INJECTING PRECISE VOLUMES OF A SOLUTION

1. A syringe, comprising:a barrel having an inner surface;
a plunger having an elongated body, a proximal end, and a distal end, the distal end being disposed within the barrel, wherein the distal end forms a fluid-impermeable seal with the inner surface of the barrel;
an ejection mechanism in a mechanical communication with the plunger, the ejection mechanism having an actuator, the actuator having a first non-depressed position and a second depressed position, whereby responsive to displacement of the actuator from the first non-depressed position to the second depressed position, the distal end of the plunger moves by a predetermined distance within the barrel;
wherein the plunger is configured to translate linearly within the barrel responsive to a force being applied onto the proximal end of the plunger, thereby enabling manual operation of the syringe while the actuator remains in the first non-depressed position or the second depressed position.

US Pat. No. 10,213,554

ACCESSORY DEVICE WITH MOUNTING SAFETY FEATURE

1. An assembly comprising a drug delivery device and a logging module adapted to create a log of expelled dose amounts of drug, the logging module being adapted to be mounted on the drug delivery device from a fully un-mounted to a fully mounted position along a path, the drug delivery device comprising:a drug reservoir or structure for receiving a drug reservoir,
dose setting structure, and
drug expelling structure for expelling a set dose,the logging module comprising electronic circuitry comprising:sensor structure adapted to capture a property value related to a dose amount of drug expelled from a reservoir by the expelling structure during an expelling event,
processor structure adapted to determine dose amounts based on captured property values,
a switch operatable between an off- and an on-state when the logging module is mounted on the drug delivery device, the switch being in the on-state when the logging module is mounted within a first distance from the fully mounted position, and in the off-state when the logging module is mounted outside the first distance from the fully mounted position, andthe assembly comprising:a snap lock comprising co-operating mating structures arranged on the logging module respectively the drug delivery device, the snap lock being operatable from an initial state through an expanded state to a snap-in state when the logging module is mounted on the drug delivery device, the snap lock being in the snap-in state when the logging module is mounted within a second distance from the fully mounted position,wherein:the second distance is shorter than the first distance to ensure that the switch will be in the on-state before the snap lock is in the snap-in state, and
the electronic circuitry with the switch in the on-state is adapted to detect an error condition corresponding to a state in which the logging module is not in a mounted position with the snap lock in the snap-in state.

US Pat. No. 10,213,553

LEVER AND GEAR FORCE MULTIPLIER MEDICATION DELIVERY SYSTEM FOR HIGH PRESSURE INJECTION SYSTEM

Becton, Dickinson and Com...

1. A method of delivering high pressure medication injections, the method comprising:storing a medicament in a cartridge;
connecting a lever assembly to a rack, said rack being curved when said cartridge is substantially full of medicament;
rotating a lever arm in said lever assembly;
rotating a dose setting wheel to set a medicament dose;
moving said lever arm from a first position to a second position when said dose setting wheel is rotated to set the medicament dose;
rotating said dose setting wheel in a direction opposite to that in which the medicament dose was set, wherein the rotating of said dose setting wheel in the direction opposite to that in which the medicament dose was set moves said lever arm to correct the medicament dose;
engaging said dose setting wheel to a lever tab of said lever assembly;
moving said rack along a curvilinear path to move a stopper through said cartridge upon rotation of said lever arm;
expelling said medicament dose from said cartridge via movement of said stopper; and
injecting said medicament dose through a needle that communicates with said cartridge.

US Pat. No. 10,213,552

RESETTABLE DRUG DELIVERY DEVICE

Sanofi-Aventis Deutschlan...

1. A resettable drug delivery device for dispensing one or more doses of a drug, comprising:a housing having a longitudinal axis,
a piston rod having a start position relative to the housing and being resettable to the start position after dispense of the one or more doses, wherein, during resetting the piston rod, the piston rod is moved backwards in a proximal direction to the start position relative to the housing,
a drive member for driving the piston rod in a dispense operation of the drug delivery device in a distal direction of the drug delivery device and
a dose member for actuating the drive member, wherein the dose member comprises a dose button accessible to the user and fixed to the dose member or forming an integral part of the dose member,
wherein the drug delivery device is configured such that at least at one point in time during resetting the piston rod, the dose member is in a pulled-out position relative to the housing,
wherein the dose member is in the pulled-out position relative to the housing already before resetting the piston rod or is moved towards the pulled-out position relative to the housing during resetting the piston rod,
wherein the dose member is constrained to an axial movement along the longitudinal axis and operable such that for setting one dose the dose button is either pulled or pushed by the user and for dispensing one dose the dose button is pushed by the user, and
wherein the drug delivery device is a fixed-dose drug delivery device.

US Pat. No. 10,213,551

ALGORITHM FOR REMOVAL OF NOISE DURING ADMINISTRATION OF FLUID TO A PATIENT

Board of Regents, the Uni...

1. A medical fluid monitor system, comprising:a hanger configured to suspend a container of a fluid to be intravenously administered to a patient;
a force transducer coupled to the hanger and configured to generate a signal that is proportional to a weight of the fluid in the container;
a display configured to present one or more fluid administration parameters indicative of the fluid intravenously administered to a patient; and
a controller configured to execute logic to iteratively:
receive a value corresponding to the signal;
update each of a plurality of candidate solutions based on the received value, wherein each candidate solution is a representation, comprised of one or more line segments, of a set of values corresponding to the signal at previous times;
generate one or more additional candidate solutions to be included in the plurality of candidate solutions;
determine a cost of each of the plurality of candidate solutions;
eliminate candidate solutions having a cost that exceeds a cost threshold;
compute one or more fluid administration parameters based on a first candidate solution, wherein the first candidate solution is selected based on its cost; and
present the one or more fluid administration parameters via the display.

US Pat. No. 10,213,550

SYSTEMS AND METHODS FOR MONITORING CLINICAL PROCEDURES USING REGIONAL BLOOD OXYGEN SATURATION

Covidien LP, Mansfield, ...

17. A physiological monitoring system comprising:a signal input configured for receiving clinical information for a subject that indicates that the subject is undergoing a clinical procedure that affects a circulatory system of the subject; and
one or more processors configured for:
monitoring regional blood oxygen saturation (rSO2) in a region of the subject that is affected by the clinical procedure;
detecting one or more changes in the rSO2 in the region of the subject;
determining status information associated with the subject that indicates an increased risk of a physiological event caused by the clinical procedure when (a) the one or more changes in the rSO2 in the region of the subject exceeds a threshold and (b) the clinical information indicates that the subject is undergoing the clinical procedure; and
triggering an action based on the status information.

US Pat. No. 10,213,549

DRUG DELIVERY DEVICE AND METHODS THEREFOR

PICOLIFE TECHNOLOGIES, LL...

1. A drug delivery device, comprising:a delivery pump system, said delivery pump system comprising a plurality of electromagnetic coils, a controller electrically coupled to said plurality of electromagnetic coils, and a power source;
a cartridge system, said cartridge system comprising:
a first reservoir and a second reservoir, said first reservoir and said second reservoir each having a substantially symmetrical body with a top end, and an opening formed in said top end;
a first inlet/outlet member securely engaged to said first reservoir, said first inlet/outlet member having a fluid receiving opening, a fluid discharge opening, and a fluid outlet component, said fluid receiving opening in fluid communication with said first reservoir and said fluid outlet component in fluid communication with said fluid discharge opening;
a second inlet/outlet member securely engaged to said second reservoir, said second inlet/outlet member having a fluid receiving opening, a fluid discharge opening, and a fluid outlet component, said fluid receiving opening in fluid communication with said second reservoir, and said fluid outlet component in fluid communication with said fluid discharge opening;
a first pump body insert having a fluid receiving opening, a fluid discharge opening, a plurality of inlet channels, and a plurality of outlet channels, said fluid receiving opening in fluid communication with said plurality of inlet channels, said plurality of inlet channels in fluid communication with said plurality of outlet channels, and said plurality of outlet channels in fluid communication with said fluid discharge opening;
a second pump body insert having a fluid receiving opening, a fluid discharge opening, a plurality of inlet channels, and a plurality of outlet channels, said fluid receiving opening in fluid communication with said plurality of inlet channels, said plurality of inlet channels in fluid communication with said plurality of outlet channels, and said plurality of outlet channels in fluid communication with said fluid discharge opening;
a pump membrane, said pump membrane being between said first pump body insert and said second pump body insert; and
a plurality of magnets, said plurality of magnets having a distal end, a proximal end and a cylindrical body connecting said distal and proximal ends, and said proximal end being in contact with said pump membrane and said distal end being housed within one of said first and second pump body inserts;
wherein said plurality of magnets and said plurality of electromagnetic coils are axially aligned,
wherein said fluid receiving opening of said first pump body insert is in fluid communication with said fluid receiving opening of said first inlet/outlet member, and said fluid discharge opening of said first pump body insert is in fluid communication with said fluid discharge opening of said first inlet/outlet member, and
wherein said fluid receiving opening of said second pump body insert is in fluid communication with said fluid receiving opening of said second inlet/outlet member, and said fluid discharge opening of said second pump body insert is in fluid communication with said fluid discharge opening of said second inlet/outlet member.

US Pat. No. 10,213,548

SYSTEMS AND METHODS FOR AUTOMATIC TERMINATION OF FLOW DUE TO NEEDLE DISLODGEMENT

Hemotek Medical Incorpora...

1. An apparatus for automatic termination of flow for fluid delivery, the apparatus comprising:a housing configured for coupling a fluid delivery tube to a needle configured for subcutaneous delivery of fluid within a tissue of a patient;
a spring-loaded activation mechanism coupled to the housing;
wherein the spring-loaded activation mechanism comprises a first orientation corresponding to a condition where the housing is disposed substantially adjacent to the tissue and the needle is lodged within the tissue;
wherein the spring-loaded activation mechanism comprises a second orientation corresponding to a condition where the housing is disposed away from the tissue or the needle is dislodged from the tissue;
a flow termination mechanism coupled to the spring-loaded activation mechanism;
wherein the flow termination mechanism comprises an open configuration allowing flow from the fluid delivery tube to the needle when the spring-loaded activation mechanism is in the first orientation;
wherein the flow termination mechanism comprises a closed configuration substantially terminating flow from the fluid delivery tube to the needle when the spring-loaded activation mechanism is in the second orientation;
wherein the spring-loaded activation mechanism comprises a contact member configured to be disposed adjacent the patient's skin when the spring-loaded activation mechanism is in the first orientation;
wherein the contact member articulates with respect to the housing to the second orientation; and
wherein the flow termination mechanism comprises a pinch valve that substantially terminates flow from the fluid delivery tube to the needle when the spring-loaded activation mechanism is in the second orientation.

US Pat. No. 10,213,546

DEVICES AND METHODS FOR DELIVERING A BENEFICIAL AGENT TO A USER

ABBVIE INC., North Chica...

1. A device for delivering a beneficial agent, comprising:a pump including a pump housing containing a pump assembly having a fluid drive component, the pump housing having a receiving region disposed proximate the fluid drive component, the pump housing comprising a rear closure portion including a membrane disposed between the receiving region and the fluid drive component; and
a cassette including a cassette housing comprising a cassette body region defining a fluid reservoir chamber therein and a delivery tube assembly extending from the fluid reservoir chamber, the cassette further including a cassette base region having a boundary configured to be received by the receiving region;
wherein the delivery tube assembly comprises a peristaltic tube that engages an occlusion sensor proximate the rear closure portion when the cassette base region boundary is received by the receiving region, and the membrane includes an occlusion sensor protrusion configured to cover a portion of the occlusion sensor.

US Pat. No. 10,213,545

BODY-WALL-CONTACT-TYPE WATER TANK AND IN-CAVITY FLUID PERFUSION SYSTEM

NIKKISO COMPANY, LTD., T...

1. A body-wall-contact-type water tank comprising:a water tank main part that includes a bottom-most surface, the bottom-most surface of the water tank main part being configured to be in contact with an outer surface of a patient's body wall for retaining a liquid that is fed into a body cavity of the patient;
a through hole formed in the bottom-most surface of the water tank main part, the through hole being configured to direct the liquid retained in the water tank main part into the patient's body cavity via an incision that is made on the patient's body wall, and
a flange section outwardly extended from an outer circumferential edge of the bottom-most surface of the water tank main part, an entirety of the flange section being disposed outside the water tank main part,
wherein the flange section is formed of a flexible material that is capable of following the outer surface of the patient's body wall, and the flange section is configured to be brought into close contact with the outer surface of the patient's body wall to provide a liquid-tight connection between the water tank main part and the patient's body wall to prevent the leakage of liquid between the patient's body wall and the water tank main part.

US Pat. No. 10,213,543

BLOOD PURIFICATION COLUMN

Toray Industries, Inc., ...

1. A blood purification column comprising an adsorbent and a casing whose two ends are open ends, wherein the adsorbent is housed inside the casing, and wherein one of two casing ends is a blood inflow-side end portion and the other of the two casing ends is a blood outflow-side end portion, and wherein a mesh filter is disposed at the blood inflow-side end portion and/or the blood outflow-side end portion of the casing, and wherein the mesh filter satisfies (1)-(6):(1) an opening rate thereof is greater than or equal to 21% and less than or equal to 66%;
(2) an equivalent diameter of an aperture thereof is greater than or equal to 10 ?m and less than or equal to 400 ?m;
(3) a ratio of the equivalent diameter of the aperture thereof to an average circle equivalent diameter of void spaces of the adsorbent is greater than or equal to 56% and less than or equal to 220%;
(4) the absorbent is in a hollow yarn and/or a solid yarn form;
(5) the adsorbent is disposed parallel to a column lengthwise direction; and
(6) a surface area of a portion open in a perpendicular direction relative to a lengthwise direction in the column is B1 and a total surface area of a portion open in a parallel direction relative to the lengthwise direction in the column is B2, wherein B1/B2 ?1.

US Pat. No. 10,213,542

SYSTEMS AND METHODS FOR FLOW STAGNATION CONTROL

Asia Pacific Medical Tech...

1. A method comprising:coupling an extracorporeal circuit to a portion of a body of a patient, the extracorporeal circuit comprising:
a flow port to return blood from the extracorporeal circuit to a vasculature at a region of the body;
an injector member coupled to the flow port, the injector member comprising a distal tip and a shaft having a lumen;
a controlled partitioning flow system, the system comprising:
at least a first pressure sensor disposed proximate to the distal tip;
at least a second pressure sensor disposed on an outer surface of the shaft of the injector member; and
an injection flow rate source coupled to the injection member to control a flow of fluid injected at the distal tip of the injector member;
controlling the flow of fluid injected at the distal tip of the injector member, using the injection flow rate source, to a predetermined flow rate pattern over a time interval T;
recording measurements of pressure using the first pressure sensor and second pressure sensor over the time interval T; and
computing at least one of a proximal exterior conductance or a distal exterior conductance at the distal tip of the injector member using data indicative of the measurements of pressure, and the predetermined flow rate pattern.

US Pat. No. 10,213,541

DUAL CHAMBER BLOOD RESERVOIR

Sorin Group Italia S.r.l....

1. A dual chamber blood reservoir comprising:a housing including a lower surface and an upper opening;
a cover spanning the upper opening;
a first vent port extending through the cover;
a second vent port extending through the cover;
a venous port extending through the cover;
a purgers port extending through the cover;
a purgers funnel having an upper portion, a lower portion and an intervening central portion, the upper portion of the purgers funnel in fluid communication with the purgers port;
a defoamer disposed within the housing such that the purgers funnel extends through the defoamer and at least part of the lower portion of the purgers funnel extends below the defoamer; and
a venous tube in fluid communication with the venous port and extending within the purgers funnel to a position near the lower surface of the housing, wherein the lower portion of the purgers funnel is configured to extend alongside a portion of the venous tube, the lower portion of the purgers funnel having an inner diameter that is greater than an outer diameter of the venous tube such that blood exiting the purgers funnel slides down an exterior surface of the venous tube.

US Pat. No. 10,213,540

METHOD AND APPARATUS FOR MACHINE ERROR DETECTION BY COMBINING MULTIPLE SENSOR INPUTS

NXSTAGE MEDICAL, INC., L...

1. A system associated with a medical treatment device for detecting a condition of a patient, the system comprising:an input device including at least one of a camera adapted to gather video/image data and a microphone; and
a medical treatment device with a controller/classifier and at least one flow controller, a pump, and/or an alarm output; and
the controller/classifier having at least one of a video-image processor and an audio processor adapted to at least one of:
recognize a face and a body in said video/image data and further to recognize changes in skin color, facial expression, or body position and further to output state data indicating the recognized changes or the recognized body position; and
recognize speech and to classify predefined normal and irregular sound patterns and further to output state data corresponding to the recognizing of the speech, wherein
the controller/classifier is connected to apply the state data to the at least one flow controller, pump, and/or alarm output;
the controller/classifier is further adapted to control the at least one flow controller, pump, and/or alarm output responsively to the state data, and
wherein the state data includes data indicating a leak of blood from a patient access.

US Pat. No. 10,213,539

EXTRACORPOREAL BLOOD CIRCUIT WITH NON-INVASIVE PRESSURE SENSOR

Gambro Lundia AB, Lund (...

1. An apparatus configured to remove one or more substances from blood, wherein the apparatus comprises:a primary filter comprising a first semipermeable membrane separating a blood compartment from a dialysate loading compartment;
a blood circuit having a blood line connected to the blood compartment of the primary filter;
a non-invasive pressure sensor configured to directly contact any exposed longitudinal portion of an exterior surface of a circular tube forming the blood line, the non-invasive pressure sensor further configured to sense pressure in the blood line, wherein the non-invasive pressure sensor includes an outer wall forming a groove leading to a sensing portion in direct contact with the exterior surface of the blood line and does not contact liquid in the blood line, the groove narrower than the sensing portion to compress the blood line upon insertion through the groove such that the blood line when uncompressed is held within the sensing portion after the insertion; and
a control unit operably connected to the non-invasive pressure sensor and to control elements of the blood circuit, wherein the control unit is configured to:
monitor a blood circuit pressure value using the non-invasive pressure sensor and operate the control elements of the blood circuit based on the monitored blood circuit pressure value, wherein operating the control elements comprises deactivating the blood pump when the monitored blood circuit pressure indicates that the blood line is not engaged with the non-invasive pressure sensor.

US Pat. No. 10,213,538

IMPLANTED DEVICE WITH WIRELESS ENERGY TRANSFER AND EXTERNAL ALIGNMENT FEATURE

HeartWare, Inc., Miami L...

1. A wireless energy transfer system comprising:an implant device including a housing and an energy receiving element disposed in the housing; and
an external charger including an energy transmitting element and a mating member, the mating member defining a protrusion extending therefrom, the external charger and the housing defining a common axis extending therethrough when the external charger is received by the housing,
wherein the implant device is configured to be mounted within a body of an animal,
wherein the housing comprises a feature having a plurality of sidewalls defining an indentation therebetween, the feature being configured to extend from within the body of the animal to outside the body of the animal through an opening in a skin of the animal and the indentation being configured to physically receive and mechanically align with the protrusion extending from the corresponding mating member of the external charger, and
wherein the energy receiving element is configured to be disposed in a parallel orientation along the common axis with the energy transmitting element, and the energy receiving element being configured to receive energy wirelessly from the energy transmitting element when the external charger is physically-mated with the housing.

US Pat. No. 10,213,537

VENTRICULAR ASSIST DEVICES AND INTEGRATED SENSORS THEREOF

HeartWare, Inc., Miami L...

1. A ventricular assist device for intraventricular placement inside a heart of a mammalian subject comprising:a pump including a housing having an inlet end, an inlet at the inlet end, and an outlet, the pump further including a moveable element disposed in the pump housing for pumping blood from the inlet to the outlet;
a base member;
a spacer member connected to the pump housing and the base member, the base member being positioned a distance from the inlet end of the pump housing to define a gap therebetween; and
one or more sensor elements mounted to at least one from the group consisting of the base member and the housing, the one or more sensor elements being configured to measure one or more blood parameters prevailing within the gap during operation of the pump, the one or more sensor elements include an ultrasonic transducer mounted on at least one from the group consisting of the pump housing and the base element, the other one from the group consisting of the pump housing and the base element has a reflective surface disposed across the gap from the ultrasonic transducer.

US Pat. No. 10,213,536

IMPLANTABLE CONNECTOR ASSEMBLY AND METHOD OF COMMUNICATING AN ELEMENT TO AN IMPLANTABLE DEVICE

CircuLite, Inc., Teaneck...

1. An apparatus for implantation within a patient, comprising;an implantable device configured for being positioned and operating at least subcutaneously within the patient;
a cable configured for communicating an element from a source to the implantable device within the patient; and
an implantable connector assembly for communicating the element from the cable to the implantable device, comprising:
a plug connected to and surrounding at least a portion of the cable, the plug including a plunger body;
a receptacle operatively connected to the implantable device, the receptacle including a sleeve and a stopper, the sleeve defining an opening sized for receiving the plunger body, the stopper resiliently mounted within the sleeve and extended in a first configuration toward the opening to cover and fluidly seal the opening for inhibiting contamination from entering within the sleeve when the plunger body is withdrawn from the sleeve; and
a pair of communication structures positioned respectively on the plunger body and the sleeve, one of the pair of communication structures operatively connecting to the cable for receiving the element from the cable and the other of the pair of communication structures operatively connecting to the implantable device for directing the element to the implantable device, inserting the plunger body into the sleeve displaces the stopper toward a compressed second configuration away from the opening and removably couples the pair of communication structures for communication of the element therebetween; and
the plug includes a groove, and the receptacle includes a holding member, the groove configured to removably receive the holding member, the holding member overcomes a bias imparted on the plunger in the compressed second configuration to retain the plug within receptacle.

US Pat. No. 10,213,535

BREAST PUMP

MURATA MANUFACTURING CO.,...

1. A breast pump comprising:a suction unit adapted to be mounted on a breast;
a suction pump absorbing a fluid from a breast side of the suction unit that is adapted to contact the breast;
a detecting unit detecting a temporal change in a sucked state of the breast by the suction unit; and
a controller performing a processing based on the temporal change in the sucked state detected by the detecting unit,
wherein the detecting unit detects the sucked state of the breast by the suction unit based on a suction pressure of the suction pump,
wherein the suction pump includes a piezoelectric element operated by an application of a driving voltage, and
wherein the detecting unit detects an impedance state of the piezoelectric element and detects the suction pressure of the suction pump based on the detected impedance state of the piezoelectric element.

US Pat. No. 10,213,534

BLOOD PROCESSING FILTER AND BLOOD PROCESSING FILTER MANUFACTURING METHOD

ASAHI KASEI MEDICAL CO., ...

1. A blood processing filter for removing undesirable components from liquid containing a blood component or blood, the filter comprising:a sheet-shaped filter element; and
a container that includes an inlet-side container element and an outlet-side container element that are disposed to clamp the filter element, and has an internal space separated by the filter element into an inlet space and an outlet space,
wherein the filter element includes a filtering surface on a side of the inlet space, a filtering surface on a side of the outlet space, and an end surface along peripheries of the pair of filtering surfaces, and
the inlet-side container element and the outlet-side container element are provided with a gripper, and the gripper clamps and compresses an outer edge portion of the pair of filtering surfaces, and is caused to adhere to the end surface with melt resin,
at the gripper, the filter element is not melted, and
the same material as that of the container is adopted for the melt resin.

US Pat. No. 10,213,533

MEDICAL TOOLS WITH ASPIRATION TIPS SUITABLE FOR CATARACT SURGERIES AND RELATED METHODS

Keith A. Walter, Lewisvi...

1. An aspiration tool for use in combination with a surgical system for cataracts after a phacoemulsification and/or laser disintegration procedure, comprising:a tip having an open leading end that defines an aspiration port, the open leading end located at a distal most end of the tip, the tip sized and configured for removing cortical and/or nuclear lens fragments, tissue and/or fibers; and
a translatable door in communication with the aspiration port configured to extend and retract about the aspiration port, wherein, in an extended position, the door travels forward to occlude the aspiration port,
wherein the door has a door aspiration port extending therethrough, the door aspiration port having a size that is smaller than the aspiration port defined by the open leading end,
wherein the door is flat across the aspiration port defined by the open leading end to completely close the aspiration port defined by the open leading end, and wherein the door aspiration port resides over the aspiration port defined by the open leading end when the door is in the extended position.

US Pat. No. 10,213,524

COATING COMPRISING STRONTIUM FOR BODY IMPLANTS

1. A coating for an implant comprising:a layer comprising strontium oxide and titanium oxide, wherein the Sr-content of said coating is between 5 and 25 at. % and the thickness of said coating is between 200 nm and 3000 nm, and said coating comprises exposed pores wherein at least 50% of said pores have diameters between 0.1 and 50 nm, thereby stimulating osseo-integration and healing in the vicinity of the implant, wherein the layer is configured to release strontium to support osseo-integration.

US Pat. No. 10,213,523

MECHANOCHEMICAL COLLAGEN ASSEMBLY

Northeastern University, ...

1. A method of organizing prefibrillar solution into an organized array of fibrils comprising:providing a collagen and/or elastin solution, wherein the collagen and/or elastin are prefibrils; and
creating a fluid flow through the prefibrillar solution by converging flow produced by hyperbolic contraction of the solution that produces a controlled extensional strain and shear strain to the collagen and/or elastin prefibrils,
wherein the extensional and shear strain are sufficient to induce the prefibrils to assemble into an organized array of fibrils.

US Pat. No. 10,213,520

SURGICAL ADJUNCTS HAVING MEDICANTS CONTROLLABLY RELEASABLE THEREFROM

Ethicon LLC, Guaynabo, P...

1. A staple cartridge assembly for use with a surgical stapler, comprising:a cartridge body having a plurality of staple cavities, each staple cavity having a surgical staple disposed therein;
a biocompatible adjunct material releasably retained on the cartridge body and configured to be delivered to tissue by deployment of the staples in the cartridge body, the adjunct material being at least partially formed of a biocompatible polymeric material; and
an effective amount of at least first and second medicants disposed within and releasable from the adjunct material, the first medicant having a first size and the second medicant having a second size larger than the first size, wherein the polymeric material of the adjunct material is responsive to at least one environmental condition upon delivery of the adjunct material to tissue such that the at least one environmental condition to which the adjunct material is subjected affects an elution profile of the at least first and second medicants such that the first and second medicants are configured to respond differently to the at least one environmental condition relative to each other,
wherein the at least one environmental condition includes strain, and the biocompatible adjunct material incudes mesh having a pore size that is configured to increase as the mesh experiences strain, the first and second medicants are disposed within the mesh, the mesh is configured to release the first medicant as the pore size reaches the first size, and the mesh is configured to release the second medicant as the pore size reaches the second size.

US Pat. No. 10,213,519

FRAGRANCE DISPENSER FOR AIR FILTER

3M Innovative Properties ...

1. An assembly comprising a framed air filter and at least one fragrance dispenser mounted in proximity thereto, the assembly comprising;a framed air filter with a perimeter frame, an upstream face with an airstream-receiving area and a downstream face,
and,
a fragrance dispenser comprising:
a base comprising at least one receptacle with a major closed end and a major open end;
a porous diffuser layer occlusively overlying the major open end of the at least one receptacle;
and,
a fragrance source provided within at least a portion of the receptacle and that comprises at least one volatilizable fragrance,
wherein the fragrance dispenser is positioned so that the at least one receptacle is proximate the airstream-receiving area of the upstream face of the air filter, with the major closed end of the receptacle facing at least generally upstream and with the major open end of the receptacle facing at least generally downstream toward the upstream face of the filter.

US Pat. No. 10,213,517

SYSTEM FOR FLUID STERILIZATION

1. A system for fluid sterilization, comprising:an inlet for operative connection to a fluid source to provide fluid along a flow path for sterilization by the system;
a heating section in fluid communication with the inlet along the flow path, the heating section heats pressurized fluid therein above prescribed thresholds for temperature, pressure, and dwell time to achieve a desired level of sterilization;
a heat exchanger having a first path disposed in fluid communication between the inlet and the heating section along the flow path to preheat fluid prior to entering the heating section and having a second path positioned between the heating section and a system outlet along the flow path to cool outflow of the heating section prior to exiting the outlet, wherein the first path and the second path of the heat exchanger are configured to pass heat energy therebetween; and
a plurality of valves disposed along the flow path, including a first valve positioned downstream of the inlet and upstream of the first path of the heat exchanger, a second valve positioned downstream of the first path of the heat exchanger and upstream of the heating section, and a third valve disposed along the flow path configured for proportional control of fluid flow therethrough;
a plurality of sensors disposed along the flow path, including (a) a temperature sensor positioned on the flow path downstream of the heating section and upstream of the second path of the heat exchanger, and (b) a pressure sensor; and
a digital controller in operative communication with the plurality of sensors to receive measurements therefrom and in operative control of at least the third valve to control flow through the system to ensure prescribed pressure and temperature profiles across prescribed ranges for pressure and temperature to achieve the desired level of sterilization without need of maintaining a fixed temperature or a fixed pressure within any portion of the system, including the heating section.

US Pat. No. 10,213,516

LABELLED CARBOXYLIC ACIDS AND THEIR USES IN MOLECULAR IMAGING

1. A composition comprising a tracer, wherein the tracer is a radionuclide-labelled 2,2-di-C1-4-alkylpropanoic acid, 2,2-di-C1-4-alkylbutanoic acid, 2,2-di-C1-4-alkylpentanoic acid, or the corresponding carboxylate, wherein the radionuclide-labelled carboxylic acid is a compound of formula (I):
Wherein
Q is a suitable radionuclide;
CL is selected from [11C]carbon, [12C]carbon, or [13C]carbon;
n is 1, 2, or 3;
R1 and R2 are independently C1-4-alkyl; and
R3 and R4 are independently H or F.

US Pat. No. 10,213,510

LONG-ACTING POLYMERIC DELIVERY SYSTEMS

Heron Therapeutics, Inc.,...

1. A semi-solid composition, comprising: a biodegradable polyorthoester, 1 wt % to 10 wt % bupivacaine, and 0.01 wt % to 1 wt % meloxicam, wherein the polyorthoester is represented by Formula I:
where:
R* is a C1-4 alkyl,
n is an integer ranging from 5 to 400, and
A is a diol, where A is R1 and/or R3, where the fraction of A units that are of formula R1 is between 0 and 25 mole percent, where
when A is R3, R3 is
where x is 2; andwhen A is R1, R1 is
R5 is H, and R6 isthe sum of p and q is, on average, 2 and s is 2,where the resulting component of the polyorthoester comprises the subunit

US Pat. No. 10,213,506

TARGETING IMMUNOTHERAPY FOR AMYLOIDOSIS

UNIVERSITY OF TENNESSEE R...

1. A method of targeting an amyloid deposit for clearance, comprising: contacting an amyloid deposit of a first amyloid type with an amyloid-reactive fusion peptide, wherein the amyloid-reactive fusion peptide comprises an amino acid that is at least 95% identical to any one of the amino acid sequences set forth as SEQ ID NOS: 1-17 and an epitope; and, contacting the amyloid-reactive fusion peptide with an antibody or functional fragment thereof, wherein the antibody or functional fragment thereof is immunoreactive to a second amyloid type that is different than the first amyloid type and wherein the epitope of the amyloid-reactive fusion peptide directs the antibody or functional fragment thereof to the first amyloid type, thereby targeting the first amyloid deposit for clearance.

US Pat. No. 10,213,491

GLUCOSE OXIDASE COMPOSITIONS AS A NEONATE ANTICONVULSANT

The Penn State Research F...

1. A method, comprising:a) providing;
i) a neonatal patient comprising glucose and exhibiting convulsions; and
ii) a composition comprising an effective amount of glucose oxidase; and
b) administering said composition to said patient under conditions such that said convulsions are reduced.

US Pat. No. 10,213,478

COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS

The Translational Genomic...

1. A method of treating a subject having an infection caused by Coccidioides, the method comprising the step of administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising a fungicidal agent or fungistatic agent selected from the group consisting of: (±)-Octoclothepin maleate, Thioridazine hydrochloride, Fluphenazine dihydrochloride, GBR-12909 dihydrochloride, GBR-12935 dihydrochloride, and Indatraline hydrochloride.

US Pat. No. 10,213,477

PEPTIDOMIMETIC MACROCYCLES

Aileron Therapeutics, Inc...

1. A method for treating a cancer, comprising administering to a subject with the cancer a therapeutically effective amount of a pharmaceutical product comprising:(a) a first therapeutic agent comprising an inhibitor of an interaction between p53 and MDM2 and/or an inhibitor of an interaction between p53 and MDMX, and
(b) a second therapeutic agent comprising a chemotherapeutic agent;
wherein the first therapeutic agent is a peptidomimetic macrocycle comprising an amino acid sequence with at least about 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ IP NOs: 10-457, or pharmaceutically acceptable salt thereof; and wherein the peptidomimetic macrocycle has a Formula:
wherein:each of Xaa3, Xaa5, Xaa6, Xaa7, Xaa8, Xaa9, and Xaa10 is independently an amino acid, wherein at least three of Xaa3, Xaa5, Xaa6, Xaa7, Xaa8, Xaa9, and Xaa10 are the same amino acids as the amino acid at the corresponding position of the sequence Phe3-X4-His5- Tyr6-Trp7-Ala8-Gln9-Leu10-X11-Ser12 (SEQ ID NO: 8) or Phe3-X4-Glu5-Tyr6-Trp7-Ala8-Gln9-Leu10/Cba10-X11-Ala12 (SEQ ID NO: 9), wherein each X4 and X11 is independently an amino acid:
each D is independently an amino acid;
each E is independently an amino acid selected from the group consisting of Ala (alanine), D-Ala (D-alanine), Aib (?-aminoisobutyric acid), Sar (N-methyl glycine), and Ser (serine);
R1 and R2 are independently -H, alkyl, alkenyl, alkyenyl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroalkyl, or heterocycloalkyl, unsubstituted or substituted with halo-; or forms a macrocycle-forming linker L? connected to the alpha position of one of said D or E amino acids;
L and L? are independently a macrocycle-forminig linker;
each R5 is independently halogen, alkyl. -OR6, -N(R6)2, -SR6, -SOR6, SO2R6, -CO2R6, a fluorescent moiety, a radioisotope or a therapeutic agent;
each R6is independently -H, alkyl, alkenyl, alkenyl, arylalkyl, cycloalkylalkyl, heterocycloalkyl, a fluorescent moiety, a radioisotope or a therapeutic agent;
R7 is -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, optionally substituted with R5, or part of a cyclic structure with a D residue;
R8 is -H, alkyl, alkenyl, alkynyl, arylalkyl, cycloalkyl, heteroalkyl, cycloalkylalkyl, heterocycloalkyl, aryl, or heteroaryl, optionally substituted with R5, or part of a cyclic structure with an E residue;
v is an integer from 1-10;
w is an integer from 3-10; and
and wherein the cancer is head and neck cancer, melanoma, lung cancer, breast cancer, glioma, or a hematological cancer.

US Pat. No. 10,213,476

COMPSTATIN ANALOGS WITH IMPROVED POTENCY AND PHARMACOKINETIC PROPERTIES

The Trustees of the Unive...

1. A method of producing one or more selected modified compstatin analogs, comprising:(a) providing a compstatin analog comprising a peptide having a sequence of SEQ ID NO:6, which is:Xaa1-Cys-Val-Xaa2-Gln-Xaa3-Xaa4-Gly-Xaa5-His-Xaa6-Cys-Xaa7 (SEQ ID NO:6), in which Gly between Xaa4 and Xaa5 is N-methylated to constrain the backbone conformation;wherein:Xaa1 is Ile or Gly;Xaa2 is Trp or an analog of Trp, wherein the analog of Trp has increased hydrophobic character as compared with Trp;Xaa3 is Asp or Asn;Xaa4 is Trp or an analog of Trp comprising a chemical modification to its indole ring wherein the chemical modification increases the hydrogen bond potential of the indole ring;Xaa5 is His, Ala, Phe or Trp;Xaa6 is Arg or Orn; andXaa7 is Thr, Ile, Leu, Nle, N-methyl Thr or N-methyl Ile, wherein a carboxy terminal —OH of any of the Thr, Ile, Leu, Nle, N-methyl Thr or N-methyl Ile optionally is replaced by —NH2, and the peptide is cyclic via a Cys-Cys or thioether bond;(b) modifying a plurality of the compstatin analogs by adding an N-terminal component to each analog that interacts with C3, C3b or C3c in a shallow groove formed by macroglobulin domain 4 of the C3 ?-chain;
(c) testing the modified compstatin analogs for interaction between the added N-terminal components thereof and a lysine residue in C3, C3b or C3c at position 386 of a C3c sequence comprising SEQ ID NO:5, or equivalent residue thereof on an equivalent sequence of C3, C3b or C3c; and
(d) selecting the modified compstatin analogs having N-terminal components that interact with the lysine residue in C3, C3b or C3c at position 386 of a C3c sequence comprising SEQ ID NO:5, or equivalent residue thereof on an equivalent sequence of C3, C3b or C3c; thereby producing the one or more selected modified compstatin analogs.

US Pat. No. 10,213,474

DELIVERY OF DRUGS

Nanomerics LTD, St Alban...

1. A method for treating pain, comprising intranasally administering to a human or animal in need thereof a composition comprising a therapeutically effective amount of a hydrophilic neuroactive peptide and an amphiphilic quaternary ammonium palmitoyl glycol chitosan (GCPQ);wherein the amphiphilic GCPQ is capable of self-assembly in aqueous media into particles having a mean particle size between 20-500 nm;
wherein intranasally administering the composition delivers the hydrophilic neuroactive peptide to the brain of the human or animal.

US Pat. No. 10,213,471

METHOD FOR MAKING A PAIN RELIEVER OIL

1. A method for producing a pain reliever oil, comprising:creating a pepper marinade from a composition of peppers containing capsaicin in cold pressed olive oil stored in a dark room for 9 to 12 months;
creating a dried flower marinade from a composition of dried flowers in cold pressed olive oil in sunlight, wherein the container is transparent or translucent;
creating a spice marinade from a composition of spices in olive oil stored in sunlight;
creating a mixture of carrier oils;
creating a mixture of essential oils;
recovering the oil extract of each of the pepper marinade, the dried flower marinade, and the spice marinade;
combining the recovered oil extracts, the mixture of carrier oils and the mixture of essential oils to create an intermediate composition;
wherein the intermediate composition comprises 4-8% pepper oil extract, 14-26% dried flower oil extract, 2-4% spice oil extract, 13-25% carrier oils, 33-65% essential oils and 2-4% magnesium oil;
covering and placing the receptacle in the dark for a period of approximately 24 hours to create the pain reliever oil; and
pouring the pain reliever oil into a bottle.

US Pat. No. 10,213,465

METHOD AND SYSTEM FOR REPAIRING DAMAGED TISSUE USING NUCLEATED PLASMA PARTICLES (NUC-P2S) AND MESODERMAL STEM CELLS (MESOSCS)

1. A system for treating damaged tissue in a subject with optimally isolated adult derived MesoSCs and Nuc-P2s the system comprising:a first apparatus effective for attaching to a first target area in the subject;
a first composition contained in said first apparatus, wherein said first apparatus is selected from the group comprising, an intravenous drip, injecting device, topical applicator and nebulizer;
a second apparatus effective for attaching to a second target area in the subject;
a second composition contained in said second apparatus wherein said second apparatus is an intravenous drip;
wherein said first composition is effective for treating damaged tissue in said first target area and consists essentially of primary treating stem cells and sterile saline, and wherein said second composition consists essentially of secondary treating stem cells, sterile saline and sodium heparin;
wherein said second composition is effective for preventing the body from diverting primary treating stem cells from said first target area.

US Pat. No. 10,213,461

COMBINED AUTOLOGOUS BIOLOGIC AND COLD THERAPY TREATMENT OF SKIN INJURIES

Arthrex, Inc, Naples, FL...

1. A method, comprising:harvesting a blood sample from a patient;
separating an autologous blood component from the blood sample;
injecting an individual dose of the autologous blood component into each of a plurality of compartments of a tray assembly, wherein the tray assembly includes a tray body that establishes the plurality of compartments, a rack removably connected to the tray body, and a plurality of handles removably connected to the rack, wherein one handle of the plurality of handles extends into each of the plurality of compartments;
positioning the tray assembly within a freezer to freeze the individual doses of the autologous blood component;
removing a first dose of the individual doses from the tray assembly, wherein removing the first dose of the individual doses includes removing a first handle of the plurality of handles from the rack; and
applying the first dose to a skin injury in frozen form,
wherein applying the first dose to the skin injury initially provides cold therapy to the skin injury, and as the first dose melts, the autologous blood component is distributed over the skin injury to promote healing.

US Pat. No. 10,213,452

PHARMACEUTICAL COMPOSITIONS CONTAINING STEVIOSIDES

FRESENIUS MEDICAL CARE DE...

1. A steviol glycoside-derivative of the general structure Iwherein one of R1 and R2 is a polyethylene glycol unit polyethylene glycol unit —(CH2—CH2—O)n—CH2—CH2—OH with n being an integer from 0 to 500, and one of R1 and R2 is H, a linear or branched C1 to C6 alkyl group, a polyethylene glycol unit —(CH2—CH2—O—)n—CH2—CH2—OH with n being an integer from 0 to 500, or one or more glucose, xylose or rhamnose units.

US Pat. No. 10,213,451

METHODS AND COMPOUNDS FOR MODULATING THE SECRETION OR EXPRESSION OF ADHESION PROTEINS OR ANGIOPOIETINS OF CELLS

1. A compound for modulating the secretion or expression of adhesion proteins or angiopoietins of cells, for inhibiting the metastasis of cancer cell in a subject, wherein the compound is selected from the following:a) A compound haying structure (ACH-Z4):

e) A compound having structure (ACH-Y7):

f) A compound having structure (ACH-Y0):

h) A compound having structure (ACH-X):

i) A compound having structure (ACH-Mb5):

j) A compound having structure (ACH-Mb12):

US Pat. No. 10,213,446

METHOD OF TREATING ACUTE CORONARY SYNDROMES

BIOrest Ltd., Tel Aviv (...

1. A method of treating a patient at increased risk of plaque rupture comprising administering an effective amount of a formulation to a patient in need thereof, said formulation comprising a bisphosphonate which is encapsulated in a particle, embedded in a particle, or in a particulate, said particle or particulate having a size of 0.05 to 1.0 microns, wherein said bisphosphonate is phagocytosed and acts intracellularly, thereby decreasing phagocytic cell activity.

US Pat. No. 10,213,435

BIARYL COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE

Athenex, Inc., Buffalo, ...

1. A compound of formula (VIIa), (VIIb), (VIIc), (VIId), or (VIIe):
or a pharmaceutically acceptable salt or solvate thereof, wherein:
n2 is 0, 1, 2, or 3;
n3 is 0, 1, or 2;
A1, A2, and A3 are each independently CR61 or N, and wherein only one of A1, A2, and A3 is N;
each R61 is independently H or R6;
R1 and R2 are each independently H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, or O—(C1-C6 alkyl);
alternatively, R1 and R2, together with the carbon atom to which they are attached, form a 3-8 membered saturated, unsaturated, or partially saturated carbocycle, or a saturated, unsaturated, or partially saturated heterocycle comprising one or two 5-7 membered rings and one or more heteroatoms selected from N, O, and S;
alternatively, one of R1 and R2, together with the carbon atom to which R1 or R2 is attached and the adjacent
ring, form a 7-12 membered saturated, unsaturated, or partially saturated carbocycle, or a 7-12 membered saturated, unsaturated, or partially saturated heterocycle comprising one or more heteroatoms selected from N, O and S;R3 is C1-C6 alkyl;
R5 is (a) halogen, (b) OH, (c) CONH2, (d) COOH, (e) CN, (f) N3, (g) C1-C6 alkyl, (h) C2-C6 alkenyl, (i) C2-C6 alkynyl, (j) O—(C1-C6 alkyl), (k) O—(C2-C6 alkenyl), (l) O—(C2-C6 alkynyl), (m) COO—(C1-C6 alkyl), (n) COO—(C2-C6 alkenyl), (o) COO—(C2-C6 alkynyl), (p) CONH—(C1-C6 alkyl), (q) CONH—(C2-C6 alkenyl), (r) CONH—(C2-C6 alkynyl), (s) CON(C1-C6 alkyl)2, (t) CON(C2-C6 alkenyl)2, (u) CON(C2-C6 alkenyl)2, (v1) (C1-C6 alkyl)v-NH(C1-C6 alkyl), (v2) (C1-C6 alkyl)v-NH(C2-C6 alkenyl), (v3) (C1-C6 alkyl)v-NH(C2-C6 alkynyl), (w1) (C2-C6 alkenyl)v-NH(C1-C6 alkyl), (w2) (C2-C6 alkenyl)v-NH(C2-C6 alkenyl), (w3) (C2-C6 alkenyl)v-NH(C2-C6 alkynyl), (x1) (C2-C6 alkynyl)v-NH(C1-C6 alkyl), (x2) (C2-C6 alkynyl)v-NH(C2-C6 alkenyl), (x3) (C2-C6 alkynyl)v-NH(C2-C6 alkynyl), (y1) (C1-C6 alkyl)w-N(C1-C6 alkyl)2, (y2) (C1-C6 alkyl)w-N(C2-C6 alkenyl)2, (y3) (C1-C6 alkyl)w-N(C2-C6 alkynyl)2, (z1) (C2-C6 alkenyl)w-N(C1-C6 alkyl)2, (z2) (C2-C6 alkenyl)w-N(C2-C6 alkenyl)2, (z3) (C2-C6 alkenyl)w-N(C2-C6 alkynyl)2, (aa1) (C2-C6 alkynyl)w-N(C1-C6 alkyl)2, (aa2) (C2-C6 alkynyl)w-N(C2-C6 alkenyl)2, (aa3) (C2-C6 alkynyl)w-N(C2-C6 alkenyl)2, (bb) S—(C1-C6 alkyl), (cc) S(O)—(C1-C6 alkyl), (dd) S(O)2—(C1-C6 alkyl), (ee) S—(C2-C6 alkenyl), (ff) S(O)—(C2-C6 alkenyl), (gg) S(O)2—(C2-C6 alkenyl), (hh) S—(C2-C6 alkynyl), (ii) S(O)—(C2-C6 alkynyl), (jj) S(O)2—(C2-C6 alkynyl), (kk) an aromatic, saturated, unsaturated, or partially saturated carbocycle comprising one or two 3-8 membered rings, or (ll) an aromatic, saturated, unsaturated, or partially saturated heterocycle comprising one or two 5-7 membered rings and one or more heteroatoms selected from N, O and S, wherein each of (g)-(ll) is optionally substituted with one or more R8;
each R6 is independently (a) halogen, (b) OH, (c) CONH2, (d) COOH, (e) CN, (f) N3, (g) C1-C6 alkyl, (h) C2-C6 alkenyl, (i) C2-C6 alkynyl, (j) O—(C1-C6 alkyl), (k) O—(C2-C6 alkenyl), (l) O—(C2-C6 alkynyl), (m) COO—(C1-C6 alkyl), (n) COO—(C2-C6 alkenyl), (o) COO—(C2-C6 alkynyl), (p) CONH—(C1-C6 alkyl), (q) CONH—(C2-C6 alkenyl), (r) CONH—(C2-C6 alkynyl), (s) CON(C1-C6 alkyl)2, (t) CON(C2-C6 alkenyl)2, (u) CON(C2-C6 alkynyl)2, (v1) (C1-C6 alkyl)-NH(C1-C6 alkyl), (v2) (C1-C6 alkyl)v-NH(C2-C6 alkenyl), (v3) (C1-C6 alkyl)v-NH(C2-C6 alkynyl), (w1) (C2-C6 alkenyl)v-NH(C1-C6 alkyl), (w2) (C2-C6 alkenyl)v-NH(C2-C6 alkenyl), (w3) (C2-C6 alkenyl)v-NH(C2-C6 alkynyl), (x1) (C2-C6 alkynyl)v-NH(C1-C6 alkyl), (x2) (C2-C6 alkynyl)v-NH(C2-C6 alkenyl), (x3) (C2-C6 alkynyl)v-NH(C2-C6 alkynyl), (y1) (C1-C6 alkyl)w-N(C1-C6 alkyl)2, (y2) (C1-C6 alkyl)w-N(C2-C6 alkenyl)2, (y3) (C1-C6 alkyl)w-N(C2-C6 alkynyl)2, (z1) (C2-C6 alkenyl)w-N(C1-C6 alkyl)2, (z2) (C2-C6 alkenyl)w-N(C2-C6 alkenyl)2, (z3) (C2-C6 alkenyl)w-N(C2-C6 alkynyl)2, (aa1) (C2-C6 alkynyl)w-N(C1-C6 alkyl)2, (aa2) (C2-C6 alkynyl)w-N(C2-C6 alkenyl)2, (aa3) (C2-C6 alkynyl)w-N(C2-C6 alkynyl)2, (bb) S—(C1-C6 alkyl), (cc) S(O)—(C1-C6 alkyl), (dd) S(O)2—(C1-C6 alkyl), (ee) S—(C2-C6 alkenyl), (ff) S(O)—(C2-C6 alkenyl), (gg) S(O)2—(C2-C6 alkenyl), (hh) S—(C2-C6 alkynyl), (ii) S(O)—(C2-C6 alkynyl), (jj) S(O)2—(C2-C6 alkynyl), (kk) an aromatic, saturated, unsaturated, or partially saturated carbocycle comprising one or two 3-8 membered rings, or (ll) an aromatic, saturated, unsaturated, or partially saturated heterocycle comprising one or two 5-7 membered rings and one or more heteroatoms selected from N, O and S, wherein each of (g)-(ll) is optionally substituted with one or more R9;
each R8 is independently halogen, OH, O—(C1-C6 alkyl), C1-C6 haloalkyl, COO—(C1-C6 alkyl), CONH—(C1-C6 alkyl), CON(C1-C6 alkyl)2, COOH, CN, N3, 5-6 membered saturated, unsaturated, or partially saturated carbocycle, or 5-6 membered saturated, unsaturated, or partially saturated heterocycle comprising one or more heteroatoms selected from N, O and S,
each R9 is independently halogen, OH, O—(C1-C6 alkyl), COO—(C1-C6 alkyl), CONH—(C1-C6 alkyl), CON(C1-C6 alkyl)2, COOH, CN, N, 5-6 membered saturated, unsaturated, or partially saturated carbocycle, or 5-6 membered saturated, unsaturated, or partially saturated heterocycle comprising one or more heteroatoms selected from N, O and S,
v is 0 or 1, and
w is 0 or 1.

US Pat. No. 10,213,433

SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT

AbbVie Inc., North Chica...

1. A process for preparing a solid dispersion, comprising:(a) dissolving in a suitable solvent (i) an active pharmaceutical ingredient (API) comprising a compound of Formula I

where:
R0 is halo;
R1 and R2 are H or are independently methyl or methoxy;
R3 and R4 are independently methyl or methoxy if R1 and R2 are H, or are H if R1 and R2 are independently methyl or methoxy;
Al and A2 are each independently CH or N;
R5 is C1-4 alkyl or haloalkyl, C1-4 alkylsulfonyl or haloalkylsulfonyl, halo, nitro or cyano;
X is —O— or —NH—;
Y is —(CH2)n—where n is 0, 1, 2 or 3; and
R6 is an unsubstituted or substituted 3- to 7-membered carbocyclic or heterocyclic, or is NR7R8;
wherein, if R6 is NR7R8, R7 and R8 are each independently H or R9—(CH2)m— groups, no more than one of R7 and R8 is H, each R9 is independently a 3- to 7-membered carbocyclic or heterocyclic ring, optionally substituted with no more than two Z1 groups as defined below, and each m is independently 0 or 1; and
wherein, if R6 is a substituted carbocyclic or heterocyclic ring, substituents thereon are no more than two Z1 groups and/or no more than one Z2 group, Z1 groups being independently selected from the group consisting of (a) C1-4 alkyl, C2-4 alkenyl, C1-4 alkoxy, C1-4 alkylthio, C1-4 alkylamino, C1-4 alkylsulfonyl, C1-4 alkylsulfonylamino, C1-4 alkylcarbonyl C1-4 alkylcarbonylamino and C1-4 alkylcarboxy, each optionally substituted with one or more substituents independently selected from the group consisting of halo, hydroxy, C1-4 alkoxy, amino, C1-4 alkylamino, di-(C1-4 alkyl)amino and cyano, (b) halo, (e) hydroxy, (f) amino and (g) oxo groups, and Z2 being (i) a further 3- to 6-membered carbocyclic or heterocyclic ring, optionally substituted with no more than two Z1 groups as defined above, or (ii) NR7R8 where R7 and R8 are as defined above;
or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable water-soluble polymeric carrier and (iii) at least one pharmaceutically acceptable surfactant; and
(b) removing the solvent to provide a solid matrix comprising the at least one pharmaceutically acceptable water-soluble polymeric carrier and the at least one pharmaceutically acceptable surfactant and having the compound or a pharmaceutically acceptable salt thereof dispersed in an essentially non-crystalline form therein.

US Pat. No. 10,213,430

NUCLEOTIDE ANALOGS

The Regents of the Univer...

1. A compound of Formula (I)
or a pharmaceutically acceptable salt thereof;
wherein
B1 is

Z1 and Z2 are oxygen;
R1 is —(CHR4)a—O—C1-24alkyl;
R2 is aryl(C1-4alkyl)—;
R3 is selected from C1-6alkyl and C3-6cycloalkyl;
R4 is hydrogen; and
a is selected from 1, 2, 3, or 4.

US Pat. No. 10,213,429

IMIDAZO-PYRAZINYL DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE ACTIVATORS

1. A compound having structural Formula I:
or a pharmaceutically acceptable salt thereof wherein:
C* is indicates a potential chiral carbon atom;
R1 is
(1) hydrogen
(2) (C1-6)alkyl,
(3) halo(C1-6)alkyl,
(4) (C1-6)alkyl-O—,
(5) halo(C1-6)alkyl-O—,
(6) (C3-7)cycloalkyl-(C1-3)alkyl-O—,
(7) —(C1-3)alkyl-(C3-7)cycloalkyl, or
(8) —(C1-3)alkyl-phenyl, wherein phenyl is unsubstituted or substituted by 1 to 3 halo;
R2 is
(1) (C1-3)alkyl, or
(2) (C3-7)cycloalkyl;
R3 is
(1) phenyl unsubstituted or substituted by 1 to 3 R7, or
(2) five- or six-membered heteroaryl containing 1, 2, or 3 heteroatoms independently selected from N, O and S, wherein heteroaryl is unsubstituted or substituted by 1 to 3 R7
(3) —C(O)NH—(C3-6)cycloalkyl,
(4) (C1-6)alkyl, or
(5) —CO2-(C1-6)alkyl;
R4 is
(1) hydrogen,
(2) (C1-6)alkyl,
(3) halo(C1-6)alkyl,
(4) (C1-6)alkoxy,
(5) halo(C1-3)alkoxy,
(6) (C3-7)cycloalkyl, or
(7) cyano;
R5 is
(1) hydrogen,
(2) (C1-6)alkyl,
(3) halo(C1-6)alkyl,
(4) halo,
(5) amino,
(6) (C1-3)alkyl-aryl,
(7) (C1-3)alkyl-(C3-6)cycloalkyl, or
(8) cyano;
R6 is
(1) hydrogen,
(2) hydroxy,
(3) (C1-6)alkyl,
(4) (C1-6)alkoxy,
(5) (C1-3)alkyl-O—(C1-3)alkoxy-
(6) (C3-6)cycloalkyl,
(7) cyano,
(8) phenyl, or
(9) —C(O)NH2; and
each R7 is independently
(1) (C1-3)alkoxy,
(2) halo(C1-3)alkoxy,
(3) halo,
(4) —CO2-(C1-6)alkyl, or
(5) C(O)NH2.

US Pat. No. 10,213,427

SUBSTITUTED IMIDAZOPYRIDAZINES AND BENZIMIDAZOLES AS INHIBITORS OF FGFR3

Incyte Corporation, Wilm...

1. A method of treating cancer in a patient comprising administering to said patient a therapeutically effective amount of a compound of Formula Ia:or a pharmaceutically acceptable salt thereof, wherein:Ar1 is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, each optionally substituted by 1, 2, 3, 4, or 5 independently selected RA1 groups;
Ar2 is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, each optionally substituted by 1, 2, 3, or 4 independently selected RA2 groups;
B is:
(i) —(CR3R4)m1—(CR1R2)—(CR3R4)m2—X;
(ii) -L1-(CR3R4)n-Cy1;
(iii) -Cy2-(L2)a-(CR3R4)p—Cy3; or
(iv) -Cy4-L3-Y;
L1 is C(O)NR, C(O)O, S(O)2NR, NRC(O)NR, NRC(S)NR, S, or S(O);
L2 and L3 are each independently selected from CO, C(O)O, C(O)NR, S(O)2NR, NR, NRC(O)NR, NRC(S)NR, O, S, S(O), and S(O)2;
X is Cy5, CN, C(O)NR5R6, NR5C(O)R7, NR5S(O)2R7, NR5S(O)2NR5R6, NR5C(O)OR8, or S(O)2NR5R6;
Y is:
(1) aryl, heteroaryl, or heterocycloalkyl, each optionally substituted by 1, 2, 3, 4, or 5 independently selected RB1 groups;
(2) C3-7 cycloalkyl substituted by 1, 2, 3, 4, or 5 independently selected RB2 groups; or
(3) C1-6 alkyl or C1-6 haloalkyl, each substituted by 1, 2, 3, 4, or 5 independently selected RX groups;
Cy1, Cy2, Cy3, Cy4, and Cy5 are each independently selected from aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, each of which is optionally substituted by 1, 2, 3, 4, or 5 independently selected RCy groups;
R is independently selected from H and C1-4 alkyl;
R1 is halo, cyano, hydroxy, C1-4 alkyl, C2-4 cyanoalkyl, C2-4 alkoxyalkyl, C1-4 haloalkyl, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl, wherein said aryl, heteroaryl, cycloalkyl, or heterocycloalkyl is optionally substituted by 1, 2, 3, 4, or 5 independently selected RD groups;
R2 and R4 are each independently selected from H, halo, hydroxy, C1-4 alkyl, C2-4 cyanoalkyl, C2-4 alkoxyalkyl, and C1-4 haloalkyl;
R3 is independently selected from H, halo, cyano, hydroxy, C1-4 alkyl, C2-4 cyanoalkyl, C2-4 alkoxyalkyl, C1-4 haloalkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, wherein said aryl, heteroaryl, cycloalkyl, or heterocycloalkyl is optionally substituted by 1, 2, 3, 4, or 5 independently selected RD groups;
R5 is independently selected from H, C1-4 alkyl, C2-4 cyanoalkyl, C2-4 alkoxyalkyl, and C1-4 haloalkyl;
R6, R7, and R8 are each independently selected from H, C1-4 alkyl, aryl, heteroaryl, cycloalkyl, and heterocycloalkyl, wherein said C1-4 alkyl, aryl, heteroaryl, cycloalkyl, or heterocycloalkyl is optionally substituted with 1, 2, 3, 4, 5, or 6 independently selected RD groups;
or R5 and R6 together with the N atom to which they are attached form a 4-, 5-, 6-, or 7-membered heterocycloalkyl ring optionally substituted by 1, 2, 3, 4, or 5 independently selected RD groups;
each RA1 is independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, halosulfanyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)ORa, OC(O)Rb, OC(O)NRcRd, NRcRd, NRcC(O)Rb, NRcC(O)ORa, NRcC(O)NRcRd, C(?NRe)Rb, C(?NRe)NRcRd, NRcC(?NRe)NRcRd, NRcS(O)Rb, NRcS(O)2Rb, NRcS(O)2NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, and S(O)2NRcRd; wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, halosulfanyl, CN, NO2, ORa, SRa, C(O)Rb, C(O)NRcRd, C(O)ORa, OC(O)Rb, OC(O)NRcRd, C(?NRe)NRcRd, NRcC(?NRe)NRcRd, NRcRd, NRcC(O)Rb, NRcC(O)ORa, NRcC(O)NRcRd, NRcS(O)Rb, NRcS(O)2Rb, NRcS(O)2NRcRd, S(O)Rb, S(O)NRcRd, S(O)2Rb, and S(O)2NRcRd;
each RA2 is independently selected from halo, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, halosulfanyl, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, C(?NRe1)Rb1, C(?NRe1)NRc1Rd1, NRc1C(?NRe1)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRe1Rd1; wherein said C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, C1-4 haloalkyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl are each optionally substituted with 1, 2, or 3 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, halosulfanyl, CN, NO2, ORa1, SRa1, C(O)Rb1, C(O)NRc1Rd1, C(O)ORa1, OC(O)Rb1, OC(O)NRc1Rd1, C(?NRe1)NRc1Rd1, NRc1C(?NRe1)NRc1Rd1, NRc1Rd1, NRc1C(O)Rb1, NRc1C(O)ORa1, NRc1C(O)NRc1Rd1, NRc1S(O)Rb1, NRc1S(O)2Rb1, NRc1S(O)2NRc1Rd1, S(O)Rb1, S(O)NRc1Rd1, S(O)2Rb1, and S(O)2NRc1Rd1;
each RB1, RB2, RCy, and RD is independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, halosulfanyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, C(?NRe2)Rb2, C(?NRe2)NRc2Rd2, NRc2C(?NRe2)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2; wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, halosulfanyl, CN, NO2, ORa2, SRa2, C(O)Rb2, C(O)NRc2Rd2, C(O)ORa2, OC(O)Rb2, OC(O)NRc2Rd2, C(?NRe2)NRc2Rd2, NRc2C(?NRe2)NRc2Rd2, NRc2Rd2, NRc2C(O)Rb2, NRc2C(O)ORa2, NRc2C(O)NRc2Rd2, NRc2S(O)Rb2, NRc2S(O)2Rb2, NRc2S(O)2NRc2Rd2, S(O)Rb2, S(O)NRc2Rd2, S(O)2Rb2, and S(O)2NRc2Rd2;
each RX is independently selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, CN, NO2, ORa3, SRa3, C(O)Rb3, C(O)NRc3Rd3, C(O)ORa3, OC(O)Rb3, OC(O)NRc3Rd3, NRc3Rd3, NRc3C(O)Rb3, NRc3C(O)ORa3, NRc3C(O)NRc3Rd3, C(?NRe3)Rb3, C(?NRe3)NRc3Rd3, NRc3C(?NRe3)NRc3Rd3, NRc3S(O)Rb3, NRc3S(O)2Rb3, NRc3S(O)2NRc3Rd3, S(O)Rb3, S(O)NRc3Rd3, S(O)2Rb3, and S(O)2NRc3Rd3; wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl are each optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from halo, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 haloalkyl, halosulfanyl, CN, NO2, ORa3, SRa3, C(O)Rb3, C(O)NRc3Rd3, C(O)ORa3, OC(O)Rb3, OC(O)NRc3Rd3, C(?NRe3)NRc3Rd3, NRc3C(?NRe3)NRc3Rd3, NRc3Rd3, NRc3C(O)Rb3, NRc3C(O)ORa3, NRc3C(O)NRc3Rd3, NRc3S(O)Rb3, NRc3S(O)2Rb3, NRc3S(O)2NRc3Rd3, S(O)Rb3, S(O)NRc3Rd3, S(O)2Rb3, and S(O)2NRc3Rd3;
each Ra, Rb, Rc, and Rd is independently selected from H, C1-6 alkyl, C1-4 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl, wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from C1-4 alkyl, C1-4 haloalkyl, halo, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(?NRf4)NRc4Rd4, NRc4C(?NRf4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4;
or any Rc and Rd together with the N atom to which they are attached form a 3-, 4-, 5-, 6-, or 7-membered heterocycloalkyl group or a heteroaryl group, each optionally substituted with 1, 2, or 3 substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(?NRf4)NRc4Rd4, NRc4C(?NRf4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4, wherein said C1-6 alkyl is optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4 NRc4C(O)ORa4, C(?NRf4)NRc4Rd4, NRc4C(?NRf4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4;
each Re and Rf is independently selected from H, C1-4 alkyl, CN, ORa4, SRb4, S(O)2Rb4, C(O)Rb4, S(O)2NRc4Rd4, and C(O)NRc4Rd4;
each Ra1, Rb1, Rc1, and Rd1 is independently selected from H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, aryl, cycloalkyl, heteroaryl, and heterocycloalkyl, wherein said C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, aryl, cycloalkyl, heteroaryl, or heterocycloalkyl is optionally substituted with 1, 2, or 3 substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(?NRf4)NRc4Rd4, NRc4C(?NRf4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4;
or any Rc1 and Rd1 together with the N atom to which they are attached form a 3-, 4-, 5-, 6-, or 7-membered heterocycloalkyl group or a heteroaryl group, each optionally substituted with 1, 2, or 3 substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(?NRf4)NRc4Rd4, NRc4C(?NRf4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4;
each Re1 and Rf1 is independently selected from H, C1-4 alkyl, CN, ORa4, SRb4, S(O)2Rb4, C(O)Rb4, S(O)2NRc4Rd4, and C(O)NRc4Rd4;
each Ra2, Rb2, Rc2, and Rd2 is independently selected from H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, and heterocycloalkylalkyl, wherein said C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, aryl, cycloalkyl, heteroaryl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, or heterocycloalkylalkyl is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from C1-4 alkyl, C1-4 haloalkyl, halo, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(?NRf4)NRc4Rd4, NRc4C(?NRf4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4;
or any Rc2 and Rd2 together with the N atom to which they are attached form a 3-, 4-, 5-, 6-, or 7-membered heterocycloalkyl group or a heteroaryl group, each optionally substituted with 1, 2, or 3 substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4 NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(?NRf4)NRc4Rd4, NRc4C(?NRf4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4, wherein said C1-6 alkyl is optionally substituted by 1, 2, or 3 substituents independently selected from halo, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(?NRf4)NRc4Rd4, NRc4C(?NRf4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4;
each Re2 and Rf2 is independently selected from H, C1-4 alkyl, CN, ORa4, SRb4, S(O)2Rb4, C(O)Rb4, S(O)2NRc4Rd4, and C(O)NRc4Rd4;
each Ra3, Rb3, Rc3, and Rd3 is independently selected from H, C1-6 alkyl, C2-6 alkenyl, and C2-6 alkynyl, wherein said C1-6 alkyl, C2-6 alkenyl, or C2-6 alkynyl, is optionally substituted with 1, 2, 3, 4, or 5 substituents independently selected from C1-4 alkyl, C1-4 haloalkyl, halo, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(?NRf4)NRc4Rd4, NRc4C(?NRf4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4;
or any Rc3 and Rd3 together with the N atom to which they are attached form a 3-, 4-, 5-, 6-, or 7-membered heterocycloalkyl group or a heteroaryl group, each optionally substituted with 1, 2, or 3 substituents independently selected from C1-6 alkyl, C1-6 haloalkyl, halo, CN, ORa4, SRa4, C(O)Rb4, C(O)NRc4Rd4, C(O)ORa4, OC(O)Rb4, OC(O)NRc4Rd4, NRc4Rd4, NRc4C(O)Rb4, NRc4C(O)NRc4Rd4, NRc4C(O)ORa4, C(?NRf4)NRc4Rd4, NRc4C(?NRf4)NRc4Rd4, S(O)Rb4, S(O)NRc4Rd4, S(O)2Rb4, NRc4S(O)2Rb4, NRc4S(O)2NRc4Rd4, and S(O)2NRc4Rd4;
each Re3 and Rf3 is independently selected from H, C1-4 alkyl, CN, ORa4, SRb4, S(O)2Rb4, C(O)Rb4, S(O)2NRc4Rd4, and C(O)NRc4Rd4;
each Ra4, Rb4, Rc4, and Rd4 is independently selected from H, C1-4 alkyl, C1-4 haloalkyl, C2-4 alkenyl, and C2-4 alkynyl, wherein said C1-4 alkyl, C1-4 haloalkyl, C2-4 alkenyl, or C2-4 alkynyl, is optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C1-4 alkyl, C1-4 alkoxy, C1-4 alkylthio, C1-4 alkylamino, di(C1-4 alkyl)amino, C1-4 haloalkyl, and C1-4 haloalkoxy;
or any Rc4 and Rd4 together with the N atom to which they are attached form a 3-, 4-, 5-, 6-, or 7-membered heterocycloalkyl group or heteroaryl group, each optionally substituted with 1, 2, or 3 substituents independently selected from OH, CN, amino, halo, C1-6 alkyl, C1-4 alkoxy, C1-4 alkylthio, C1-4 alkylamino, di(C1-4 alkyl)amino, C1-4 haloalkyl, and C1-4 haloalkoxy;
each Re4 and Rf4 is independently selected from H, C1-4 alkyl, and CN;
a is 0 or 1;
m1 is 0, 1, 2, 3, or 4;
m2 is 0, 1, 2, 3, or 4;
n is 1, 2, 3, 4, 5, or 6; and
p is 1, 2, 3, 4, 5, or 6;
wherein said cancer is associated with elevated expression or activity of FGFR3; and
wherein said cancer is selected from bladder cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, head and neck cancer, liver cancer, lung cancer, ovarian cancer, esophageal cancer, gall bladder cancer, multiple myeloma, acute myelogenous leukemia, and glioblastoma.

US Pat. No. 10,213,421

PHARMACEUTICAL FORMULATIONS COMPRISING CCR3 ANTAGONISTS

Alkahest, Inc., San Carl...


US Pat. No. 10,213,420

COMBINATION THERAPY FOR TREATMENT OF HBV INFECTIONS

NOVIRA THERAPEUTICS, INC....

1. A method of treating an HBV infection in a subject in need thereof, comprising administering to the subject a capsid assembly inhibitor and interferon, wherein the capsid assembly inhibitor is a compound of Formula IVc:
or a pharmaceutically acceptable salt thereof;
wherein
X is halo;
G1 is hydrogen or halo;
G2 is H, C1-C4 alkyl, or halo; and
G4 is H, halo, C1-C4 alkyl, or OH.

US Pat. No. 10,213,419

COMPOUND IMPURITIES AND METHODS OF DETECTING SAME

Aegerion Pharmaceuticals,...

1. A lomitapide product having the following structure:

US Pat. No. 10,213,417

FATTY ACIDS AS ANTI-INFLAMMATORY AGENTS

1. A method of treating an inflammatory condition comprising administering to the subject in need thereof a formulation comprising a therapeutically effective amount of a compound having the formula:
wherein:
R1 is a heterocyclyl;
is an optional double bond;
W is —OH, —C(O)H, —C(O), —C(O)Rp, —COOH, —COORp, —Cl, —Br, —I, —CF3, —CN, —SO3, —SO2Rp, —SO3H, —NH3+, —NH2Rp+, —NRpRqRt, —NO2, ?O, ?NRp, ?CF2, or —CHF;
each V is, independently —CH or —C—, wherein:
V is —CH— when W is —OH, —H, —C(O)H, —C(O), —C(O)Rp, —COOH, —COORp, —Cl, —Br, —I, —F, —CF3, —CN, —SO3, —SO2Rp, —SO3H, —NH3+, —NH2Rp+, —NRpRqRt or —NO2; or
V is —C— when W is ?O, ?NRp, ?CF2 or ?CHF;
Rp and Rq are each, independently, H, (C1-C8) alkyl, aryl, or (C1-C8) haloalkyl;
Rt is (C1-C8) alkyl, aryl, or (C1-C8) haloalkyl;
Rb and Rb? are each independently, —H, —OH, —C(O)H, —C(O), —C(O)Rp, —COOH, —COORp, —Cl, —Br, —I, —F, —CF3, —CHF2, —CH2F, —CN, —SO3, —SO2Rp, SO3H, —NH3+, —NH2Rp+, —NRpRqRt or —NO2, wherein:
Rb and Rb? are not simultaneously non-hydrogen groups;
a is an integer between 5 and 15 inclusive, c is an integer from 1 and 15 inclusive, and f is an integer between 5 and 15 inclusive; and
a pharmaceutically acceptable carrier.

US Pat. No. 10,213,416

SUBSTITUTED BENZOXAZOLONE DERIVATIVES AS ACID CERAMIDASE INHIBITORS, AND THEIR USE AS MEDICAMENTS

The Regents of the Univer...

1. A compound of Formula (I) or a pharmaceutically acceptable salt thereof
wherein:
X is a bond, CO, CH(OH) or CH2 group; wherein X can be attached to any position of the ring to which it is connected;
R, R1 and R2 are independently hydrogen or linear or branched C1-6 alkyl;
n is an integer from 1 to 6;
A is a linear or branched C1-9 alkyl, C2-9 alkenyl or C2-9 alkynyl group or a group:

wherein:
m is 0 or an integer from 1 to 6;
G is a 3-10 membered saturated or unsaturated, aromatic or heteroaromatic, single or fused ring comprising up to three heteroatoms selected from N, O, and S; and R6 and R7 are as defined below;
R3 is hydrogen, halogen, linear or branched C1-6 alkyl, C1-6 alkoxy or OH; wherein R3 can be attached to any position of the ring to which it is connected;
R4 and R5 are independently selected from the group consisting of hydrogen, halogen, linear or branched C1-6 alkyl, C1-6 alkoxy, hydroxy C1-6 alkyl, OH, CN, NO2, fluoro C1-6 alkyl, fluoro C1-6 alkoxy, COOR8, CONR9R10, SO2NR9R10, and SO2R11;
R6 and R7 are independently selected from the group consisting of hydrogen, halogen, linear or branched C1-6 alkyl, optionally substituted C3-6 cycloalkyl, C1-6 alkoxy, hydroxy C1-6 alkyl, OH, CN, NO2, fluoro C1-6 alkyl, fluoro C1-6 alkoxy, optionally substituted aryl or heteroaryl, COOR8, CONR9R10, SO2NR9R10, and SO2R11;
wherein
R4, R5, R6 and R7 can be attached to any position of the ring to which they are connected;
Y is a bond or a heteroatom selected from the group consisting of O, S, SO, SO2 and NR12; and
R8, R9, R10, R11 and R12 are independently selected from the group consisting of hydrogen and linear or branched C1-6 alkyl;
with the proviso that when Y is a bond, n+m is ?4 and A is a group

US Pat. No. 10,213,415

COMPOUNDS AS OPIOID RECEPTOR MODULATORS

Janssen Pharmaceutica NV,...

1. A method for treating visceral pain in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound having the structure:
or a pharmaceutically acceptable salt thereof.

US Pat. No. 10,213,414

GLUCOCORTICOID RECEPTOR MODULATORS TO TREAT PANCREATIC CANCER

Corcept Therapeutics, Inc...

1. A method of treating a subject hosting a non-ACTH-secreting pancreatic tumor, the method comprising administering to the subject an effective amount of a chemotherapeutic agent and orally administering an effective amount of a nonsteroidal selective glucocorticoid receptor modulator to reduce the tumor load of the pancreatic tumor, wherein the nonsteroidal selective glucocorticoid receptor modulator is a compound comprising a fused azadecalin structure having the formula:whereinL1 and L2 are members independently selected from a bond and unsubstituted alkylene;
R1 is a member selected from unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted heterocycloalkyl, —OR1A, NR1CR1D, —C(O)NR1CR1D, and —C(O)OR1A, wherein
R1A is a member selected from hydrogen, unsubstituted alkyl and unsubstituted heteroalkyl,
R1C and R1D are members independently selected from unsubstituted alkyl and unsubstituted heteroalkyl,
wherein R1C and R1D are optionally joined to form an unsubstituted ring with the nitrogen to which they are attached, wherein said ring optionally comprises an additional ring nitrogen;
R2 has the formula:

wherein
R2G is a member selected from hydrogen, halogen, unsubstituted alkyl, unsubstituted heteroalkyl, unsubstituted cycloalkyl, unsubstituted heterocycloalkyl, —CN, and —CF3;
J is phenyl;
t is an integer from 0 to 5;
X is —S(O2)—; and
R5 is phenyl optionally substituted with 1-5 R5A groups, wherein
R5A is a member selected from hydrogen, halogen, —OR5A1, S(O2)NR5A2R5A3, —CN, and unsubstituted alkyl, wherein
R5A1 is a member selected from hydrogen and unsubstituted alkyl, and
R5A2 and R5A3 are members independently selected from hydrogen and unsubstituted alkyl,
or salts and isomers thereof.

US Pat. No. 10,213,413

ANTIVIRAL AGENTS DIRECTED AGAINST RESPIRATORY SYNCYTIAL VIRUS

CENTRE NATIONAL DE LA REC...

1. A method for treating an infection by respiratory syncytial virus (RSV), comprising administering to a subject an agent, wherein said agent is represented in formula (I):wherein :R1 and R2 are identical or different and are independently chosen among hydrogen, hydroxyl, halogen, haloalkyl, alkyl, aryl, arylalkyl, nitro, cyano, amino, alkoxy, alkoxyalkyl, heteroaryl, cycloalkyl and heterocyclyl; and
R3 and R4 are identical or different and are independently chosen among carboxylate, ester, substituted or non-substituted alkyloxycarbonyl, halogen, haloalkyl, alkyl, aryl, arylalkyl, nitro, cyano, amino, alkoxy, alkoxyalkyl, heteroaryl, cycloalkyl, heterocyclyl, boronate, phosphate, phosphonate, sulfinyl, sulfonyl, sulfonate, and sulfonamino, sulfonamido.

US Pat. No. 10,213,412

MODULATORS OF CA2+ RELEASE-ACTIVATED CA2+ (CRAC) CHANNELS AND PHARMACEUTICAL USES THEREOF

VIVREON BIOSCIENCES, LLC,...

1. A compound having the structure of Formula (I), or a pharmaceutically acceptable salt or solvate thereof:
wherein,
each R1 is independently H, halogen, C1-C6alkyl, C1-C6fluoroalkyl, C1-C6deuteroalkyl, C3-C6cycloalkyl, C1-C6hydroxyalkyl, or C1-C6heteroalkyl;
R2 is C1-C6alkoxy or hydroxy;
R3 is C1-C6alkoxy or hydroxy;
or R2 and R3 are taken together with the carbon atom to which they are attached to form —C(?O)—, —C(?NR13)—, —C(?N—OR13)—, or a heterocyclic ring containing 2 O atoms;
R13 is H or C1-C6alkyl;
R4 is H, halogen, C1-C6alkyl, C1-C6fluoroalkyl, or C1-C6deuteroalkyl;
R5 is H, halogen, C1-C6alkyl, C1-C6fluoroalkyl, or C1-C6deuteroalkyl;
or R4 and R5 are taken together with the carbon atom to which they are attached to form a substituted or unsubstituted C3-C6cycloalkyl ring, or a substituted or unsubstituted C3-C6heterocyclic ring containing 1 or 2 heteroatoms selected from —O—, —NR12— and —S—;
R6 is H, halogen, C1-C6alkyl, C1-C6fluoroalkyl, or C1-C6deuteroalkyl;
R7 is H, halogen, C1-C6alkyl, C1-C6fluoroalkyl, or C1-C6deuteroalkyl;
or R6 and R7 are taken together with the carbon atom to which they are attached to form a substituted or unsubstituted C3-C6cycloalkyl ring, or a substituted or unsubstituted C3-C6heterocyclic ring containing 1 or 2 heteroatoms selected from —O—, —NR12— and —S—;
R8 is halogen, C1-C6alkyl, C1-C6fluoroalkyl, C1-C6deuteroalkyl, C1-C6cycloalkyl, C1-C6hydroxyalkyl, C1-C6heteroalkyl, —CN, —NO2, —OH, —OR11, —SR11, —S(?O)R11, —S(?O)2R11, —S(?O)2N(R12)2, —NR12S(?O)2R11, —C(?O)R11, —OC(?O)R11, —CO2R12, —OCO2R11, —N(R12)2, —C(?O)N(R12)2, —OC(?O)N(R12)2, —NHC(?O)R11, or —NHC(?O)OR11;
R9 is halogen, C1-C6alkyl, C1-C6fluoroalkyl, C1-C6deuteroalkyl, C1-C6cycloalkyl, C1-C6hydroxyalkyl, C1-C6heteroalkyl, —CN, —NO2, —OH, —OR11, —SR11, —S(?O)R11, —S(?O)2R11, —S(?O)2N(R12)2, —NR12S(?O)2R11, —C(?O)R11, —OC(?O)R11, —CO2R12, —OCO2R11, —N(R12)2, —C(?O)N(R12)2, —OC(?O)N(R12)2, —NHC(?O)R11, or —NHC(?O)OR11;
each R10 is independently H, halogen, C1-C6alkyl, C1-C6fluoroalkyl, C1-C6deuteroalkyl, C1-C6cycloalkyl, C1-C6hydroxyalkyl, C1-C6heteroalkyl, —CN, —NO2, —OH, —OR11, —SR11, —S(?O)R11, —S(?O)2R11, —S(?O)2N(R12)2, —NR12S(?O)2R11, —C(?O)R11, —OC(?O)R11, —CO2R12, —OCO2R11, —N(R12)2, —C(?O)N(R12)2, —OC(?O)N(R12)2, —NHC(?O)R11, or —NHC(?O)OR11;
each RH is independently C1-C6alkyl, C1-C6fluoroalkyl, C1-C6deuteroalkyl, or C3-C6cycloalkyl;
each R12 is independently H, C1-C6alkyl, C1-C6fluoroalkyl, C1-C6deuteroalkyl, or C3-C6cycloalkyl;
n is 0, 1, 2, or 3; and
m is 0, 1, 2, or 3.

US Pat. No. 10,213,409

SUBSTITUTED BENZOFURANS, BENZOTHIOPHENES, BENZOSELENOPHENES AND INDOLES AND THEIR USE AS TUBULIN POLYMERISATION INHIBITORS

BIONOMICS LIMITED, Theba...

1. A combination comprising a compound of formula (I)or a salt thereof, whereinX represents O, S, SO, SO2, Se, SeO, SeO2 or NR where R is selected from H, O, optionally substituted acyl, optionally substituted alkenyl, optionally substituted alkyl, optionally substituted aryl, optionally substituted cycloalkenyl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted heterocyclyl, and optionally substituted sulfonyl;
R1A and R1B each independently represents H, carboxy, cyano, dihalomethoxy, halogen, hydroxy, nitro, pentahaloethyl, phosphorylamino, phosphono, phosphinyl, sulfo, trihaloethenyl, trihalomethanethio, trihalomethoxy, trihalomethyl, optionally substituted acyl, optionally substituted acylamino, optionally substituted acylimino, optionally substituted acyliminoxy, optionally substituted acyloxy, optionally substituted arylalkyl, optionally substituted arylalkoxy, optionally substituted alkenyl, optionally substituted alkenyloxy, optionally substituted alkoxy, optionally substituted alkyl, optionally substituted alkynyl, optionally substituted alkynyloxy, optionally substituted amino, optionally substituted aminoacyl, optionally substituted aminoacyloxy, optionally substituted aminosulfonyl, optionally substituted aminothioacyl, optionally substituted aryl, optionally substituted aryloxy, optionally substituted cycloalkenyl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted heterocyclyl, optionally substituted oxyacyl, optionally substituted oxyacylamino, optionally substituted oxyacyloxy, optionally substituted oxyacylimino, optionally substituted oxysulfinylamino, optionally substituted oxysulfonylamino, optionally substituted oxythioacyl, optionally substituted oxythioacyloxy, optionally substituted sulfinyl, optionally substituted sulfinylamino, optionally substituted sulfonyl, optionally substituted sulphonylamino, optionally substituted thio, optionally substituted thioacyl, optionally substituted thioacylamino, or R1A and R1B together form an optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heteroaryl, optionally substituted cycloalkyl, or optionally substituted cycloalkenyl;
R1C represents C1-3 alkoxy, C1-3 alkylthio, C1-3 alkylamino, or C1-3 dialkylamino;
R1D represents hydroxy, amino, or phosphate ester;
L represents C?O, O, S, SO, SO2, Se, SeO, SeO2, C?NZ?, or NR? where Z? is H, optionally substituted alkyl, optionally substituted aryl or optionally substituted amino; and where R? is selected from H, O, optionally substituted acyl, optionally substituted alkenyl, optionally substituted alkyl, optionally substituted aryl, optionally substituted cycloalkenyl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted heterocyclyl, or optionally substituted sulfonyl;
R2A-R2E each independently represents H, carboxy, cyano, dihalomethoxy, halogen, hydroxy, nitro, pentahaloethyl, phosphorylamino, phosphono, phosphinyl, sulfo, trihaloethenyl, trihalomethanethio, trihalomethoxy, trihalomethyl, optionally substituted acyl, optionally substituted acylamino, optionally substituted acylimino, optionally substituted acyliminoxy, optionally substituted acyloxy, optionally substituted arylalkyl, optionally substituted arylalkoxy, optionally substituted alkenyl, optionally substituted alkenyloxy, optionally substituted alkoxy, optionally substituted alkyl, optionally substituted alkynyl, optionally substituted alkynyloxy, optionally substituted amino, optionally substituted aminoacyl, optionally substituted aminoacyloxy, optionally substituted aminosulfonyl, optionally substituted aminothioacyl, optionally substituted aryl, optionally substituted aryloxy, optionally substituted cycloalkenyl, optionally substituted cycloalkyl, optionally substituted heteroaryl, optionally substituted heterocyclyl, optionally substituted oxyacyl, optionally substituted oxyacylamino, optionally substituted oxyacylimino, optionally substituted oxyacyloxy, optionally substituted oxysulfinylamino, optionally substituted oxysulfonylamino, optionally substituted oxythioacyl, optionally substituted oxythioacyloxy, optionally substituted sulfinyl, optionally substituted sulfinylamino, optionally substituted sulfonyl, optionally substituted sulphonylamino, optionally substituted thio, optionally substituted thioacyl, optionally substituted thioacylamino, or optionally substituted thioacyloxy; or any of R2A and R2B, R2B and R2C, R2C and R2D, and R2D and R2E, together form an optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted heteroaryl, optionally substituted cycloalkyl, or optionally substituted cycloalkenyl; and
Q represents C1-4 alkyl,and,at least one further compound that is cytotoxic.

US Pat. No. 10,213,407

COMPOUNDS AND METHODS FOR INHIBITING PRODUCTION OF TRIMETHYLAMINE

THE CLEVELAND CLINIC FOUN...

1. A method of inhibiting the conversion of choline or carnitine to trimethylamine (TMA) by a bacterium comprising: contacting the bacterium with a compound as set forth in Formula (I):
wherein
Y+ is selected from a quaternary nitrogen; X? is an anion; n is selected from 1, 2 or 3; R2 and R3 are independently selected from C1-4 alkyl or bound together forming an aliphatic, aromatic or heterocyclic ring system;
R4 is selected from C1-4 alkyl, alkenyl, alkynyl, alkoxy carbonyl, alkoxy dicarbonyl, acrylic, alkoxy, alkoxy alkyl, aryloxy alkyl, alkyl carboxylate as part of a betaine, inner salt, or Zwitterion form, halo alkyl, hydroxy alkyl, nitrile, or propargyl;
R6 is selected from C1-4 alkyl, alkoxy, hydroxy, alkoxy alkyl, hydroxy alkyl, or epoxy; and
including any acceptable salts or solvates thereof.

US Pat. No. 10,213,406

?- AND ?-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF

THE RESEARCH FOUNDATION F...

1. A method of inhibiting the activity of a Fatty Acid Binding Protein (FABP) comprising contacting the FABP with a compound having the structure:
wherein
one of R1 or R2 is —C(?O)R13, —C(?O)OR13, —C(?O)NR13R14, -alkyl-OC(?O)OR13, -alkyl-OC(?O)R13, -alkyl-OR13, -alkyl-NR13R14, -alkyl-NHC(?O)R13, -alkyl-NHC(?O)OR13, -alkyl-NHC(?O)NR13R14, -alkyl-NHC(?S)NR13R14, or -alkyl-NHC(?NR13)NR13R14,
wherein R13 and R14 are each, independently, H, CF3, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, heteroalkyl, cycloalkyl, aryl, heteroaryl, heterocyclyl or combine to form a cycloalkyl or heterocyclyl; and
the other of R1 or R2 is —C(?O)OR13, wherein R13 is H;
R3, R4, R5, R6, R7, R8, R9, R10, R11 and R12 are each independently, H, halogen, —NO2, —CN, —NHR15, —NR15R16, —SR15, —SO2R15, —OR15, —CO2R15, CF3, -alkyl-NHR15, -alkyl-NHR15R16, -alkyl-OR15, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, aryl, heteroaryl, or heterocyclyl,
wherein R15 and R16 are each, independently, H, CF3, C1-10 alkyl, C2-10 alkenyl, C2-10 alkynyl, heteroalkyl, cycloheteroalkyl, aryl, heteroaryl, or heterocyclyl,
or a pharmaceutically acceptable salt thereof.

US Pat. No. 10,213,404

CONTROLLED RELEASE DOSAGE FORM

OSMOTICA KERESKEDELMI ES ...

1. A method of treating a condition, disorder or disease that is therapeutically responsive to (R)-baclofen (ARBAC), the method comprising orally administering to a subject in need thereof at least one controlled release oral dosage form comprising: a) a core ARBAC and at least two water-swellable excipients; and b) a semipermeable membrane surrounding the core, said membrane comprising at least two film-forming cellulose esters and at least one preformed passageway; whereinfollowing oral administration of said dosage form, the dosage form releases a majority of ARBAC downstream of the stomach and upstream of the colon.

US Pat. No. 10,213,403

CONTROLLED RELEASE DOSAGE FORM

OSMOTICA KERESKEDELMI ES ...

1. A method of treating a condition, disorder or disease that is therapeutically responsive to (R)-baclofen (ARBAC), the method comprising orally administering to a subject in need thereof at least one controlled release oral dosage form comprising: a) a core comprising ARBAC, at least one disintegrant, at least one osmotic agent, at least one binder, at least one water swellable cellulose derivative (CD) polymer and at least one water swellable polyalkylene oxide (PAO) polymer, wherein the amount of PAO polymer exceeds the amount of CD polymer; and b) a semipermeable membrane surrounding the core, said membrane comprising at least two different grades of cellulose acetate polymer and at least one preformed passageway; wherein:about 60 to about 100% wt of the drug is released over a period of about 6 to about 16 hours under conditions defined in USP <711> using a Type II apparatus with 0.1 N HCl stirred at 50 rpm and maintained at a temperature of 37±0.5° C.; and
following oral administration to a subject, the dosage form provides a majority of drug release from the core downstream of the stomach and upstream of the colon.

US Pat. No. 10,213,402

CONTROLLED RELEASE DOSAGE FORM

OSMOTICA KERESKEDELMI ES ...

1. A controlled release oral dosage form comprising: a) a core comprising at least one GABAB receptor agonist and at least two water-swellable excipients; and b) a semipermeable membrane surrounding the core, said membrane comprising at least two film-forming cellulose esters; wherein the at least one GABAB receptor agonist is (R)-baclofen (ARBAC); and following oral administration of said dosage form, the dosage form releases a majority of ARBAC downstream of the stomach and upstream of the colon.

US Pat. No. 10,213,401

IMMUNOMODULATORY AND DIFFERENTIATING FUNCTION SELECTIVE RETINOID AND REXINOID COMPOUNDS IN COMBINATION WITH IMMUNE MODULATORS FOR CANCER IMMUNOTHERAPY

Io Therapeutics, Inc., S...

1. A method of potentiating chimeric antigen receptor-modified immune cells (CAR-MIC) cancer immunotherapy comprising administering an immunomodulatory retinoid active agent and/or rexinoid active agent (RAR/RXR active agent), and a differentiating RAR active agent to a cancer patient who is receiving, has received, or is scheduled to receive, CAR-MIC, wherein the immunomodulatory RAR/RXR active agent is:a) a RAR? antagonist, wherein the RAR? antagonist is:
i) a compound of general formula (I)

wherein R1, R2, R3, and R6 are independently H or C1-6 alkyl; R4 and R5 are independently H or F; Ar is phenyl, pyridyl, thienyl, furyl, or naphthyl; X is C(CH3)2, O, S, or NR7, wherein R7 is H or C1-6 alkyl; X1 is H or halogen such as F, Cl or Br; and R8 is H or OH; or
ii) a compound of general formula (II)

wherein R1 and R2 are independently C1-6 alkyl; X is O, S, or CH2; Y is O, S, CH2, or NR3, wherein R3 is C1-6 alkyl; Z is Cl or Br; W is H or OH; and U is independently H or F; or
iii) a compound of general formula (III):

wherein R1 and R2 are independently H or C1-6 alkyl; R3 is H or F; Ar is phenyl, pyridyl, thienyl, furyl, or naphthyl; X is O, S, N, or CH2; W is H or OH; and Z is Cl or Br; or
iv) BMS185411, BMS614, Ro41-5253, Ro46-5471, or AGN 194777; or
b) a RAR? agonist, wherein the RAR? agonist is:
i) a compound of general formula (IV):

wherein R1 and R2 are independently H or C1-6 alkyl; R3 is H or F; and X is O, S, CH2, C(R4)2, or NR5, wherein R4 and R5 are independently H or C1-6 alkyl; or
oriii) CD437, CD2325, CD666, or BMS961; or
c) a RXR antagonist, wherein the RXR antagonist is:
AGN195393, LGN100849,
ord) a combination thereof; andwherein the differentiating RAR active agent is a RAR? agonist, wherein the RAR? agonist is a compound of general formula (V):
wherein R1 is H or C1-6 alky, R2 and R3 are independently H or F, and R4 is a halogen.

US Pat. No. 10,213,395

TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT

Aldeyra Therapeutics, Inc...

1. A method of treating uveitis, comprising:administering to a subject with uveitis a therapeutically effective amount of a compound of formula (I):
or a pharmaceutically acceptable salt thereof, wherein,X is CH; Z is N; and Y is C with the —NH2 attached;
p is 0, 1, 2, or 3;
each RB is independently a halogen, hydroxyl, carbamoyl, amino, or aryl;
RA is
andeach Qa is independently a C1-C6 straight chain alkyl.

US Pat. No. 10,213,392

PHARMACEUTICAL COMPOSITION FOR USE IN MEDICAL AND VETERINARY OPHTHALMOLOGY

MITOTECH SA, Luxembourg ...

1. A method of treating an eye pathology, comprising administering to a subject afflicted with such an eye pathology a therapeutically-effective amount of a pharmaceutical composition comprising:(a) from 1 nm to 25000 nm of a mitochondria-addressed antioxidant comprising:

(b) from 0.01% to 0.2% of a lipophilic, cationic concentration stabilizer that stabilizes a concentration of the mitochondria-addressed antioxidant by preventing reversible and irreversible absorption of the antioxidant to walls of a vial containing the pharmaceutical composition, the stabilizer comprising a benzalkonium salt, berberine, palmatine, tetraphenylphosphonium, tetrabutyl ammonium, or combinations thereof; and
(c) from 0.001% to 1% of a prolongator comprising a disaccharide, a trisaccharide, a polysaccharide, methylcellulose, hydroxyethylcellulose, hydroxypropyl-methyl cellulose, carboxymethylcellulose, sodium chondroitin sulfate, sodium hyaluronate, carboxyvinyl polymer, polyvinyl ethanol, polyvinylpyrrolidone, macrogol, or combinations thereof.

US Pat. No. 10,213,382

NANOSUSPENSION OF NATURAL MATERIALS AND PREPARATION METHOD THEREOF

APURANO PHARMACEUTICALS G...

1. A method for the preparation of a nanosuspension, the method comprising:dispersing at least one natural material having a particle size (D100) of less than 320 ?m in a solvent, thereby obtaining a dispersion; and
milling the dispersion to a particle size (D90) of below 500 nm,
wherein the nanosuspension comprises the at least one natural material,
wherein the at least one natural material is at least one selected from the group consisting of plants, cyanobacteria, algae and fungi, and
wherein the at least one natural material is not an extract.

US Pat. No. 10,213,377

TOPICAL SKIN COMPOSITIONS FOR TREATING WRINKLES

Mary Kay Inc., Addison, ...

1. A method of stimulating adipogenesis in a person's skin, the method comprising topically applying to skin in need thereof, a composition comprising an effective amount of Commiphora mukul resin or an extract thereof that includes oleo gum resin, wherein adipogenesis in the person's skin is stimulated.

US Pat. No. 10,213,371

STABLE COSMETIC PREPARATION WITH A HIGH PIGMENT CONTENT

BEIERSDORF AG, Hamburg (...

1. A cosmetic preparation, wherein the preparation is present as an emulsion and comprises, based on a total weight of the preparation:(a) at least 4% by weight of a compound of formula (I):

(b) at least 20% by weight of (i) titanium dioxide having a surface coating consisting of one or more of sodium hexametaphosphate, sodium metaphosphate, iron oxide, aluminum stearate, stearic acid, lauric acid, dimethicone, methicone, methylhydrogenpolysiloxane, octyltrimethylsilane, triethoxycapryl silane, and/or of (ii) zinc oxide having a surface coating consisting of one or both of dimethicone and methicone.

US Pat. No. 10,213,367

DENTAL MATERIALS WITH DEBONDING-ON-DEMAND PROPERTIES

Ivoclar Vivadent AG, Sch...

1. Radically polymerizable dental material which contains at least one compound of Formula I:
with:
A=H; —CN; a phenyl residue which can carry one or more substituents; or an aliphatic linear or branched C1-C20 alkylene residue which can be interrupted by one or more 1,4-phenylene groups, urethane groups, O or S and which can carry in the terminal position a polymerizable vinyl, (meth)acryloyloxy or (meth)acrylamide group;
R1=H, an aliphatic linear or branched C1-C9 alkyl radical, tolyl or phenyl;
L=SO2R3, wherein R3 is CH3 or tolyl;
X=—COO—, —CON(R10)— or is absent, wherein the bond to A takes place via O or N and
R10=H; or is an aliphatic linear or branched C1-C20 alkylene residue which can be interrupted by one or more O or S and which can carry in the terminal position a polymerizable vinyl, (meth)acryloyloxy, (meth)acrylamide group, —C(?CH2)—COOR11 or —C(?CH2)—CO—NR12R13, wherein R11-13 in each case independently of each other are a linear or branched C1-6 residue;
n=an integer from 1 to 6,
and at least one thermolabile radically polymerizable compound and/or at least one photolabile radically polymerizable compound.

US Pat. No. 10,213,366

PACIFIER ASSEMBLY COMPRISING OUTER CONTAINER, WRISTBAND, AND TETHER

TWL, LLC, Richland, NC (...

1. An assembly comprising:a container defining a cavity for housing a bulbous portion of a pacifier;
a tether for coupling the container to a ring, the ring selectively engageable with the pacifier;
a spool housed within the container for retracting the pacifier into a stored position from an extended position, wherein the bulbous portion is housed within the cavity in the stored position and is a distance from the cavity in the extended position; and
the ring and the container each including at least one magnet for selectively engaging the ring to the container and positioning the pacifier within the cavity when the ring is engaged with the pacifier and the pacifier is retracted by the spool.

US Pat. No. 10,213,365

DOSE INDICATION DEVICE

1. A dose indicator device for attachment to a container cap on a container, comprising:a. a base disk having a first upper surface and a second lower surface where in the first upper surface includes a center mount axle extending from center of the first upper surface of the base disk, wherein the center mount axle includes a shaft and a head and wherein a circumference of the head is larger than a circumference of the shaft, wherein the first upper surface supports an overlay plate with a center-spaced opening placed over the base disk such that the opening is placed over the center mount axle, wherein the overlay plate displays dose indicia for indicating time and the second lower surface of the base disk contains an adhesive, magnet base, or hook-and-loop fastener material which allows the base disk to be attached to a surface;
b. a reminder dial rotatably positioned at the center of the base disk by means of the center mount axle and extending outwardly toward the dose indicia for indicating time; and
c. a second pointer directly attached to the base disk for designating a second date/time of interest.

US Pat. No. 10,213,363

ACUPUNCTURE NEEDLES WITH ACCESSORIES FOR SENSING AND STIMULATION

Acumedical, Inc., North ...

1. An apparatus configured to provide an interface between a medical device and a person having skin and tissue under the skin, the apparatus comprising:an acupuncture needle configured to be connected to the medical device, the acupuncture needle including:
a handle; and
a needle body coupled to the handle, the needle body including a proximal end portion connected to the handle, a distal end portion including a needle tip suitable for piercing the skin and the tissue, and an elongate body shaft coupled between the proximal end portion and the distal end portion; and
a guiding tube configured to assist percutaneous insertion of a substantial portion of the needle body into the tissue, the guiding tube including:
an elongate tube of electrically non-conductive material, the elongate tube including a proximal end including a proximal opening, a distal end including a distal opening for contacting the skin and a lumen between the proximal opening and the distal opening, the lumen configured to allow the needle tip to enter the proximal opening and exit from the distal opening;
an electrode incorporated into the distal end of the elongate tube; and
a connector configured to allow for electrical connection between the electrode and the medical device.

US Pat. No. 10,213,362

PORTABLE HYDRO-THERMAL THERAPY SYSTEM FOR USE WITH A VESSEL FOR CONTAINING WATER AND METHOD FOR USE OF SAME

Hobson A. Howell, Woodwa...

1. A portable hydro-thermal therapy kit, comprising:a vessel having an open top, the vessel being an open water tank source for a cool water supply water device having water;
a portable hydro-thermal therapy system comprising:
a mobile trailer having a platform, the mobile trailer including four wheels and a handle mounted to the platform, the mobile trailer physically configured for an individual to achieve point-to-point haulage thereof;
the mobile trailer having a design weight of about 200 pounds;
the cool water supply device mounted on the platform, the cool water supply device having an inlet port and an outlet port, the cool water supply device including:
a closed water circulation path within the cool water supply device defining a path from the inlet port to the outlet port with the open water tank source consisting of a water source,
a thermometer monitoring the temperature of water pumping into the inlet port, and the thermometer monitoring the temperature of water pumping from the outlet port,
a water pump coupled to the closed water circulation path, the water pump for pumping water from the inlet port to the outlet port,
a refrigeration cycle contained within the cool water supply device, the refrigeration cycle including a refrigerant circulating through a condensing coil, an expansion valve, a evaporator coil, and a compressor under the thermal control of a thermostat in communication with the thermometer, and
the closed water circulation path including a water thermal exchange chamber interposed between the inlet port and outlet port, the water thermal exchange chamber being thermally proximate to the evaporator coil,
the thermostat and water pump cooperating in combination to provide water between about 50° F. and about 55° F.;
a flow restrictor secured to an outlet tubing to regulate the back pressure in order to ensure proper pressure is maintained,
the closed water circulation path being thermally proximate to the evaporator coil in order to cool the water being pumped through the water circulation path;
inlet tubing coupled to the inlet port, the cool water supply device configured to pump water out of the vessel through the inlet tubing as the sole source of water to the cool water supply device;
the cool water supply device having a design with flow of about seven gallons/minute with an about 300 gallons cooling capacity;
the outlet tubing coupled to the outlet port, the cool water supply device configured to pump water into the vessel through the outlet tubing; and
a controller located within the cool water supply device in communication with the closed water circulation path and the refrigeration cycle, the controller including memory, which is accessible to a processor, the memory includes processor-executable instructions that, when executed cause the processor to execute instructions for measuring temperature via the thermometer, selectively activating the water pump, and selectively activating the refrigeration cycle to achieve a change in temperature of the water flowing through the closed water circulation path based on matching the desired temperature with the rate of flow and refrigeration cooling coefficient in view of the constant pressure maintained by the flow restriction.

US Pat. No. 10,213,361

MUSCLE FIBER EXCITATION SYSTEM FOR PREVENTING BLOOD CLOT AND MUSCULAR-SKELETAL DECLINE

1. A muscle fiber excitation system (WES) for use in stimulating circulation to ameliorate formation of a blood clot and to prevent muscular-skeletal decline in a patient, the system comprising:a) an enclosure comprising a base and two pillar blocks, wherein the pillar blocks each comprise a first and a second channel, the first and the second channel comprising bearings, the pillar blocks being parallel to each other such that the first channel on the first pillar block is aligned with the first channel on the second parallel pillar block and the second channel on the first pillar block is aligned with the second channel on the second parallel pillar block;
b) a first and a second shaft, each shaft affixed with two cams, wherein the first shaft is mounted in the first channels of the first and second pillar block and the second shaft is mounted in the second channels of the first and second pillar block, the first and second shafts being rotatably mounted off the enclosure base in the bearings in the channels of the pillar blocks;
c) a direct current motor mounted within the enclosure, the direct current motor being operably linked to a power source, and being configured to drive at least one timing belt, wherein the at least one timing belt is coupled to the first and the second shaft such that operation of the direct current motor drives the timing belt and thereby rotates the first and the second shafts;
d) four plungers, each plunger being positioned at a corner of the enclosure; and
e) a telescoping platform configured to be mounted on the enclosure, the telescoping platform having a patient contact surface, a cam contact surface, and four telescoping plunger channels, each channel being configured to receive one of the four plungers, wherein the cam contact surface comprises one or more cam contact areas aligned with one or more of the cams within the enclosure;
wherein operation of the direct current motor rotates the shafts and each cam affixed thereto, causing rotation of the cams and subsequent contacting of the respective cam contact areas of the telescoping platform,
wherein each of the two cams affixed to each shaft is unique and comprises peaks of varying heights and ascend gradients, and troughs of varying depths and descend gradients,
wherein each cam is assembled to be out of phase with the other cams, and
wherein the system is configured to execute multiple displacements of equal magnitude in each of a vertical, a medial-lateral, and an anterior-posterior direction.

US Pat. No. 10,213,360

DIAGNOSTIC AND TREATMENT METHODS

MC HEALTH TECH S.L., Bar...

1. A method of treating a tensional myofascial chain the tensional myofascial chain having a plurality of links and dominating an affected area where the patient is reporting symptoms selected from the group of muscular pain, fascial pain, inflammation, limitation of the joint articulation movement, and stenosis in the vascular, lymphatic or nervous systems, the tensional myofascial chain beginning at an asymptomatic primary lesion and ending at a symptomatic lesion distal from the primary lesion, said method comprising;(i) identifying which link of the chain is the primary lesion, the primary lesion being the link within the tensional myofascial chain which is in the most caudal position; and,
(ii) treating the primary lesion by applying a series of vacuum pulses, each of the vacuum pulses representing a series having a trapezoidal form when the vacuum intensity is represented in the Y axis and time is represented in the X axis.

US Pat. No. 10,213,359

SCAR REDUCTION APPARATUS

I2R MEDICAL LIMITED, Dor...

13. A method of reducing scar tissue prominence, the method comprising the step of imparting a localised positive urging force directly to formed scar tissue via a uniformly or substantially uniformly localised negative pressure differential above the scar tissue, the negative pressure differential being imparted by an at least partially air-evacuated chamber above the scar tissue and wherein said chamber is at least partially air-evacuated prior to application above the scar tissue.

US Pat. No. 10,213,358

MINIATURISED INSTRUMENT FOR SIMULATING SIMULTANEOUS VISION BY GENERATING MASKS

CONSEJO SUPERIOR DE INVES...

1. A miniaturised instrument for simulating simultaneous vision by generating masks, characterised in that it comprises:a mask-generating element which generates at least two complementary masks, with a temporal frequency of alternation such that, sequentially, each mask lets an incident light from an object partially pass, at the same time as the at least one other mask partially blocks said incident light;
an adjustable lens of variable optical power which generates, with said temporal frequency of alternation, at least two different optical powers corresponding to at least two observation distances;wherein the mask-generating element and the adjustable lens are located in a single optical channel wherethrough said incident light circulates, such that each mask of the mask-generating element is temporally synchronised with each power of the adjustable lens, obtaining, via temporal fusion, a combined pupil pattern of at least two observation distances.

US Pat. No. 10,213,357

AMBULATORY EXOSKELETON AND METHOD OF RELOCATING EXOSKELETON

Ekso Bionics, Inc., Rich...

10. An ambulatory exoskeleton comprising:a control system configured to control the exoskeleton in at least two different modes, with one mode constituting an unworn propulsion mode, used when the exoskeleton is not worn by a user, and another mode constituting a default or worn propulsion mode, used when the exoskeleton is worn by a user;
means for causing the control system to enter or exit the unworn propulsion mode; and
means for controlling movement of the exoskeleton in the unworn propulsion mode, wherein the means for controlling includes a handle having a sensor, wherein the control system causes the exoskeleton to move based on a magnitude and a direction of a force applied to the handle as measured by the sensor, wherein the force applied determines when and how fast to take a step, and wherein, when the control system determines that the force is applied to only one side, the control system causes the exoskeleton to take repeated steps on one leg to facilitate turning.

US Pat. No. 10,213,356

ORTHOSIS DEVICE

Cadence Biomedical, Seat...

1. An apparatus comprising:a harness, wherein the harness circumferentially secures a first enclosed region; and
at least one brace comprising:
an articulated frame articulably attached to the harness comprising an upper component, a lower component, and a force-directing device;
the upper component articulably attached to the harness;
the lower component formed to hingeably attach to the upper component at a knee joint;
a pre-tensioning device, wherein the pre-tensioning device is coupled to the harness opposite of the first enclosed region, comprising at least one pawl, a pre-tensioning rim, and a centrally-located gear;
an energy-transforming mechanism comprising an energy storage device coupled to the pre-tensioning device via a superior exotendon and coupled to a lower assembly via an inferior exotendon;
the energy storage device elastically positioned between the force-directing device and the lower assembly; and
the lower assembly coupled to the articulated frame, wherein the lower assembly further comprises a tensioner, a lower wheel coupled to the inferior exotendon, and a foot plate hingeably attached to the lower wheel.

US Pat. No. 10,213,355

THERAPEUTIC PILLOW

1. An adjustable pillow comprising:a foam body having a top surface, an opposing bottom surface, a rear edge and an opposing front edge and lateral sides, wherein the foam body is defined by a first region that includes the front edge, a second region adjacent the first region and a third region adjacent the second region and defining the rear edge, wherein the first region has a convex shape, the second region has a concave shape and the third region has a convex shape, the pillow having a maximum thickness in the first region and a minimum thickness in the second region, the first region having a first section that extends to the front edge and has a positive slope and an adjacent second section that has a negative slope and extends to the second region, wherein the front edge has a height greater than the rear edge; and
a plurality of ribs extending longitudinally between the lateral sides and being located exclusively within the first section of the first region which has positive slope; and one or more foam inserts or foam pads for altering the thickness of the pillow.

US Pat. No. 10,213,354

WHEELED TRANSPORTATION DEVICE

IDEAssociates (IOM) Limit...

1. A wheeled transportation device comprising a base, where the base comprises a front end, a rear end, an upper part and a lower part,said lower part comprising a number of wheels and said upper part comprising at least one substantially horizontal and plane surface,
said wheeled transportation device comprising at least one movable first engagement member adapted to engage a frame part of a bed,
said movable first engagement member being movable between a resting engagement member position and an activated engagement member position, said movable first engagement member extending above said substantially horizontal and plane surface in the activated engagement member position,
wherein said upper part comprises a further engagement member located above said at least one substantially horizontal and plane surface, and
wherein said resting engagement member position is located at or below said at least one substantially horizontal and plane surface.

US Pat. No. 10,213,353

BED STEP STOOL AND METHOD OF USE

1. A bed step stool for assisting a user into and out of bed including opposite sides, a head, and a foot, comprising:a first support to be disposed closer to the head of the bed;
a second support to be disposed closer to the foot of the bed;
a step assembly supported between the first support and the second support, the step assembly to enable the user to step thereon for assisting the user into and out of the bed,
wherein the first support and the second support define an unobstructed pathway for entry and exit with respect to the bed and the bed step stool that is perpendicular with respect to the sides of the bed whereby the user goes between the first support and the second support to step onto the step assembly and off the step assembly without any obstruction.

US Pat. No. 10,213,352

HAND-HELD CONTROL FOR AN ELECTROMOTIVE FURNITURE DRIVE, METHOD FOR DETECTING ACTUATION OF A HAND-HELD CONTROL, AND ELECTROMOTIVE FURNITURE DRIVE

DewertOkin GmbH, Kirchle...

1. A method for detecting an actuation of a hand-held control for an electromotive furniture drive, wherein the hand-held control has at least one detector, comprising the steps of:applying an electric periodic test signal from at least one evaluation unit to at least one sensor surface of at least one detector via detector conductor paths, wherein the at least one evaluation unit is connected to the at least one detector in an electrically conducting manner;
recording a response signal by means of a test signal modified by actuation of the at least one detector;
evaluating the test signal thus obtained using the at least one evaluation unit and producing a logic switching signal for detecting the actuation of the hand-held control,
wherein a height of a signal level of the response signal of the sensor surface of the detector is previously assigned to a related actuation.

US Pat. No. 10,213,351

MOBILE SCREENING APPARATUS

FRAZER, LTD., Houston, T...

1. A mobile screening apparatus comprising:a patient compartment having a floor, an end wall, a first sidewall and a second sidewall, said second sidewall having an expanding wall that is slidable between a retracted position and an extended position;
a vehicle having a chassis upon which said patient compartment is positioned, said vehicle having wheels rotatably mounted to said chassis so as to allow said vehicle to move along an underlying surface;
a scanner positioned in said patient compartment, said scanner having a length dimension and a width dimension, said length dimension extending longitudinally within said patient compartment such that said length dimension of said scanner is aligned with a longitudinal axis of said patient compartment, said length dimension being greater than said width dimension, said scanner having a circular or oval opening.

US Pat. No. 10,213,350

RADIALLY TENSIONED WOUND OR SKIN TREATMENT DEVICES AND METHODS

Neodyne Biosciences, Inc....

1. A dressing system, comprising:a dressing comprising a first edge and a second edge, wherein the second edge has an orientation that is non-parallel and non-orthogonal to the first edge when the dressing is in an unstrained state, and a first face comprising an adhesive;
a frame removably attached to the first edge and the second edge of the dressing, the frame comprising an outer edge, an inner edge, and an opening surrounded by the inner edge wherein the dressing is releasably attached to the frame by an attachment structure and is positioned over the opening; and
a straining structure configured to be pushed through the opening to apply a straining force to a central region of the dressing that radiates from the central region orthogonally to the first edge of the dressing and to the second edge of the dressing by displacing the central region of the dressing by a predetermined distance from the opening.

US Pat. No. 10,213,349

PATIENT INCONTINENCE AND LIFTING PAD

1. A patient incontinence and lifting pad comprises:a bed pad;
a first securing strap;
a second securing strap;
an absorbent incontinence pad insert;
the bed pad comprises a base surface, a cover surface, an outer edge, an inner edge, and a slot;
the base surface and the cover surface being opposite surfaces of the bed pad;
the first securing strap being connected onto the base surface, adjacent to the outer edge;
the second securing strap being connected onto the base surface, opposite to the first securing strap;
the slot traversing through the bed pad from the cover surface to the base surface;
the slot being delineated by the inner edge;
the absorbent incontinence pad insert being positioned within the slot;
the absorbent incontinence pad insert being peripherally mounted to the cover surface; and
the bed pad, the first securing strap, the second securing strap, and the absorbent incontinence pad insert are composed of superabsorbent polymer.

US Pat. No. 10,213,348

ELASTIC STRUCTURE FOR ABSORBENT SANITARY PRODUCTS, AND A METHOD AND APPARATUS FOR ITS PRODUCTION

FAMECCANICA.DATA S.P.A., ...

1. An elastic structure for absorbent sanitary products, comprisinga sleeve comprising a first layer and a second layer overlapping each other,
at least one elastic thread which extends within said sleeve in a longitudinal direction; and
a plurality of first connecting portions spaced apart in the longitudinal direction, wherein each of said first connecting portions comprises two first welds arranged on opposite sides of the thread, wherein the first welds weld said first layer and said second layer to each other in a first longitudinal portion of said sleeve, and wherein said first welds of each of said first connecting portions have respective proximal surfaces facing the thread spaced apart by a distance, less than the diameter of the untensioned thread, in order to anchor the thread to first said longitudinal portion of the sleeve,
characterized in that it comprises a plurality of second connecting portions spaced apart in the longitudinal direction, wherein each of said second connecting portions comprises at least one second weld, wherein said second welds weld said first layer and said second layer to each other in a second longitudinal portion of said sleeve without axially connecting the thread to said second longitudinal portion of the sleeve.

US Pat. No. 10,213,347

ABSORBENT ARTICLE WITH AN APERTURED MULTI-LAYERED TOPSHEET

Kimberly-Clark Worldwide,...

1. An absorbent article that extends in a plane defined by a longitudinal direction and a transverse direction, wherein the article comprises:a liquid permeable multi-layered topsheet having a length in the longitudinal direction, a width in the transverse direction, a longitudinal centerline, and a transverse centerline, wherein the multi-layered topsheet defines a body-facing surface of the absorbent article, the multi-layered topsheet comprising at least a first topsheet layer disposed above a second topsheet layer, wherein the first topsheet layer defines a first opening having a first perimeter, wherein the first topsheet layer and the second topsheet layer are joined by a seal, and further wherein the multi-layered topsheet extends in the longitudinal direction to define a distal end and an opposing proximal end of the absorbent article and in the transverse direction to define a first edge and an opposing second edge of the absorbent article;
a liquid impermeable baffle, wherein the baffle defines a garment-facing surface of the absorbent article;
a first sub-topsheet layer positioned between the second topsheet layer and the baffle, wherein the first sub-topsheet layer defines a second opening having a second perimeter, wherein the first perimeter surrounds the second perimeter; and
a second sub-topsheet layer positioned between the first sub-topsheet layer and the baffle, wherein the second sub-topsheet layer has a shape that includes a first bulge facing the first edge in the transverse direction and a second bulge facing the second edge in the transverse direction, wherein the first bulge and the second bulge are visible from the body-facing surface of the absorbent article, and further wherein the second sub-topsheet layer defines a third opening having a third perimeter.

US Pat. No. 10,213,346

UNIT FOR FORMING ABSORBENT SANITARY ARTICLES AND METHOD FOR MAKING ABSORBENT SANITARY ARTICLES

GDM S.p.A., Bologna (IT)...

1. A unit for forming absorbent sanitary articles, comprising:a drum rotatable about an axis of rotation and having a circumferential peripheral surface movable along a feed direction;
a first feeding device including a rotatable member for feeding a succession of pairs of panels of material facing the circumferential peripheral surface and configured to position each pair such that two panels of each pair of panels are facing each other and transversely aligned with the feed direction;
a second feeding device including a roller for feeding a continuous web of material suitable for defining at least part of a main body of an absorbent sanitary article, and configured to position the continuous web on the circumferential peripheral surface such that each of the two panels projects partly sideways from the continuous web;
an ultrasonic sealing station located along the circumferential peripheral surface, in a zone located operatively downstream of the second feeding device, and configured to attach each of the two panels to the continuous web at at least one plurality of sealing points arranged in succession along the feed direction; the ultrasonic sealing station comprising at least one first sonotrode and at least one second sonotrode facing the circumferential peripheral surface and spaced from each other transversely to the feed direction such that each acts on a respective one of the two panels;
wherein the at least one first sonotrode and the at least one second sonotrode are movable towards and away from each other in order to adapt to a size of the absorbent article.

US Pat. No. 10,213,345

APPARATUS AND PROCESS FOR PROVIDING A COILED COLLAGEN CARRIER

TAKEDA AS, Asker (NO)

1. An apparatus for providing one or more coiled collagen carriers each configured for application to a patient, the apparatus comprising:a device for applying moisture to a collagen carrier so as to moisturise the collagen carrier; and
a coiling device to which the moisturised collagen carrier is conveyed from the moisturising device, the coiling device comprising:
a pair of elongated members for gripping along an edge of the moisturised collagen carrier and coiling the moisturised collagen carrier in a lengthwise or widthwise direction thereof to produce the coiled collagen carrier; and
a support device comprising a tray defining a cavity within which said coiling takes place by the rotatable gripping means, said cavity formed by wall segments of the tray against which the moisturised collagen carrier is supported during said coiling, wherein the support device maintains the coiled shape of the moisturised collagen carrier within the apparatus downstream of the coiling device.

US Pat. No. 10,213,344

DRESSING WITH MOISTURE INDICATOR

Availtek LLC, Carmel, IN...

1. A medical dressing comprising:an adhesive, permeable layer configured to adhere to skin near a wound;
a fabric support disposed on the adhesive, permeable layer;
a hydrochromatic layer disposed on the fabric support configured to change a color appearance responsive to contact with moisture; and
wherein each of the permeable layer and the fabric support define an outer periphery, the outer periphery having a notch therein defining an entry point for a percutaneous device, and wherein the fabric support includes a void spaced apart from the notch, the void configured to align with a percutaneous device insertion site when said dressing is applied to the wound.

US Pat. No. 10,213,343

THREE-LAYERED WOUND DRESSING AND METHOD OF MANUFACTURING THE SAME

FOSHAN UNITED MEDICAL TEC...

1. A method of manufacturing a three-layered wound dressing, the three-layered wound dressing comprising a first layer, a second layer, and a third layer; the first layer comprising a blend of first hydrophilic fibers and first hydrophobic fibers; the second layer comprising a blend of second hydrophilic fibers and second hydrophobic fibers; and the third layer comprising hydrophobic fibers; the second layer being disposed between the first layer and the third layer; and the first layer being adapted to contact a wound; the method comprising one of the following three steps:1) manufacturing the first layer, the second layer and the third layer separately using a heat binding method, or a needle punching method or a hydro entanglement method; then laminating three layers together by heat bonding, or needle punching or chemical bonding, followed by cutting, packing and sterilization;
2) manufacturing the first layer, the second layer and the third layer separately using a heat binding method, or a needle punching method or a hydro entanglement method; laminating the first layer and the second layer together by heat bonding, or needle punching or chemical bonding; and then manufacturing the third layer onto the laminated first/second layer directly, followed by cutting, packing and sterilization; and
3) manufacturing the second layer and the third layer separately using a heat binding method, or a needle punching method or a hydro entanglement method; laminating the second layer and the third layer together by heat bonding, or needle punching or chemical bonding; and manufacturing the first layer onto the laminated second layer/third layer directly, followed by cutting, packing and sterilization.

US Pat. No. 10,213,342

OPHTHALMIC KNIFE AND METHODS OF USE

1. An ophthalmic knife, comprising:a shaft;
a first platform extending radially from a first radial side of the shaft; and
a second platform extending radially from a second radial side of the shaft, opposite the first radial side;
wherein each of the first and second platforms comprises:
a ramp that increases from a first thickness at a distal side of the ramp to a second thickness, greater than the first thickness and at a proximal side of the ramp; and
first and second blades that (i) are separated by a gap and (ii) extend from the proximal side of the ramp to the shaft; and
wherein the shaft, the first platform, and the second platform define a single flat and continuous bottom surface that is opposite each of the first and second blades.

US Pat. No. 10,213,341

LASER PROBE WITH A REPLACEABLE OPTIC FIBER

1. A device comprising:a machine adapter having a machine adapter distal end and a machine adapter proximal
end, the machine adapter configured to interface with an ophthalmic laser to perform a laser
photocoagulation procedure;
a machine adapter inner bore of the machine adapter;
a machine interface of the machine adapter, the machine interface disposed between the
machine adapter distal end and the machine adapter inner bore;
a handle adapter having a handle adapter distal end and a handle adapter proximal end;
an actuation handle having a plurality of actuation arms and a plurality of extension mechanisms;
a replaceable optic fiber;
a pair of connectors of the replaceable optic fiber;
a housing tube having a housing tube distal end and a housing tube proximal end wherein the optic fiber distal end is adjacent to the housing tube distal end;
a first connector of the pair of connectors having a first connector distal end, a first connector proximal end, a first temporary fixation channel, a first interface, a first connector inner bore, a first connector guide cone, and a first optic fiber housing wherein a portion of the first connector is disposed within the handle adapter;
a second connector of the pair of connectors having a second connector distal end, a second connector proximal end, a second temporary fixation channel, a second interface, a second connector inner bore, a second connector guide cone, and a second optic fiber housing wherein a portion of the second connector is disposed within the machine adapter wherein the second connector is identical to the first connector; and
an optic fiber of the replaceable optic fiber having an optic fiber distal end, an optic fiber proximal end, a core, a cladding, and a polyimide buffer wherein the optic fiber is disposed within the first connector and the second connector wherein the optic fiber distal end extends a distal extension distance from the first connector distal end and the optic fiber proximal end extends a proximal extension distance from the second connector distal end wherein the distal extension distance is equal to the proximal extension distance and wherein the optic fiber is fixed in the first connector and wherein the optic fiber is fixed in the second connector and wherein a portion of the replaceable optic fiber is disposed in the machine adapter wherein the optic fiber proximal end is adjacent to the machine adapter distal end.

US Pat. No. 10,213,340

METHODS AND SYSTEMS TO PROVIDE EXCLUDED DEFINED ZONES FOR INCREASING ACCOMMODATIVE AMPLITUDE

Lensar, Inc., Orlando, F...

1. A system for changing the refractive power of an eye, the system comprising:a. a laser for providing a therapeutic laser beam;
b. an optical path for delivery of the therapeutic laser beam from the laser to a natural crystal lens of an eye;
c. optics located along the optical path, the optics providing the capability to direct the laser beam in at least the x and y directions;
d. a control system, comprising a controller, the controller comprising a laser beam delivery pattern, whereby the control system is configured to direct the optics to deliver the laser beam in the laser beam delivery pattern to a predetermined area of the lens of the eye;
e. the laser beam delivery pattern defining an axial excluded zone and an equatorial excluded zone; and,
f. whereby, the delivery of the laser beam in the laser beam pattern to the natural crystalline lens of the eye changes the refractive power of the lens of the eye.

US Pat. No. 10,213,339

METHOD AND DEVICE FOR PRODUCING CURVED CUTS IN A TRANSPARENT MATERIAL

Carl Zeiss Meditec AG, J...

12. An apparatus for isolating a volume of material within a cornea of an eye by producing curved cuts in the cornea, said apparatus comprising:a laser radiation source which focuses laser radiation into the cornea at a focal point and causes optical breakthroughs therein;
a scanning unit which three-dimensionally shifts the focal point, wherein the scanning unit comprises adjustable optics for shifting the focal point in one spatial direction which is parallel to a direction in which the laser radiation is applied;
a control unit which controls the scanning unit, to form the cut surface by sequential arrangement of the optical breakthroughs in the cornea; and
wherein the control unit controls the scanning unit such that the focal point is guided in two other spatial directions on contour lines of the cut, the contour lines being located in planes that are perpendicular to the first spatial direction.

US Pat. No. 10,213,338

DEVICE FOR PRODUCING CUTS OR PERFORATIONS ON AN EYE

1. A device for producing cuts or perforations on a human or animal eye at the anterior or posterior opening of the eye lens (capsulatomy, rhexis), the device comprising a cutting element that can be inserted into an associated interior of an associated eye and a drive device which is arranged outside of the associated eye in order to cause movement, in articular oscillatory vibrations or rotation of the cutting element inside the associated interior of the associated eye, the drive device having a field generator for generating a magnetic or electromagnetic excitation field and the cutting element can be excited, in particular driven, by way of the field generated by the field generator, the cutting element is formed as a continuous cutting ring.

US Pat. No. 10,213,337

VITRECTOMY PROBE

Erre Quadro S.R.L., Pisa...

1. Vitrectomy probe for removing the vitreous humour comprising a single closed-tip tube adapted to be put into direct contact, at least partially, with said vitreous, defining a main axis and including an internal passage and at least one lateral opening to enable said vitreous to enter the internal passage; a suction system for the creation of vacuum within said internal passage sucking said vitreous into said opening; wherein said at least one opening comprises at least one cutting edge; and wherein the probe comprises a drive unit adapted to move said tube with a vibrational motion (A), which vibration motion generates pressure waves reducing the viscosity of said vitreous, and a reciprocating motion (B), which reciprocating motion allows at least one cutting edge to cut said vitreous; and wherein said vibrational motion (A) has a frequency which is higher than the frequency of said reciprocating motion (B).

US Pat. No. 10,213,336

EYE DROP ASSIST APPARATUS

Ocunelis LLC, Ann Arbor,...

1. An eye drop assist apparatus for sequentially administering ocular medication from an eye drop bottle having a dispensing tip to a patient's two eyes, the two eyes separated from one another, said apparatus comprising:a holder defining a bottle support axis, said holder configured to support the eye drop bottle so that the dispensing tip is disposed along said bottle support axis,
a first nasal locator connected to said holder, said first nasal locator extending laterally from said bottle support axis a first offset distance, and
a second nasal locator connected to said holder and spaced from said first nasal locator, said second nasal locator extending laterally from said bottle support axis a second offset distance equal to said first offset distance,
wherein said first nasal locator is defined by a first concave abutment and said second nasal locator is defined by a second concave abutment, said first and second concave abutments including respective first and second apex points, said first and second offset distance measured from said bottle support axis to said respective first and second apex points, the distance between said first and second apex points equal to 60 mm.

US Pat. No. 10,213,335

METHODS AND APPARATUS FOR CRYOGENIC TREATMENT OF A BODY CAVITY OR LUMEN

Channel Medsystems, Inc.,...

1. A tissue treatment system, comprising:an elongate lumen having a distal tip and a length;
at least one infusion lumen positioned through or along the elongate lumen;
at least one delivery lumen in fluid communication with the infusion lumen, wherein the delivery lumen defines one or more openings therealong;
a liner defining an interior in which the elongate lumen is positionable; and
a sheath translatable relative to the elongate lumen, wherein translation of the sheath selectively controls a number of the one or more openings which remain unobstructed and also correspondingly adjusts an expanded length of the liner according to the number of one or more openings which are unobstructed.

US Pat. No. 10,213,333

METHOD OF CONTROLLING IMMUNE CELLS

1. A method for regulating immune cells comprising:applying a stimulus to a specific area to be stimulated at a body surface by a stimulus applying apparatus so as to bring an increase rate of a blood flow to 60% or more, preferably, 100% or more,
wherein the blood flow is measured by a laser Doppler tissue blood flow meter attached to a central part of an inner side of a wrist joint,
wherein the increase rate of blood flow by thermal therapy enables a regulatory T cell to regulate and balance the immune cells and regulating and balancing these T cell groups finely is essential to maintain the immune system of human beings, and
wherein the specific area is at least one area selected from the group consisting of os metatarsale primam 1 and 2 interosseous, os metatarsale primam 2 and 3 interosseous, and part that intersects the perpendicular line of the medial malleolus on an extension line of the medial margin on os metatarsale primam 1 and 2 in foot sole of right and left.

US Pat. No. 10,213,332

SUPRAPUBIC REGION COMPRESSION ASSEMBLY AND METHOD

1. A suprapubic region compression assembly for compressing a suprapubic region of a user, the assembly comprising:a compression plate having opposite inner and outer surfaces and opposite left and right side edge margins, the compression plate defining a notch positioned between the left and right side edge margins, the notch configured to receive a penis of the user, the compression plate comprising a lower portion including the notch and an upper portion, the lower portion having the notch being curved or angled inward toward the inner surface relative to the upper portion to compress the suprapubic region of the user; and
a belt configured to urge the compression plate toward the user such that the compression plate engages the suprapubic region of the user to apply pressure to the suprapubic region thereby increasing a measurable, visible, or usable length of the penis.

US Pat. No. 10,213,330

ORTHOPAEDIC DEVICE FOR A LOWER LIMB OF A HUMAN, FOOTWEAR AND PROSTHESIS PROVIDED WITH SUCH A DEVICE

1. An orthopaedic device for a lower limb of a human comprising:a front segment which is adapted to receive a sole of a forefoot of a foot, said front segment being formed from a first plate;
a rear segment which is adapted to receive a lower face of a heel of said foot, said rear segment being formed from a second plate which is longitudinally spaced from the first plate such that the first plate and the second plate are distinct;
wherein:
said front segment and said rear segment are formed from two pieces which are distinct from one another;
said front segment and said rear segment are connected by at least one upper arch that is resilient in flexion, and
which:
extends above said front segment and said rear segment, providing a recess for receiving said foot;
is adapted to keep said front segment and said rear segment in an inactive position; and
is adapted to make possible a relative displacement of said front segment and said rear segment in relation to one another, starting from the inactive position, and to bring back said front segment and said rear segment resiliently into the inactive position providing a propulsive dynamic effect, said upper arch exerting a force for bringing back said front segment and said rear segment into said inactive position.

US Pat. No. 10,213,329

EVERTABLE SHEATH DEVICES, SYSTEMS, AND METHODS

1. A medical device delivery system comprising:an elongate member having proximal and distal ends;
a medical device having proximal and distal ends; and
an inverted sheath having a delivery profile and a deployment profile, a proximal end and a distal end;
wherein the medical device is located about the distal end of the elongate member with the inverted sheath in the delivery profile disposed about the medical device,
wherein when the inverted sheath is transitioned to the deployment profile, the medical device can be deployed without requiring further eversion of the inverted sheath,
wherein the inverted sheath comprises an inner layer and an outer layer defining a chamber, and
wherein pressurization of the chamber by introducing a fluid into the chamber causes the inverted sheath to evert and causes the transition from the delivery profile to the deployment profile wherein the inverted sheath has an expanded diameter and a shortened length in the deployment profile relative to the delivery profile.

US Pat. No. 10,213,328

PARTIAL ENCAPSULATION OF STENTS

Bard Peripheral Vascular,...

1. An implantable medical device, comprising:an elongate inner tube of expanded polytetrafluoroethylene;
an elongate outer sleeve of expanded polytetrafluoroethylene having a length, the outer sleeve including a plurality of slits oriented longitudinally along a longitudinal axis of the outer sleeve, the plurality of slits having a first group of slits and a second group of slits, wherein the first group of slits and the second group of slits are staggered around a circumference of the outer sleeve, and each of the plurality of slits spanning less than half of the length without extending to either a proximal end or a distal end of the outer sleeve; and
a radially expandable support layer partially encapsulated between the inner tube and the outer sleeve, wherein the support layer comprises a plurality of individual ring stents having a zigzag pattern defining alternating peaks and valleys, and wherein the plurality of slits of the outer sleeve are aligned over the peaks in the zigzag pattern of ring stents of the support layer.

US Pat. No. 10,213,327

IMPLANT WITH ATTACHED ELEMENT AND METHOD OF MAKING SUCH AN IMPLANT

1. A method of making a medical device, comprising:providing an implant defining a longitudinal axis and a terminal end, the implant comprising a plurality of marker carriers disposed at the terminal end;
providing a tube comprising a radiopaque metal, the tube including:
a body portion including an uninterrupted tubular wall defining a lumen;
a ring of spoons, each spoon of the ring of spoons comprising an internal cavity; and
a plurality of bridges connecting the ring of spoons to the body portion, each spoon connected to one of the plurality of bridges, each bridge of the plurality of bridges having a width less than a width of each spoon;
mounting the implant and the tube on separate cores;
aligning each marker carrier of the plurality of marker carriers with the internal cavity of each spoon of the ring of spoons; and
joining the plurality of marker carriers with the ring of spoons, comprising abutting a peripheral surface of each spoon against an exterior surface of a respective marker carrier, wherein each of the peripheral surface and the exterior surface have a complementary taper in a direction across a thickness thereof.

US Pat. No. 10,213,326

STENT GRAFT WITH FENESTRATION

Cook Medical Technologies...

1. An endovascular prosthesis comprising:a tubular body having a wall and comprising a graft material;
a shaped protrusion extending from the wall and comprising a cured thermoset graft material formed into a curved shape, the shaped protrusion having an outer edge and an inner edge at least partially surrounded by the outer edge and being void of structures other than the thermoset material that extends radially between the edges; and
a fenestration having fluid communication through the wall and disposed within the inner edge of the shaped protrusion,
wherein the shaped protrusion is semi-rigid.

US Pat. No. 10,213,325

SUSPENSION LINER WITH SEAL COMPONENT

OSSUR HF, Reykjavik (IS)...

1. A liner for providing an interface between a residual limb and a prosthetic socket, comprising:an elongate, generally conical liner body being radially elastically extensible and including proximal and distal end areas, the liner body having an exterior surface and defining a longitudinal axis defined between the proximal and distal end areas;
the liner body formed with a circumferential recess defining first and second exterior surfaces within the recess and axially separated from one another by a circumferential edge;
a seal component located within the circumferential recess;
wherein the seal component defines a base portion secured to the second exterior surface of the recess;
wherein an interior surface of the base portion is anchored circumferentially to the second exterior surface;
wherein the interior surface of the base portion extends to a pivot line defined by the seal component, a lip extends above the base portion and is parallel to the first exterior surface of the circumferential recess.

US Pat. No. 10,213,324

MINIMUM JERK SWING CONTROL FOR ASSISTIVE DEVICE

Rehabilitation Institute ...

1. A method for control of an assistive device, comprising:a. computing a first set of coefficients of a first polynomial function, to determine at least one angle position for an ankle joint of the assistive device when the assistive device is in a swing phase;
b. computing a second set of coefficients of a second polynomial function and a third set of coefficients of a third polynomial function, to determine at least one angle position for a knee joint of the assistive device when the assistive device is in the swing phase;
c. determining the at least one angle position for the knee joint and determining the at least one angle position for the ankle joint; and
d. setting the ankle joint to the determined ankle position and setting the knee joint to the determined knee position;
wherein the second polynomial function determines the angle position for the knee joint during a first portion of the swing phase and the third polynomial function determines the angle position for the knee joint during a second portion of the swing phase;
wherein the first portion of the swing phase is defined by a period from the beginning of the swing phase to a maximum knee flexion position; and
wherein the second portion of the swing phase is defined by a period from the end of the first portion of the swing phase to the end of the swing phase.

US Pat. No. 10,213,323

HYBRID TERRAIN-ADAPTIVE LOWER-EXTREMITY SYSTEMS

Bionx Medical Technologie...

1. An apparatus comprising:a foot member,
a lower leg member,
an ankle joint for connecting the foot member to the lower leg member, and
a controller configured to:
analyze a cost function based on a projected force imparted on the lower leg member during a period of time between when a heel of the foot member strikes underlying terrain to when the foot member is positioned in a flat-foot position relative to the underlying terrain, and
adjusting an impedance of the apparatus based on the cost function.

US Pat. No. 10,213,322

INTERVERTEBRAL DISC AND INSERTION METHODS THEREFOR

SpineCore, Inc., Allenda...

1. A surgical method comprising the steps of:selecting a dispenser engaged with two members of an implant, each of the first and second members including at least one protrusion for association with one of a first vertebral body and a second vertebral body, the dispenser shaped so that at least a portion of the protrusion on each of the first and second members is exposed while the dispenser holds the first and second members in registration;
providing an inserter shaft; and
implanting the first and second members between the first and second vertebral bodies by manipulating the inserter shaft.

US Pat. No. 10,213,321

BONE FUSION SYSTEM, DEVICE AND METHOD INCLUDING DELIVERY APPARATUS

Neuropro Technologies, In...

1. A bone fusion system for inserting material into a bone fusion device in a desired location, the system comprising:a bone fusion device having a body with one or more device channels, a positioning element having a positioning aperture and one or more extendable tabs, wherein manipulation of the positioning element enables the tabs to be extended away from the body; and
a delivery apparatus comprising a docking rod and a delivery member having an elongated hollow shaft that leads to an exit aperture, wherein a tip of the docking rod detachably couples to the bone fusion device within the positioning aperture and the delivery member detachably couples with the docking rod such that the exit aperture aligns with one of the device channels when the rod is coupled to the bone fusion device,
wherein the delivery member includes a funneling chamber having a threaded chamber end, wherein the elongated hollow shaft provides a path from the funneling chamber to the exit aperture.

US Pat. No. 10,213,320

SURGICAL GUIDE FOR IMPLANTING A KNEE PROSTHESIS

MEDACTA INTERNATIONAL SA,...

1. A surgical guide for implanting a knee prosthesis, the surgical guide comprising:a first component intended for coupling with a distal epiphyseal end of a femur and comprising
at least one attachment portion configured to be fixed to the distal epiphyseal end of the femur, and
an attachment plate having a substantially triangular shape and comprising a connection to said at least one attachment portion configured to be adjacent to the distal epiphyseal end of the femur;
a template configured to guide a marking operation of the distal epiphyseal end of the femur to determine a position of the knee prosthesis;
said template configured to be rotatably mounted relative to said first component, and comprising a slot perpendicular to a symmetry axis of said template; and
a second component configured to couple said template with a proximal epiphyseal end of a tibia corresponding to the distal epiphyseal end of the femur;
said second component comprising
a grip,
a coupling portion extending from said grip and towards said template for placement adjacent the distal epiphyseal end of the femur, and
a tab being parallel to said coupling portion and extending from said grip, said tab configured to be inserted into said slot.

US Pat. No. 10,213,319

NAVIGATION DEVICE FOR JOINT REPLACEMENT AND SURGICAL SUPPORT DEVICE

ARTHRODESIGN, LTD., Kawa...

1. A navigation device for joint replacement, the navigation device comprising:a guide instrument for guiding a position of a surgical instrument when performing a joint replacement, the guide instrument having
a fixing support unit for fixing and supporting the guide instrument to a surgical object,
an operating unit to which the surgical instrument or a shape measuring instrument is detachably attached,
an imaging unit slidably held by the fixing support unit for detecting signals from the shape measuring instrument when the shape measuring instrument is attached to the operating unit, and
a positioning arm unit joined to the operating unit for adjusting positions of the operating unit and the imaging unit relative to a position of the fixing support unit;
a bone shape calculating means configured to calculate a virtual three-dimensional bone shape of a joint part of a surgical object based on image data of a patient before surgery;
a guide installation position calculating means configured to calculate an ideal installation position of the guide instrument based on the virtual three-dimensional bone shape before surgery;
a bone shape obtaining means configured to obtain an actual three-dimensional bone shape of the joint part of the surgical object, during surgery, by the shape measuring instrument attached to the guide instrument actually installed;
a guide installation position obtaining means configured to obtain an actual installation position of the guide instrument, during surgery, by the shape measuring instrument attached to the guide instrument actually installed; and
an error detecting means configured to compare the virtual three-dimensional bone shape, ideal installation position of the guide instrument, actual three-dimensional bone shape and actual installation position of the guide instrument of the respective means, and to detect an error between the actual installation position and the ideal installation position of the guide instrument by shifting the actual installation position to align with the ideal installation position.

US Pat. No. 10,213,318

SPINAL CAGE DEVICE, SYSTEM, AND METHODS OF ASSEMBLY AND USE

REFAI TECHNOLOGIES, LLC, ...

1. A cage system, comprising:a cage, comprising:
a body portion;
at least one opening through the body portion in a superior-inferior direction; and
at least one hole in an anterior surface of the body portion extending into the at least one opening, wherein the at least one hole comprises:
a first section near the anterior surface of the cage; and
a second section adjacent to the first section and extending into the at least one opening in the body portion,
wherein the first section has a larger diameter than the second section and the first section and second section are threaded; and
at least one locking screw assembly configured to couple to the cage.

US Pat. No. 10,213,317

IMPLANT WITH SUPPORTED HELICAL MEMBERS

Institute for Musculoskel...

1. An implant, comprising:a body;
the body defining a transverse plane dividing the implant into a superior half and an inferior half;
a peripheral frame portion defining a periphery of the body;
a central wall extending from a first side of the peripheral frame portion to a second side of the peripheral frame portion;
a first helical bone contacting member attached to the body and disposed within the superior half of the implant;
a second helical bone contacting member attached to the body and disposed within the superior half of the implant;
a first support member extending from a first point on a superior side of the peripheral frame portion to the first the bone contacting member and further extending inwardly of the bone contacting member into a central region of the implant and terminating at a second point on an inferior side of the peripheral frame portion adjacent to the first point from which the first support member extends; and
a second support member extending from a third point on the peripheral frame portion opposite the first point to the second helical bone contacting member and further extending inwardly of the bone contacting members and terminating at a fourth point on the peripheral frame portion;
wherein the first support member and the second support member are substantially U-shaped and are connected to one another at the bottoms of the two U-shapes in the central region of the implant inward of the bone contacting members.

US Pat. No. 10,213,316

PROSTHESIS

SWEMAC INNOVATION AB, (S...

1. Wrist prosthesis for replacement of a wrist joint (arthroplasty), and subsequently for arthrodesis of the wrist joint,wherein the prosthesis (1) comprises two elongated prosthesis members (2, 3) which each is configured for attachment thereof to at least one of the bones at the joint,
wherein one of the prosthesis members (2) comprises a first screw-like attachment member (4) which is configured for attachment to at least one of the bones at the joint and the other prosthesis member (3) comprises a second screw-like attachment member (5) which is configured for attachment to at least one other bone at the joint, and
wherein said one prosthesis member (2) originally comprises a socket member (6) and said other prosthesis member (3) originally comprises a head member (7),
wherein said socket member (6) is configured with an attachment pin (16) which is insertable into a hole (8) in the first screw-like attachment member (4) for attachment of the socket member therein,
wherein said head member (7) is configured with an attachment pin (19) which is insertable into a hole (9) in the second screw-like attachment member (5) for attachment of the head member therein,
wherein the hole (9) in the second screw-like attachment member (5) is configured to define a press fit with the attachment pin (19) of the head member (7),
wherein the hole (8) in the first screw-like attachment member (4) is configured to define a press fit with the attachment pin (16) of the socket member (6) and at least partly threaded (14) to subsequently permit, after removal of the socket member (6) during arthrodesis, securing by screwing in said hole of a locking member (33c) which is configured to cooperate with a lockable member (34c),
wherein said one prosthesis member (2) further comprises a locking member (33c) and said other prosthesis member (3) further comprises a lockable member (34c),
wherein the locking member (33c) is configured with an attachment portion (16c) which is insertable into said hole (8) in said first screw-like attachment member (4) for subsequent attachment or location of the locking member therein when the socket member (6) is removed from the first screw-like attachment member (4),
wherein the lockable member (34c) is configured with an attachment portion (19c) which is insertable into said hole (9) in said second screw-like attachment member (5) for subsequent attachment or location of the lockable member therein when the head member (7) is removed from the second screw-like attachment member (5),
wherein the locking member (33c) is also configured with a locking portion (37c) which is connected to the attachment portion (16c) and configured for fixation or attachment of the lockable member (34c) thereto, and wherein the attachment portion (16c) is configured with a hole (38c) which extends through said attachment portion and in the longitudinal direction thereof for insertion therein of a partly threaded attachment means (39c) for tightening or securing by screwing the locking member (33c) to the first screw-like attachment member (4) by bringing said attachment means (39c) to cooperate with a threaded portion (14c) of the hole (8) in said first screw-like attachment member (4),
wherein the locking portion (37c) of the locking member (33c) is substantially U-shaped and comprises two shanks (40c) with two holes (41c, 42c) provided in each shank (40c) opposite each other and substantially in line in the longitudinal direction of the locking portion (37c), whereby one hole (41c) is configured for a locking means (43c) for fixation or attachment of the lockable member (34c) to the locking member (33c) and whereby the other hole (42c) is configured for a pivoting axis member (44c) about which the lockable member can pivot for adjustable setting thereof relative to the locking member,
wherein the lockable member (34c) comprises a lockable portion (45c) which is configured for insertion between the shanks (40c) of the locking portion (37c) of the locking member (33c), wherein the lockable portion (45c) is configured with a curved long-hole (46c) for said locking means (43c) that extends transversely therethrough, and with a hole (47c), also extending transversely through said lockable portion, for the pivoting axis member (44c) about which the lockable member (34c) can pivot for adjustable setting thereof relative to the locking member, and wherein at insertion of the lockable portion (45c) between the shanks (40c) of the locking portion (37c) of the locking member (33c), portions of the long-hole (46c) are brought in line with the holes (41c) in said shanks to allow the locking means (43c) to pass through the long-hole (46c) and the holes (41c) for fixation or attachment of the lockable portion to the locking portion of the locking member and the hole (47c) for the pivoting axis member (44c) is brought in line with the holes (42c) for said pivoting axis member (44c) in said shanks,
wherein said lockable member (34c) is configured for adjustable setting thereof relative to the locking member (33c) and for fixation thereof, in set position, to the locking member, and
wherein one prosthesis member (2) is configured for attachment to the radius (25) and the other prosthesis member (3) is configured for attachment to one of the bones (27) of the carpus (26) and a metacarpal bone (28).

US Pat. No. 10,213,315

ATTACHMENTS FOR ORTHOPEDIC IMPLANTS

Zimmer, Inc., Warsaw, IN...

1. A prosthesis positionable between a first bone surface and a second bone surface in a patient, comprising:a first prosthetic component with a first attachment profile that is associable with a mating profile of the first bone surface in a male-female mating relationship and a second attachment profile that is associable with a mating profile of the second bone surface in a male-female mating relationship; and
a stackable, second prosthetic component stackable onto the first prosthetic component, the second prosthetic component including an attachment profile that replicates the first attachment profile of the first prosthetic component to allow association with the mating profile of the first bone surface in a male-female mating relationship and a mating profile that replicates the mating profile of the first bone surface to allow association with the first attachment profile of the first prosthetic component in a male-female mating relationship.

US Pat. No. 10,213,314

FEMORAL COMPONENT FOR AN IMPLANTABLE HIP PROSTHESIS

DEPUY SYNTHES PRODUCTS, I...

1. A method of manufacturing an orthopaedic hip prosthesis comprising:forming a core from a material having a high tensile strength and a high elastic modulus, and
attaching a polymeric shell to the core to position a proximal end of the core in a base of a tapered post of the polymeric shell, wherein attaching the polymeric shell includes placing a cover layer of the polymeric shell only on a lateral surface of a distal end of the core,
wherein the tapered post of the polymeric shell extends from the base to a proximal tip, and the tapered post is sized to be received in a tapered bore of an implantable head component.

US Pat. No. 10,213,313

FEMORAL HEADS, MOBILE INSERTS, ACETABULAR COMPONENTS, AND MODULAR JUNCTIONS FOR ORTHOPEDIC IMPLANTS AND METHODS OF USING FEMORAL HEADS, MOBILE INSETS, ACETABULAR COMPONENTS, AND MODULAR JUNCTIONS FOR ORTHOPEDIC IMPLANTS

The General Hospital Corp...

1. An orthopedic implant comprising:a femoral head implant that includes a portion of an outer surface thereof having a peripheral portion that is contoured so as to achieve an inward shift of the outer surface relative to an overall spherical geometry of the femoral head implant;
wherein the femoral head implant has a femoral head rim comprising an edge or surface marking an end of a femoral head articular surface of the femoral head implant;
wherein the femoral head implant has a femoral head axis defined by a reference line passing through a center of the overall spherical geometry of the femoral head implant to a geometric center of the femoral head rim of the femoral head implant;
wherein the inward shift occurs at an angle greater than about 80° measured from an intersection of the femoral head axis with the outer surface of the femoral head implant; and
wherein the portion that is contoured extends to the femoral head rim, and the inward shift of the outer surface is achieved using at least one convex radius having a value no less than 15% of the overall spherical radius of the femoral head implant.

US Pat. No. 10,213,312

HEATED BOLT FOR MODULAR HIP STEM

Zimmer, Inc., Warsaw, IN...

1. A modular hip stem, comprising:a distal stem configured to be implanted within a femur of a patient;
a proximal body configured to attach to a proximal end of the distal stem;
a bolt configured to secure the proximal body to the distal stem, the bolt defining an internal volume extending longitudinally within the bolt from a proximal end of the bolt toward a distal end of the bolt;
an electrical resistive heater, disposed within the internal volume of the bolt, extending from the proximal end of the bolt toward the distal end of the bolt, and configured to heat the bolt to a temperature greater than average human core body temperature; and
a first electrode extending proximally from the electrical resistive heater to an exterior of the bolt, the first electrode configured to supply current to the electrical resistive heater, the first electrode attached to the electrical resistive heater at a narrowed portion of the first electrode, the narrowed portion being defined by a perforation, the first electrode configured to irreversibly detach from the electrical resistive heater by tearing at the narrowed portion when the first electrode is pulled away from the bolt.